


Fundamentals of Biochemistry 6th Edition PDF Wiley

Visit the link below to download the full version of the ebook

[DOWNLOAD NOW](#)



Scan to Download
or Type the Link

ebook.ac/fundamentals6e

8.5 x 10.875 in

WILEY

Loose-Leaf Print Companion


→ Use with your digital solution

Voet | Voet | Pratt

FUNDAMENTALS OF BIOCHEMISTRY

SIXTH EDITION

Destin Heilman
Stephen Woski



Cover Design: Wiley
Cover Image: Courtesy of Destin Heilman and Stephen Woski

www.wiley.com

WILEY

ISBN 978-1-119-90350-5



9 781119 903505

Fundamentals of Biochemistry

Life at the Molecular Level

Sixth Edition

DONALD VOET

University of Pennsylvania

JUDITH VOET

Swarthmore College

CHARLOTTE W. PRATT

Seattle Pacific University

DESTIN HEILMAN

Worcester Polytechnic Institute

STEPHEN WOSKI

The University of Alabama

WILEY

Vice President: Lyssa Vanderbeek
Editorial Director: Michelle Renda
Executive Editor: Natalie Ruffatto
Associate Marketing Director: Michael Olsen

Sr. Director, Advanced Content: Angela Cohen
Sr. Managing Editor: Kimberly Monroe-Hill
Sr. Creative Product Designer: Thomas Nery
Cover Photo: Courtesy of Destin Heilman and Stephen Woski

This book was typeset in STIX Two Text 9.5/12 by Lumina Datamatics.

Wiley is a global leader in research and education, unlocking human potential by enabling discovery, powering education, and shaping workforces. For over 200 years, Wiley has fueled the world's knowledge ecosystem. Today, our high-impact content, platforms, and services help researchers, learners, institutions, and corporations achieve their goals in an ever-changing world. Visit us at [Wiley.com](http://wiley.com).

Copyright © 2024 by Destin Heilman, Stephen Woski

Copyright © 2016, 2013, 2008, 2006 by Donald Voet, Judith G. Voet, Charlotte W. Pratt

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying recording, scanning or otherwise, except as permitted under Sections 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher or authorization through payment of the appropriate per copy fee to the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 646-8600. Visit us at <http://www.wiley.com/permissions> to request permission for re-use or reproduction of Wiley content.

Readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Evaluation copies are provided to qualified academics and professionals for review purposes only, for use in their courses during the next academic year. These copies are licensed and may not be sold or transferred to a third party. Upon completion of the review period, please return the evaluation copy to Wiley. Return instructions and a free of charge return shipping label are available at www.wiley.com/go/returnlabel. If you have chosen to adopt this textbook for use in your course, please accept this book as your complimentary desk copy. Outside of the United States, please contact your local representative.

EPUB ISBN: 978-1-119-90348-2

The inside back cover will contain printing identification and country of origin if omitted from this page. In addition, if the ISBN on the back cover differs from the ISBN on this page, the one on the back cover is correct.

Library of Congress Cataloging-in-Publication Data

Names: Voet, Donald, author. | Voet, Judith G., author. | Pratt, Charlotte W., author.

Title: Fundamentals of biochemistry : life at the molecular level / Donald Voet, University of Pennsylvania, Judith G. Voet, Swarthmore College, Charlotte W. Pratt, Seattle Pacific University, Destin Heilman, Stephen Woski.

Description: Sixth edition. | Hoboken, NJ : Wiley, [2024] | Revised edition of: Fundamentals of biochemistry : life at the molecular level / Donald Voet, Judith G. Voet. 5th edition. 2016.

Identifiers: LCCN 2024008983 (print) | LCCN 2024008984 (ebook) | ISBN 9781119903505 (cloth) | ISBN 9781119903499 (adobe pdf) | ISBN 9781119903482 (epub)

Subjects: LCSH: Biochemistry—Textbooks.

Classification: LCC QD415 .V65 2024 (print) | LCC QD415 (ebook) | DDC 572—dc23/eng/20240314

LC record available at <https://lcn.loc.gov/2024008983>

LC ebook record available at <https://lcn.loc.gov/2024008984>

Printed in the United States of America.

10 9 8 7 6 5 4 3 2 1

Dedication to Don Voet

This book owes its existence to the vision of Donald Voet, who passed away in 2023. Don's love of biochemistry and his commitment to train future biochemists originally led him to collaborate with Judith Voet to write *Biochemistry*. Don's expertise in structure and Judy's in function made them a perfect team. *Biochemistry* was a comprehensive textbook that later served as the basis for *Fundamentals of Biochemistry*. These textbooks focused not just on the myriad details of molecular structures and functions but also addressed the big ideas that Don felt were essential for conveying the beauty of biochemistry. He worked tirelessly to ensure that students would appreciate the molecular mechanisms that are common to all organisms while recognizing the importance of evolutionary variations and the power of using biochemical information to understand and solve biomedical challenges.

Don was more than a researcher and professor. He was a discerning writer with wide-ranging interests and an appetite for adventures that included extensive travel and outdoor activities of all kinds. His sense of wonder permeates his writing. Although he was thorough and exacting in his work, he never let attention to detail detract from the larger story. At the same time, he was reluctant to oversimplify or omit a detail that could reveal a subtle truth about the organization or regulation of biochemical processes. His genius was in understanding what students needed and delivering that content in a way that would be interesting and useful. He was also generous in giving credit to the researchers whose discoveries he wrote about.

Don Voet, along with Judy Voet, was highly active in the biochemical education community and earned the respect of countless instructors. Students who encountered Don and Judy at national conferences would greet them like rock stars. Even those who had never taken a biochemistry course knew about *Biochemistry*. Over the years, countless researchers needing an informative and accessible resource have made a place on their shelves for the Voets' book—work that continues to influence the professional lives of scientists worldwide.

Charlotte Pratt, Ph.D.
Seattle Pacific University
Seattle, Washington

About the Authors to the Sixth Edition



DESTIN HEILMAN received his B.S. in Microbiology/Biochemistry and Molecular Biology from Penn State University in 2000, and his Ph.D. from the University of Massachusetts Chan Medical School in 2005 under the direction of Michael R. Green. He joined the Faculty of the Worcester Polytechnic Institute in 2006 where he has taught a variety of biochemistry courses as well as introductory chemistry and analytical techniques. Motivated by the nationally renowned project-based curriculum at WPI, Dr. Heilman has engaged in extensive pedagogical innovation in both Chemistry and Biochemistry courses as well as in undergraduate capstone projects. In concert with colleagues, he spearheaded the creation of an entirely project-based general chemistry laboratory series at WPI as well as inquiry-based biochemistry laboratory courses at the capstone level. As one of the founding members of the Center for Project-Based Learning at WPI, Dr. Heilman has served as a mentor for many faculty teams from universities around the world and he routinely delivers workshops in the development of outcomes-based design of authentic projects in the classroom and laboratory. His disciplinary research focuses on the discovery and characterization of novel virus proteins that have cancer-selective toxicity. His focus on understanding these proteins has led to the development of new techniques for studying cell-selective activities and the characterization of pathways that induce programmed cell death in cancer. Leveraging his passion for teaching alongside his research, he has advised over 100 undergraduate students in his laboratory and has developed impactful pedagogical methods in integrative learning for capstone projects. Dr. Heilman has also developed and directed several local and national-level summer outreach programs including those dedicated to increasing opportunities for underrepresented students. Outside of academia, he enjoys watchmaking, woodworking, mountaineering, and gaming with his family. He is also an avid amateur astronomer and astrophotographer, and an advocate for the preservation of open land and dark skies.



STEPHEN WOSKI received his B.S. degree in Chemistry in 1986 from Emory University and his Ph.D. in 1991 from the University of Michigan under the direction of Prof. Masato Koreeda. He was then an NIH postdoctoral fellow under the supervision of Prof. Peter B. Dervan at the California Institute of Technology. Since joining the faculty of the Department of Chemistry & Biochemistry at The University of Alabama in 1994, Dr. Woski has focused on education and research at the interface between biochemistry and organic chemistry. He has taught chemistry and biochemistry courses from the introductory through graduate levels and has been involved in the creation of a new active-learning biochemistry laboratory course, a graduate literature and presentation course, and an integrated foundational core graduate course in structure and reactivity. While serving for 11 years as Director of Graduate Studies at Alabama, he actively worked to develop pipelines to broaden participation in STEM fields through involvement in the Research Experiences for Undergraduates (REU), Graduate Assistantships in Areas of National Need (GAANN), and Louis Stokes Alliance Bridge to the Doctorate programs. In research, Dr. Woski has focused on the application of the tools of synthetic organic chemistry to address problems in nucleic acid biochemistry. His research group's current active projects involve the utilization of non-natural nucleosides to examine base-base interactions in nucleic acid complexes and the structural characterization of chromium-DNA adducts to elucidate the mechanism behind chromate carcinogenicity. Dr. Woski has mentored the research of 25 doctoral and master's students and more than 80 undergraduate students. When away from campus, Dr. Woski frequently travels to locations throughout the world. There, he annoys his family by stopping to take photographs of landscapes and architecture while never missing an ancient Roman historical site.

About the Authors to the Fifth Edition

DONALD VOET received his B.S. in Chemistry from the California Institute of Technology in 1960, a Ph.D. in Chemistry from Harvard University in 1966 under the direction of William Lipscomb, and then did his postdoctoral research in the Biology Department at MIT with Alexander Rich. Upon completion of his postdoc in 1969, Don became a faculty member in the Chemistry Department at the University of Pennsylvania, where he taught a variety of biochemistry courses as well as general chemistry and X-ray crystallography. Don's research focused on the X-ray crystallography of molecules of biological interest.

JUDITH (“JUDY”) VOET received her B.S. in Chemistry from Antioch College, and her Ph.D. in Biochemistry from Brandeis University under the direction of Robert H. Abeles. She was a postdoctoral researcher at the University of Pennsylvania, Haverford College, and the Fox Chase Cancer Center. Judy's main area of research involves enzyme reaction mechanisms and inhibition. She taught biochemistry at the University of Delaware before moving to Swarthmore College, where she taught biochemistry, introductory chemistry, and instrumental methods for 26 years, reaching the position of James H. Hammons Professor of Chemistry and Biochemistry. She has been a National Councilor for the American Chemical Society (ACS) Biochemistry Division and a member of the Education and Professional Development Committee of the American Society for Biochemistry and Molecular Biology (ASBMB).

Don and Judy were coauthors of four previous editions of *Fundamentals of Biochemistry* (first published in 1999) as well as four editions of *Biochemistry*, a more advanced textbook (first published in 1990). Together they were Co-Editors-in-Chief of the journal *Biochemistry and Molecular Biology Education* from 2000 to 2014. They were members of the Education Committee of the International Union of Biochemistry and Molecular Biology (IUBMB) and together, they received the 2012 award for Exemplary Contributions to Education from the ASBMB.

CHARLOTTE PRATT received her B.S. in Biology from the University of Notre Dame and her Ph.D. in Biochemistry from Duke University under the direction of Salvatore Pizzo. Although she originally intended to be a marine biologist, she discovered that biochemistry offered the most compelling answers to many questions about biological structure–function relationships and the molecular basis for human health and disease. She conducted postdoctoral research in the Center for Thrombosis and Hemostasis at the University of North Carolina at Chapel Hill. She has taught at the University of Washington and currently teaches and supervises undergraduate researchers at Seattle Pacific University. In addition to working as an editor of several biochemistry textbooks, she has co-authored *Essential Biochemistry* and previous editions of *Fundamentals of Biochemistry*.

Preface

We are delighted and deeply honored to author the *Voet, Voet, & Pratt Fundamentals of Biochemistry* for its sixth edition. As long-time users of this textbook, we cherish its focus on the structural nature of biochemistry and the depth with which the chemistry that drives life on Earth is presented. We started this project with the goal of substantively updating the prior edition while remaining faithful to the central principle that structure = function, continuing in the spirit of the previous authors. Many of the choices we have made are designed to renew the textbook for contemporary students who approach learning quite differently than in years past. Our goal is to elevate this foundational textbook to an integrative and effective learning platform for the modern biochemistry student.

Perhaps the most striking change to the textbook is a massive update to the art program, for which we have produced more than 400 new renderings of figures and graphics. These are modern, more effective renderings that better enable understanding of the subject matter. We have also included many new figures, which in large part are due to the current explosion in the number and quality of biomolecular structures. Researchers are depositing new X-ray crystallographic and NMR structures at accelerating rates. A revolution is also occurring with the development of cryoEM methods that allow for the elucidation of high resolution structures of large, multiprotein complexes. Such cryoEM techniques have also illustrated the dynamic behavior and transient species that exist in some of the most complex and amazing biochemical processes (see example Figure 25.25).

Learning biochemistry is heavily dependent on the visualization and perception of how chemistry is organized in three-dimensional space. As such, we have embedded interactive versions of molecular structures in the text to allow students to easily manipulate and better understand the complex structure of biomolecules. These interactives are integrated seamlessly into the text; students require no additional software or instruction to make use of them. A number of videos have also been embedded in the text that illustrate approximations of allosteric motions, highlighting the dynamic nature of protein function.

In the sixth edition, we have also focused on streamlining the student experience to better focus attention on the critical subject matter, integrating topics contextually rather than presenting them as separate elements. We have also reorganized the text to curate biochemical methods in one consolidated section, to allow the chapter material to be presented contiguously and without interruption. This provides a comprehensive, organized, and easily referenced presentation of up-to-date methods that are relevant for the modern biochemical field.

We also believe that the effectiveness of a text is not only dependent upon presenting material well but also on improved facilitation of self-assessment. Students are more successful when they are easily able to recognize what they do not understand. To streamline this process, terminal and enabling

learning outcomes have been added throughout the text and these are scaffolded such that outcomes will scale with the content. For particularly critical and/or challenging learning outcomes, in-line and interactive assessments (Check Your Understanding) have been developed to provide self-assessment right where it can have the most impact. We have also identified ten challenging concepts that students find especially difficult and have targeted these with additional interactive figures, animations, and short video presentations to provide students with curated learning resources in a familiar and convenient format.

It is our hope that both students and faculty will continue to benefit from the extraordinary quality and legacy of this text and that this substantive evolution of its structure and presentation will better foster the interest and excellence of the students that have the benefit of engaging with it.

Hallmark features for this edition:

- Extensive renewal of art program that updates on modern discoveries and understanding
- Scaffolded learning outcomes that organize and facilitate student competencies
- Targeted Check Your Understanding Questions
- In-line interactive structural models
- Integration of many topics into contextualized Biochemistry in Focus sections
- Organized and updated appendix of biochemical methods
- Consolidation of topics in nucleic acid structure to better facilitate first semester outcomes
- Focus on modern search for and development of life on other worlds
- Introduction of “partially ionizable” category in amino acids
- Addition of P_{II} strand as regular secondary structure
- Reorganization and revision of catalytic mechanics
- Updates to translation mechanics and inclusion of ensemble cryoEM structures
- Consolidation of glycolytic flux into one chapter
- Reorganization of chromatin and protein-DNA interactions

What’s New in the Sixth Edition

Fundamentals of Biochemistry, 6e provides a solid biochemical foundation that is rooted in chemistry while continuing in the tradition of presenting complete and balanced coverage that is clearly written and relevant to human health and disease. This edition includes new pedagogy and enhanced visuals that better adapt the text for the modern student, including a focus on enhanced self-assessment tools and scaffolding of learning outcomes throughout the text.

Key pedagogical changes:

- Scaffolded learning outcomes in each section that both streamline and elevate the effectiveness of student learning
- In-line Check Your Understanding exercises offer self-assessment where most relevant and challenge students to contextualize and combine topics
- Re-established narrative throughout the text to focus on the chemical nature of life
- Refreshed material to reinforce the integration of chemistry content
- Updated material to reflect modern discoveries and techniques in biochemistry
- Increased focus on engagement and contextual learning
- Overall art update with integrated, interactive molecular structures
- More digital resources to support 10 of the most common challenging topics for students
- Organized and updated methods section consolidates and streamlines student learning
- Contextualized Biochemistry in Focus sections add new content and accentuate understanding of the material with contextualized examples where relevant

Key changes to the Table of Contents:

- Updated Table of Contents with the number of chapters reduced
- Material involving nucleic acids, previously covered in fifth edition Chapters 3 and 24, is now in Chapter 6, a consolidated chapter on DNA structure, to better serve a first semester biochemistry curriculum
- Biomacromolecular structure are now presented as an consolidated series in Chapters 4 through 7
- Content on protein function (previously covered in the fifth edition Chapter 7), as well as newly developed content, has been presented separately and where contextually relevant in a series of new Biochemistry in Focus sections
- Topics on gluconeogenesis are now presented with glycolysis in Chapter 13
- DNA repair and recombination has been reorganized into a chapter separate from that of DNA replication (Chapters 22 and 23, respectively)
- DNA-protein interactions have been presented in context as part of regulation of gene expression in Chapter 26
- Methods content spread throughout the text has been updated and consolidated into an organized Methods Appendix

WileyPLUS Resources for Success

WileyPLUS makes it easier for you to focus on your students and easily deliver assignments that adapt to your students. With assessments you can trust, our author-branded assessment content creates a cohesive student experience. WileyPLUS allows you to meet students where they are by providing instant targeted feedback. WileyPLUS also seamlessly connects with all major learning management software systems.

Accessible resources support learners no matter their abilities.

The enriched assessment content in WileyPLUS students the opportunity to gauge their conceptual understanding and receive immediate feedback to address misconceptions.

Traditional hallmark features of WileyPLUS:

- Brief bioinformatics exercises
- Case studies
- Sample calculation videos
- Animated process diagrams
- Guided explorations
- Interactive exercises
- Test banks and lecture slides
- Answer Keys
- Image library

New to WileyPLUS for the Sixth edition:

- Interactive structural models integrated directly into the eText
- Morph animations that approximate conformational changes with many proteins
- Interactive Check Your Understanding Questions for timely self-assessment
- New WileyPlus media resources that address ten of the most difficult topics for students:
 1. Open systems and the non-equilibrium steady-state
 2. The hydrophobic effect
 3. The relationship between structure and function
 4. The relationship between primary structure and organization of R groups in 3D space
 5. Membrane dynamics and the consequences of the liquid crystalline model
 6. Energy of ES and EP, not just S and P
 7. How kinetics informs mechanics/allostery
 8. Coupled reactions and non-standard dG (pushing and pulling reactions)
 9. Coordinate control and glycolytic flux
 10. Holliday junction complex dynamics and resolution

Students and instructors will appreciate the additional resources to help them learn and teach these difficult topics.

Additional resources in WileyPLUS include assessment created around these media resources that will report to the gradebook.

Acknowledgments

We would first like to acknowledge the tremendous work and dedication that Don, Judy, and Charlotte have put into this amazing text over the years, setting the standard for biochemistry curricula. We have had the privilege of using this text for many years and have seen the tremendous impact it has had on our students and the influence it has had on biochemical pedagogy. We are honored to continue this work and to evolve this text for the next generation of students.

This edition marks a substantial update to the organization and substance of the text, and as such, has been years in the making. Along the way, we have worked with a gifted collection of colleagues who have provided their support, knowledge, and expertise in bringing the vision of this edition to fruition. Foremost, we would like to thank our team of Wiley editors, marketers, production staff, and others who played an essential role in the successful launch of this revision. In particular, we would like to thank our Developmental Editor Karen Trost, who tirelessly slogged through every word, sentence, and paragraph with us. We would also like to thank Paul Thomas (PANTHER Project) for assistance with genomics analysis, David Dixon for computational analyses, and Andrei Korostelev for lending his expertise, feedback, and ensemble cryoEM images. The excellent support team at UCSF Chimera were also critical in helping us to surmount our challenges in producing the new manipulable models, animated morphs, and hundreds of structural renderings new to this edition. Our colleagues at WPI and UA were also invaluable, and we are grateful for their help and fruitful discussions.

Finally, we would like to acknowledge our wives, Susan and Kori, our partners in life and in science. It is through their limitless patience, support, and input that our accomplishments flourish, and we are grateful to have them with us on the journey.

Aditi Das, *Georgia Tech*
 Alexander G. Zestos, *American University*
 Alexandra Masterson, *George Mason University*
 Alfredo Hernandez, *Tufts University*
 Alice H. Surovec, *Berry College*
 Allison Tracy, *UMBC*
 Andy McMillan, *Metropolitan State University of Denver*
 Anthony Amaro, *University of Jamestown*
 Arjun Sharma, *Purdue University Fort Wayne*
 Artem Domashevskiy, *John Jay College of Criminal Justice, CUNY*
 Ashley DaDalt, *University of Michigan*
 Athar Ansari, *Wayne State University*
 Bonnie Hall, *Grand View University*
 Brenna Traver, *Penn State Schuylkill*
 Brian K. Mohny, *Ashland University*
 Chavela Carr, *Texas A&M University*
 Christopher Brigham, *University of Massachusetts Dartmouth*
 Christopher Wendtland, *Monroe Community College*
 Collin T. Mant, *University of Colorado Denver*
 Daniel Marous, *Wittenberg University*
 Daniel R. Dries, *Juniata College*
 David C. Hawkinson, *University of South Dakota*

David J. Merkler, *University of South Florida*
 Debra Margaret Moriarity, *The University of Alabama in Huntsville*
 Dipak K. Ghosh, *North Carolina A and T State University*
 Dr. Chris Kule, *Pennsylvania College of Technology*
 Edith Osborne, *Angelo State University*
 Elizabeth Komives, *University of California - San Diego*
 Erik D. Holmstrom, *University of Kansas*
 Eugene Mueller, *University of Louisville*
 Francisco Villa, *Northern Arizona University*
 James Chappell, *Rice University*
 Janae Brown, *Spelman College*
 Jeff Watson, *Gonzaga University*
 Jennifer Axe, *American University*
 Joel Gaikwad, *Oral Robert's University*
 Jonathan Ouellet, *Monmouth University*
 Jon-Paul Bingham, *University of Hawaii, Manoa*
 Joseph Deweese, *Freed-Hardeman University*
 Joshua Telsler, *Roosevelt University*
 Kasandra Riley, *Rollins College*
 Kavita Shah, *Purdue University*
 Kelli Slunt, *University of Mary Washington*
 Kelly Johanson, *Xavier University of Louisiana*
 Kevin Louis Francis, *Texas A&M University - Kingsville*
 Kevin Siebenlist, *Marquette University*
 Kyle Di Vito, *Georgetown University*
 Larry Byers, *Tulane University*
 Leah Cohen, *College of Staten Island, CUNY*
 Lisa Burden, *Wheaton College*
 Lisa Gloss, *Washington State University*
 Lisa Zuraw, *The Citadel*
 Marc Harrold, *Duquesne University*
 Marie Williams Julien, *University of Michigan, Flint*
 Martin St. Maurice, *Marquette University*
 Marvin W. Makinen, *University of Chicago*
 Michael Cascio, *Duquesne University*
 Michael Marvin, *Rockhurst University*
 Michael Welsh, *Hamilton College*
 Michelle Steiger, *University of St. Thomas*
 Mindy Reynolds, *Washington College*
 Nathan Derr, *Smith College*
 Newton P. Hilliard, Jr., *Arkansas Tech University*
 Partho Ghosh, *University of California - San Diego*
 Paul DeLaLuz, *Lee University*
 Paul Himes, *University of Louisville*
 Rajendra Goswami, *IIT Chicago*
 Rebecca Switzer, *Bucknell University*
 Rene Fuanta, *East Stroudsburg University*
 Robert J. Warburton, *Shepherd University*
 Ruth Elliot, *University of Pennsylvania*
 Savita Chaurasia, *Bellarmine University*
 Shanaka Paranhewage, *Carl Albert State College*
 Shari U. Dunham, *Moravian University*
 Stephanie R. Dillon, *Florida State University*
 Steven Theg, *University of California - Davis*
 Timothy Durrett, *Kansas State University*
 Todd Eckroat, *Penn State Behrend*
 Tracey Ward, *Ferris State University*
 Wendy Pogozeleski, *SUNY Geneseo*
 William Loffredo, *East Stroudsburg University*
 WT Godbey, *Tulane University*

One- and Three-Letter Symbols for the Amino Acids^a

A	Ala	Alanine
B	Asx	Asparagine or aspartic acid
C	Cys	Cysteine
D	Asp	Aspartic acid
E	Glu	Glutamic acid
F	Phe	Phenylalanine
G	Gly	Glycine
H	His	Histidine
I	Ile	Isoleucine
K	Lys	Lysine
L	Leu	Leucine
M	Met	Methionine
N	Asn	Asparagine
O	Pyl	Pyrrolysine
P	Pro	Proline
Q	Gln	Glutamine
R	Arg	Arginine
S	Ser	Serine
T	Thr	Threonine
U	Sec	Selenocysteine
V	Val	Valine
W	Trp	Tryptophan
Y	Tyr	Tyrosine
Z	Glx	Glutamine or glutamic acid

^aThe one-letter symbol for an undetermined or nonstandard amino acid is X.

Thermodynamic Constants and Conversion Factors

Joule (J)

$$1 \text{ J} = 1 \text{ kg}\cdot\text{m}^2\cdot\text{s}^{-2} \quad 1 \text{ J} = 1 \text{ C}\cdot\text{V (coulomb-volt)}$$

$$1 \text{ J} = 1 \text{ N}\cdot\text{m (newton-meter)}$$

Calorie (cal)

$$1 \text{ cal raises temperature of 1 g of H}_2\text{O by 1 }^\circ\text{C}$$

$$1 \text{ cal} = 4.184 \text{ J}$$

Nutritional calorie (Cal)

$$1 \text{ Cal} = 1 \text{ kcal} \quad 1 \text{ Cal} = 4184 \text{ J}$$

Avogadro's number (N)

$$N = 6.0221 \times 10^{23} \text{ molecules}\cdot\text{mol}^{-1}$$

Coulomb (C)

$$1 \text{ C} = 6.241 \times 10^{18} \text{ electron charges}$$

Faraday (F)

$$1 \mathcal{F} = n \text{ electron charges}$$

$$1 \mathcal{F} = 96,485 \text{ C}\cdot\text{mol}^{-1} = 96,485 \text{ J}\cdot\text{V}^{-1}\cdot\text{mol}^{-1}$$

Kelvin temperature scale (K)

$$0 \text{ K} = \text{absolute zero} \quad 273.15 \text{ K} = 0^\circ\text{C}$$

Boltzmann constant (k_B)

$$k_B = 1.3807 \times 10^{-23} \text{ J}\cdot\text{K}^{-1}$$

Gas constant (R)

$$R = Nk_B \quad R = 1.9872 \text{ cal}\cdot\text{K}^{-1}\cdot\text{mol}^{-1}$$

$$R = 8.3145 \text{ J}\cdot\text{K}^{-1}\cdot\text{mol}^{-1} \quad R = 0.08206 \text{ L}\cdot\text{atm}\cdot\text{K}^{-1}\cdot\text{mol}^{-1}$$

The Standard Genetic Code

First Position (5' end)	Second Position				Third Position (3' end)
	U	C	A	G	
U	UUU Phe	UCU Ser	UAU Tyr	UGU Cys	U
	UUC Phe	UCC Ser	UAC Tyr	UGC Cys	C
	UUA Leu	UCA Ser	UAA Stop	UGA Stop	A
	UUG Leu	UCG Ser	UAG Stop	UGG Trp	G
C	CUU Leu	CCU Pro	CAU His	CGU Arg	U
	CUC Leu	CCC Pro	CAC His	CGC Arg	C
	CUA Leu	CCA Pro	CAA Gln	CGA Arg	A
	CUG Leu	CCG Pro	CAG Gln	CGG Arg	G
A	AUU Ile	ACU Thr	AAU Asn	AGU Ser	U
	AUC Ile	ACC Thr	AAC Asn	AGC Ser	C
	AUA Ile	ACA Thr	AAA Lys	AGA Arg	A
	AUG Met ^a	ACG Thr	AAG Lys	AGG Arg	G
G	GUU Val	GCU Ala	GAU Asp	GGU Gly	U
	GUC Val	GCC Ala	GAC Asp	GGC Gly	C
	GUA Val	GCA Ala	GAA Glu	GGA Gly	A
	GUG Val	GCG Ala	GAG Glu	GGG Gly	G

^aAUG forms part of the initiation signal as well as coding for internal Met residues.

Brief Contents

1	Introduction to the Chemistry of Life	1
2	Water	24
3	Amino Acids and Polypeptides	47
4	Proteins: Three-Dimensional Structure	69
5	Carbohydrates	123
6	Nucleotides, Nucleic Acids, and Genetic Information	152
7	Lipids and Biological Membranes	187
8	Membrane Transport	234
9	Enzymatic Catalysis	262
10	Enzyme Kinetics, Inhibition, and Control	303
11	Biochemical Signaling	343
12	Introduction to Metabolism	392
13	Glucose Metabolism	427
14	Glycogen Metabolism	485
15	Citric Acid Cycle	512
16	Electron Transport and Oxidative Phosphorylation	544
17	Photosynthesis	595
18	Lipid Metabolism	633
19	Amino Acid Metabolism	690
20	Mammalian Fuel Metabolism: Integration and Regulation	747
21	Nucleotide Metabolism	778
22	DNA Replication	810
23	DNA Repair and Recombination	839
24	Transcription and RNA Processing	875
25	Protein Synthesis	919
26	Regulation of Gene Expression	973
APPENDIX A	Methods	1051
APPENDIX B	Element Color Key	1100
	Solutions to Odd Problems	SP-1
	Glossary	G-1
	Index	I-1

1 Introduction to the Chemistry of Life 1

- 1.1 The Origin of Life 2**
- 1.1A Biological Molecules Arose from Inanimate Substances 3
 - Box 1.1 The Search for Life on Other Worlds 4
 - 1.1B Complex Self-Replicating Systems Evolved from Simple Molecules 6
- 1.2 Cellular Architecture 7**
- 1.2A Cells Carry Out Metabolic Reactions 8
 - 1.2B There Are Two Types of Cells: Prokaryotes and Eukaryotes 9
 - 1.2C Molecular Data Reveal Three Evolutionary Domains of Organisms 9
 - 1.2D Organisms Continue to Evolve 11
 - Box 1.2 Pathways of Discovery 12
- 1.3 Thermodynamics 13**
- 1.3A The First Law of Thermodynamics States That Energy Is Conserved 13
 - Box 1.3 Perspectives in Biochemistry 14
 - 1.3B The Second Law of Thermodynamics States That Entropy Tends to Increase 15
 - 1.3C The Free Energy Change Determines the Spontaneity of a Process 16
 - 1.3D Free Energy Changes Can Be Calculated from Reactant and Product Concentrations 18
 - 1.3E Life Achieves Homeostasis While Obeying the Laws of Thermodynamics 20

Summary / Key Terms / Answers to Check Your Understanding / Problems

2 Water 24

- Introduction 25
- 2.1 Physical Properties of Water 25**
- 2.1A Water Is a Polar Molecule 25
 - 2.1B Hydrophilic Substances Dissolve in Water 27
 - 2.1C The Hydrophobic Effect Causes Nonpolar Substances to Aggregate in Water 30
 - 2.1D Water Moves by Osmosis and Solutes Move by Diffusion 34
- 2.2 Chemical Properties of Water 35**
- 2.2A Water Ionizes to Form H_3O^+ and OH^- 36
 - 2.2B Acids and Bases Alter the pH 37
 - Box 2.1 Perspectives in Biochemistry 37
 - 2.2C Buffers Resist Changes in pH 40

Box 2.2 Biochemistry in Health and Disease 43

Summary / Key Terms / Answers to Check Your Understanding / Problems

3 Amino Acids and Polypeptides 47

- 3.1 Amino Acid Structure 48**
- 3.1A The Common Amino Acids Share the Same General Structure 48
 - 3.1B Amino Acids Are Zwitterions at Physiological pH 49
 - 3.1C Amino Acid Side Chains Are Nonpolar, Polar, or Charged 49
 - 3.1D The $\text{p}K_a$ Values of Ionizable Groups Depend on Nearby Groups 54
 - 3.1E Amino Acid Names Are Abbreviated 55
- 3.2 Stereochemistry 56**
- 3.2A Chiral Centers Give Rise to Enantiomers 57
 - Box 3.1 Perspectives in Biochemistry 58
 - 3.2B Life is Based on Chiral Molecules 58
- 3.3 Amino Acid Derivatives 60**
- 3.3A Protein Side Chains May Be Modified 60
 - Box 3.2 Perspectives in Biochemistry 61
 - 3.3B Some Amino Acids Are Biologically Active 61
- 3.4 Polypeptides and Proteins 63**
- 3.4A Peptide Bonds Link Amino Acids 63
 - 3.4B Primary Structure of Proteins 64

Summary / Key Terms / Answers to Check Your Understanding / Problems

4 Proteins: Three-Dimensional Structure 69

- 4.1 Secondary Structure 71**
- 4.1A The Planar Peptide Group Limits Polypeptide Conformations 72
 - 4.1B The Most Common Regular Secondary Structures Are the α Helix, the β Strand, and the P_{II} Helix 75
 - Box 4.1 Pathways of Discovery 76
 - Box 4.2 Perspectives in Biochemistry 78
 - 4.1C Proteins Also Include Nonrepetitive Structure 81
- 4.2 Tertiary Structure 82**
- 4.2A Tertiary Structures Contain Combinations of Secondary Structure 82
 - Box 4.3 Perspectives in Biochemistry 83
 - 4.2B Side Chain Location Varies with Polarity 87

4.2C	Tertiary Protein Structures Are Stabilized by Several Forces	89
4.2D	Structure Is Conserved More Than Sequence	91
4.3	Quaternary Structure and Multiprotein Complexes	93
4.3A	Proteins Assemble into Multiprotein Complexes	93
4.3B	Identical Subunits Can Be Symmetrically Arranged	93
4.3C	Diverse Proteins Can Be Assembled into Active Multiprotein Complexes	97
4.3D	Proteins Are Flexible	97
4.4	Protein Folding and Unfolding	99
4.4A	Proteins Can Be Thermally and Chemically Denatured	99
	Box 4.4 Perspectives in Biochemistry	100
4.4B	Proteins Follow Folding Pathways	101
	Box 4.5 Perspectives in Biochemistry	103
4.4C	Molecular Chaperones Assist Protein Folding	105
	Box 4.6 Protein Misfolding Can Cause Disease	108
	Biochemistry in Focus: Oxygen Transport	111
	Myoglobin Is a Monomeric Oxygen-Binding Protein	111
	Hemoglobin Is a Tetramer with Two Conformations	112
	Oxygen Binds Cooperatively to Hemoglobin	113
	Hemoglobin's Two Conformations Exhibit Different Affinities for Oxygen	114
	Summary / Key Terms / Answers to Check Your Understanding / Problems	

5 Carbohydrates 123

5.1	Monosaccharides	124
5.1A	Monosaccharides Are Aldoses or Ketoses	124
5.1B	Monosaccharides Vary in Configuration and Conformation	126
5.1C	Sugars Can Be Modified and Covalently Linked	128
5.2	Polysaccharides	131
5.2A	Lactose and Sucrose Are Disaccharides	132
	Box 5.1 Biochemistry in Health and Disease	132
	Box 5.2 Perspectives in Biochemistry	133
5.2B	Starch and Glycogen Are Storage Polysaccharides	134
5.2C	Cellulose and Chitin Are Structural Polysaccharides	136
5.2D	Glycosaminoglycans Form Highly Hydrated Gels	137
5.3	Glycoproteins	140
5.3A	Proteoglycans Contain Glycosaminoglycans	140

5.3B	Bacterial Cell Walls Are Made of Peptidoglycan	141
	Box 5.3 Biochemistry in Health and Disease	143
5.3C	Many Eukaryotic Proteins Are Glycosylated	143
5.3D	Oligosaccharides May Determine Glycoprotein Structure, Function, and Recognition	146
	Summary / Key Terms / Answers to Check Your Understanding / Problems	

6 Nucleotides, Nucleic Acids, and Genetic Information 152

6.1	Nucleotides and Polynucleotides	153
6.1A	Nucleobases, Nucleosides, and Nucleotides	153
6.1B	Polynucleotide Primary Structure	156
6.2	Nucleic Acid Structure: DNA	157
6.2A	DNA Typically Forms a Double Helix	158
6.2B	Helical Stability Depends on Hydrogen Bonding, Stacking, and Ionic Interactions	161
6.2C	DNA Can Undergo Denaturation and Renaturation	162
6.2D	Double-Stranded DNAs Can Adopt Different Secondary Structures	163
	Box 6.1 Pathways of Discovery	165
6.2E	Tertiary Structure of Double-Stranded DNA: Supercoiling	168
	Box 6.2 Biochemistry in Health and Disease	174
6.3	Nucleic Acid Structure: RNA	175
6.3A	RNA Structures Are Highly Variable	176
6.3B	Some RNAs Are Catalysts	178
	Box 6.3 Perspectives in Biochemistry	179
6.4	Overview of Nucleic Acid Function	180
6.4A	DNA Carries Genetic Information	181
6.4B	Genes Direct Protein Synthesis	182
	Summary / Key Terms / Answers to Check Your Understanding / Problems	

7 Lipids and Biological Membranes 187

7.1	Lipid Classification	188
7.1A	The Properties of Fatty Acids Depend on Their Hydrocarbon Chains	188
7.1B	Triacylglycerols Contain Three Esterified Fatty Acids	190
7.1C	Glycerophospholipids Are Amphiphilic	191
7.1D	Sphingolipids Are Amino Alcohol Derivatives	192
	Box 7.1 Biochemistry in Health and Disease	193
7.1E	Steroids Contain Four Fused Rings	194

- 7.1F Other Lipids Perform a Variety of Metabolic Roles **197**
 Box 7.2 Biochemistry in Health and Disease **200**
- 7.2 Lipid Bilayers 201**
 7.2A Bilayer Formation Is Driven by the Hydrophobic Effect **201**
 7.2B Lipid Bilayers Have Fluidlike Properties **202**
- 7.3 Membrane Proteins 204**
 7.3A There Are Several Types of Membrane Proteins **204**
 7.3B Integral Membrane Proteins Interact with Hydrophobic Lipids **205**
 7.3C Lipid-Linked Proteins Are Anchored to the Bilayer **208**
 7.3D Peripheral Membrane Proteins Associate Loosely with Membranes **210**
- 7.4 Membrane Structure and Assembly 210**
 7.4A The Fluid Mosaic Model Accounts for Lateral Diffusion **211**
 7.4B The Membrane Skeleton Helps Define Cell Shape **213**
 7.4C Membrane Lipids Are Distributed Asymmetrically **215**
 7.4D The Secretory Pathway Generates Secreted and Transmembrane Proteins **218**
 7.4E Intracellular Vesicles Transport Proteins **221**
 7.4F Proteins Mediate Vesicle Fusion **225**
 Box 7.3 Biochemistry in Health and Disease **226**

Summary / Key Terms / Answers to Check Your Understanding / Problems

8 Membrane Transport 234

- 8.1 Thermodynamics of Transport 235**
- 8.2 Passive-Mediated Transport 237**
 8.2A Ionophores Carry Ions across Membranes **237**
 8.2B Porins Contain β Barrels **239**
 8.2C Ion Channels Are Highly Selective **240**
 8.2D Aquaporins Mediate the Transmembrane Movement of Water **245**
 8.2E Transport Proteins Alternate between Two Conformations **246**
 Box 8.1 Perspectives in Biochemistry **247**
 Box 8.2 Perspectives in Biochemistry **249**
- 8.3 Active Transport 250**
 8.3A P-Type ATPases Transport Ions in Opposite Directions **251**
 Box 8.3 Biochemistry in Health and Disease **253**
 8.3B ABC Transporters Pump a Diverse Collection of Molecules and Can Be Responsible for Drug Resistance **255**

- 8.3C Active Transport May Be Driven by Ion Gradients **257**

Summary / Key Terms / Answers to Check Your Understanding / Problems

9 Enzymatic Catalysis 262

- 9.1 General Properties of Enzymes 263**
 9.1A Enzymes Differ from Ordinary Chemical Catalysts **264**
 9.1B Enzymes Are Classified by the Type of Reaction They Catalyze **264**
 9.1C Enzymes Act on Specific Substrates **265**
- 9.2 Enzymes Work by Lowering Activation Energy 267**
 9.2A Transition State Theory Explains How Enzymes Catalyze Chemical Reactions **267**
 9.2B Catalysts Reduce ΔG^\ddagger **268**
 9.2C Enzymes Preferentially Bind the Transition State **269**
 Box 9.1 Perspectives in Biochemistry **270**
- 9.3 Catalytic Mechanisms 271**
 9.3A Enzymes Often Catalyze Reactions in Association with Cofactors **271**
 Box 9.2 Perspectives in Biochemistry **272**
 9.3B Acid-Base Catalysis Occurs by Proton Transfer **273**
 Box 9.3 Perspectives in Biochemistry **274**
 9.3C Covalent Catalysis Usually Requires a Nucleophile **276**
 9.3D Metal Ion Cofactors Act as Catalysts **277**
 9.3E Catalysis Can Occur through Proximity and Orientation Effects **278**
- 9.4 Lysozyme 280**
 9.4A Lysozyme Uses Several Strategies for Catalysis **281**
 9.4B Lysozyme's Catalytic Site Was Identified through Model Building **281**
 9.4C The Lysozyme Reaction Proceeds via a Covalent Intermediate **283**
- 9.5 Serine Proteases 287**
 9.5A Active Site Residues Were Identified by Chemical Labeling **287**
 Box 9.4 Biochemistry in Health and Disease **288**
 9.5B X-Ray Structures Provide Information about Catalysis, Substrate Specificity, and Evolution **289**
 9.5C Serine Proteases Use Several Catalytic Mechanisms **292**
 9.5D Zymogens Are Inactive Enzyme Precursors **297**
 Box 9.4 Biochemistry in Health and Disease **298**

Summary / Key Terms / Answers to Check Your Understanding / Problems

10 Enzyme Kinetics, Inhibition, and Control 303

10.1 Reaction Kinetics 304

10.1A Chemical Kinetics Is Described by Rate Equations 304

10.1B Enzyme Kinetics Often Follows the Michaelis–Menten Equation 307

Box 10.1 Pathways of Discovery 309

10.1C Kinetic Data Can Provide Values of V_{\max} and K_M 312

10.1D Bisubstrate Reactions Follow One of Several Rate Equations 314

10.2 Enzyme Inhibition 316

10.2A Competitive Inhibition Involves Inhibitor Binding at an Enzyme's Substrate Binding Site 316

Box 10.2 Biochemistry in Health and Disease 318

10.2B Uncompetitive Inhibition Involves Inhibitor Binding to the Enzyme–Substrate Complex 322

10.2C Mixed Inhibition Involves Inhibitor Binding to Both the Free Enzyme and the Enzyme–Substrate Complex 324

10.3 Control of Enzyme Activity 326

10.3A Allosteric Control Involves Binding at a Site Other than the Active Site 327

10.3B Control by Covalent Modification Usually Involves Protein Phosphorylation 331

Biochemistry in Focus: Enzymes as Targets for Drug Design 335

Drug Discovery Employs a Variety of Techniques 335

A Drug's Bioavailability Depends on How It Is Absorbed and Transported in the Body 336

Clinical Trials Test for Efficacy and Safety 336

Cytochromes P450 Are Often Implicated in Adverse Drug Reactions 337

Summary / Key Terms / Answers to Check Your Understanding / Problems

11 Biochemical Signaling 343

11.1 Hormones 344

11.1A Pancreatic Islet Hormones Control Fuel Metabolism 345

Box 11.1 Pathways to Discovery 346

11.1B Epinephrine and Norepinephrine Prepare the Body for Action 347

11.1C Steroid Hormones Regulate a Wide Variety of Metabolic and Sexual Processes 348

11.1D Growth Hormone Binds to Receptors in Muscle, Bone, and Cartilage 349

11.2 Receptor Tyrosine Kinases 351

11.2A Receptor Tyrosine Kinases Transmit Signals across the Cell Membrane 351

Box 11.2 Perspectives in Biochemistry 352

11.2B Kinase Cascades Relay Signals to the Nucleus 355

Box 11.3 Biochemistry in Health and Disease 359

11.2C Some Receptors Are Associated with Nonreceptor Tyrosine Kinases 360

11.2D Protein Phosphatases Are Signaling Proteins in Their Own Right 363

11.3 Heterotrimeric G Proteins 366

11.3A G-Protein–Coupled Receptors Contain Seven Transmembrane Helices 367

11.3B Heterotrimeric G Proteins Dissociate on Activation 368

11.3C Adenylate Cyclase Synthesizes cAMP to Activate Protein Kinase A 370

Box 11.4 Biochemistry in Health and Disease 374

11.3D Phosphodiesterases Limit Second Messenger Activity 374

11.4 The Phosphoinositide Pathway 375

11.4A Ligand Binding Results in the Cytoplasmic Release of the Second Messengers IP_3 and Ca^{2+} 376

11.4B Calmodulin Is a Ca^{2+} -Activated Switch 377

11.4C DAG Is a Lipid-Soluble Second Messenger That Activates Protein Kinase C 379

11.4D Complex Systems Have Emergent Properties 380

Biochemistry in Focus: Chemical Signaling and Movement 382

Muscle Consists of Interdigitated Thick and Thin Filaments 382

Muscle Contraction Occurs When Myosin Heads Walk Up Thin Filaments 386

Summary / Key Terms / Answers to Check Your Understanding / Problems

12 Introduction to Metabolism 392

12.1 Overview of Metabolism 393

12.1A Nutrition Involves Food Intake and Use 393

12.1B Vitamins and Minerals Assist Metabolic Reactions 394

12.1C Metabolic Pathways Consist of Series of Enzymatic Reactions 395

Box 12.1 Perspectives in Biochemistry 397

12.1D Thermodynamics Dictates the Direction and Regulatory Capacity of Metabolic Pathways 399

12.1E Metabolic Flux Must Be Controlled 400

12.2 “High-Energy” Compounds 402

Box 12.2 Pathways of Discovery 403

12.2A ATP Has a High Phosphoryl Group-Transfer Potential 403

Box 12.3 Perspectives in Biochemistry 405

- 12.2B Phosphoryl Group Transfers Can Drive Endergonic Processes **406**
- 12.2C Some Other Phosphorylated Compounds Have High Phosphoryl Group-Transfer Potentials **407**
- 12.2D Thioesters Are Energy-Rich Compounds **410**
- 12.3 Oxidation–Reduction Reactions 412**
 - 12.3A NAD⁺ and FAD Are Electron Carriers **412**
 - 12.3B The Nernst Equation Describes Oxidation–Reduction Reactions **414**
 - 12.3C Spontaneity Can Be Determined by Measuring Reduction Potential Differences **416**
- 12.4 Experimental Approaches to the Study of Metabolism 419**
 - 12.4A Labeled Metabolites Can Be Traced **419**
 - 12.4B Studying Metabolic Pathways Often Involves Perturbing the System **421**
 - 12.4C Systems Biology Has Entered the Study of Metabolism **422**

Summary / Key Terms / Answers to Check Your Understanding / Problems

13 Glucose Metabolism **427**

- Box 13.1 Pathways of Discovery **429**
- 13.1 Overview of Glycolysis 430**
- 13.2 The Reactions of Glycolysis 432**
 - 13.2A Hexokinase Uses the First ATP **432**
 - 13.2B Phosphoglucose Isomerase Converts Glucose-6-Phosphate to Fructose-6-Phosphate **434**
 - 13.2C Phosphofructokinase Uses the Second ATP **435**
 - 13.2D Aldolase Converts a 6-Carbon Compound to Two 3-Carbon Compounds **436**
 - 13.2E Triose Phosphate Isomerase Interconverts Dihydroxyacetone Phosphate and Glyceraldehyde-3-Phosphate **437**
 - 13.2F Glyceraldehyde-3-Phosphate Dehydrogenase Forms the First “High-Energy” Intermediate **441**
 - 13.2G Phosphoglycerate Kinase Generates the First ATP **443**
 - 13.2H Phosphoglycerate Mutase Interconverts 3-Phosphoglycerate and 2-Phosphoglycerate **444**
 - Box 13.2 Perspectives in Biochemistry **446**
 - 13.2I Enolase Forms the Second “High-Energy” Intermediate **446**
 - 13.2J Pyruvate Kinase Generates the Second ATP **447**
- 13.3 Metabolism of Hexoses Other than Glucose 450**
 - 13.3A Fructose Is Converted to Fructose-6-Phosphate or Glyceraldehyde-3-Phosphate **450**
 - 13.3B Galactose Is Converted to Glucose-6-Phosphate **452**

- 13.3C Mannose Is Converted to Fructose-6-Phosphate **454**
- 13.4 Fermentation: The Anaerobic Fate of Pyruvate 454**
 - 13.4A The Pyruvate Produced by Glycolysis Has Three Common Fates **455**
 - 13.4B Homolactic Fermentation Converts Pyruvate to Lactate **455**
 - 13.4C Alcoholic Fermentation Converts Pyruvate to Ethanol and CO₂ **456**
 - 13.4D Fermentation Is Energetically Favorable **459**
 - Box 13.3 Perspectives in Biochemistry **460**
- 13.5 Gluconeogenesis 461**
 - 13.5A Pyruvate Is Converted to Phosphoenolpyruvate in Two Steps **461**
 - 13.5B Hydrolytic Reactions Bypass Irreversible Glycolytic Reactions **466**
- 13.6 Regulation of Glycolysis and Gluconeogenesis 466**
 - 13.6A Phosphofructokinase Is the Major Flux-Controlling Enzyme of Glycolysis in Muscle **467**
 - 13.6B Substrate Cycling Fine-Tunes Flux Control **470**
 - 13.6C Gluconeogenesis and Glycolysis Are Independently Regulated **471**
- 13.7 The Pentose Phosphate Pathway 474**
 - 13.7A NADPH and NADH Are Not Metabolically Interchangeable **474**
 - 13.7B Oxidative Reactions Produce NADPH in Stage 1 **476**
 - 13.7C Isomerization and Epimerization of Ribulose-5-Phosphate Occur in Stage 2 **477**
 - 13.7D Stage 3 Involves Carbon–Carbon Bond Cleavage and Formation **477**
 - 13.7E The Pentose Phosphate Pathway Must Be Regulated **478**
 - Box 13.4 Biochemistry in Health and Disease **480**

Summary / Key Terms / Answers to Check Your Understanding / Problems

14 Glycogen Metabolism **485**

- 14.1 Glycogen Breakdown 487**
 - Box 14.1 Pathways of Discovery **488**
 - 14.1A Glycogen Phosphorylase Degrades Glycogen to Glucose-1-Phosphate **489**
 - 14.1B Glycogen Debranching Enzyme Acts as a Glucosyltransferase **491**
 - 14.1C Phosphoglucomutase Interconverts Glucose-1-Phosphate and Glucose-6-Phosphate **492**
 - Box 14.2 Biochemistry in Health and Disease **493**
- 14.2 Glycogen Synthesis 494**
 - 14.2A UDP–Glucose Pyrophosphorylase Activates Glucosyl Units **495**

- 14.2B Glycogen Synthase Extends Glycogen Chains **496**
 - 14.2C Glycogen Branching Enzyme Transfers Seven-Residue Glycogen Segments **498**
 - 14.3 Control of Glycogen Metabolism 499**
 - 14.3A Glycogen Phosphorylase and Glycogen Synthase Are under Allosteric Control **499**
 - 14.3B Glycogen Phosphorylase and Glycogen Synthase Undergo Control by Covalent Modification **500**
 - 14.3C Glycogen Metabolism Is Subject to Hormonal Control **504**
 - 14.4 Other Carbohydrate Biosynthetic Pathways 506**
 - 14.4A Nucleotide Sugars Power the Formation of Glycosidic Bonds **506**
 - Box 14.3 Perspectives in Biochemistry **507**
 - 14.4B O-Linked Oligosaccharides Are Posttranslationally Formed **508**
 - 14.4C N-Linked Oligosaccharides Are Constructed on Dolichol Carriers **508**
 - Box 14.4 Biochemistry in Health and Disease **509**
- Summary / Key Terms / Answers to Check Your Understanding / Problems

15 Citric Acid Cycle **512**

- 15.1 Overview of the Citric Acid Cycle 514**
 - Box 15.1 Pathways of Discovery **516**
- 15.2 Synthesis of Acetyl-S-Coenzyme A 517**
 - 15.2A Pyruvate Dehydrogenase Is a Multienzyme Complex **517**
 - 15.2B The Pyruvate Dehydrogenase Complex Catalyzes Five Reactions **519**
- 15.3 Enzymes of the Citric Acid Cycle 523**
 - 15.3A Citrate Synthase Joins an Acetyl Group to Oxaloacetate **523**
 - 15.3B Aconitase Interconverts Citrate and Isocitrate **525**
 - 15.3C NAD⁺-Dependent Isocitrate Dehydrogenase Releases CO₂ **526**
 - 15.3D α -Ketoglutarate Dehydrogenase Resembles Pyruvate Dehydrogenase **527**
 - 15.3E Succinyl-S-CoA Synthetase Produces GTP **527**
 - 15.3F Succinate Dehydrogenase Generates FADH₂ **529**
 - 15.3G Fumarase Produces Malate **530**
 - 15.3H Malate Dehydrogenase Regenerates Oxaloacetate **530**
- 15.4 Regulation of the Citric Acid Cycle 531**
 - 15.4A Pyruvate Dehydrogenase Is Regulated by Product Inhibition and Covalent Modification **532**

- 15.4B Three Enzymes Control the Rate of the Citric Acid Cycle **533**
- 15.5 Reactions Related to the Citric Acid Cycle 535**
 - 15.5A Other Pathways Use Citric Acid Cycle Intermediates **535**
 - 15.5B Some Reactions Replenish Citric Acid Cycle Intermediates **537**
 - Box 15.2 Perspectives in Biochemistry **538**
 - 15.5C The Glyoxylate Cycle Shares Some Steps with the Citric Acid Cycle **539**

Summary / Key Terms / Answers to Check Your Understanding / Problems

16 Electron Transport and Oxidative Phosphorylation **544**

- 16.1 The Mitochondrion 546**
 - 16.1A Mitochondria Contain a Highly Folded Inner Membrane **546**
 - 16.1B Ions and Metabolites Enter Mitochondria via Transporters **547**
- 16.2 Electron Transport 550**
 - 16.2A Electron Transport Is an Exergonic Process **550**
 - 16.2B Electron Carriers Operate in Sequence **551**
 - 16.2C Complex I Accepts Electrons from NADH **554**
 - 16.2D Complex II Contributes Electrons to Coenzyme Q **559**
 - Box 16.1 Perspectives in Biochemistry **560**
 - 16.2E Complex III Translocates Protons via the Q Cycle **561**
 - 16.2F Complex IV Reduces Oxygen to Water **565**
- 16.3 Oxidative Phosphorylation 568**
 - 16.3A The Chemiosmotic Theory Links Electron Transport to ATP Synthesis **568**
 - Box 16.2 Pathways of Discovery **570**
 - Box 16.3 Perspectives in Biochemistry **571**
 - 16.3B The Structure of ATP Synthase Is Arranged into Two Domains **572**
 - 16.3C ATP Synthase Is Driven by the Flow of Protons **574**
- 16.4 Control of Oxidative Metabolism 580**
 - 16.4A The Rate of Oxidative Phosphorylation Depends on the ATP and NADH Concentrations **580**
 - 16.4B Oxidative Phosphorylation Can Be Uncoupled from Electron Transport **582**
 - Box 16.4 Perspectives in Biochemistry **583**
 - 16.4C Aerobic Metabolism Has Some Disadvantages **584**
 - Box 16.5 Biochemistry in Health and Disease **584**

Biochemistry in Focus: The Mitochondrion and Cell Death 586Apoptosis Is an Orderly Process **586**Mitochondrial Membrane Integrity Is Regulated **589**

Summary / Key Terms / Answers to Check Your Understanding / Problems

17 Photosynthesis 595**17.1 Chloroplasts 597**17.1A The Light Reactions Take Place in the Thylakoid Membrane **597**17.1B Pigment Molecules Absorb Light **598****17.2 The Light Reactions 601**17.2A Light Energy Is Transformed to Chemical Energy **601**17.2B Electron Transport in Photosynthetic Bacteria Follows a Circular Path **603**17.2C Two-Reaction-Center Electron Transport Is a Linear Pathway That Produces O₂ and NADPH **605**Box 17.1 Perspectives in Biochemistry **616**17.2D The Proton Gradient Drives ATP Synthesis by Photophosphorylation **616****17.3 The Dark Reactions 618**17.3A The Calvin Cycle Fixes CO₂ **618**17.3B Calvin Cycle Products Are Converted to Starch, Sucrose, and Cellulose **623**17.3C The Calvin Cycle Is Controlled Indirectly by Light **624**17.3D Photorespiration Competes with Photosynthesis **626**

Summary / Key Terms / Answers to Check Your Understanding / Problems

18 Lipid Metabolism 633**18.1 Lipid Digestion, Absorption, and Transport 634**18.1A Triacylglycerols Are Digested before They Are Absorbed **635**18.1B Lipids Are Transported as Lipoproteins **637****18.2 Fatty Acid Oxidation 641**18.2A Fatty Acids Are Activated by Their Attachment to Coenzyme A **642**18.2B Carnitine Carries Acyl Groups across the Mitochondrial Membrane **643**18.2C β Oxidation Degrades Fatty Acids to Acetyl-SCoA **644**18.2D Oxidation of Unsaturated Fatty Acids Requires Additional Enzymes **647**18.2E Oxidation of Odd-Chain Fatty Acids Yields Propionyl-SCoA **649**Box 18.1 Pathways of Discovery **651**18.2F Peroxisomal β Oxidation Differs from Mitochondrial β Oxidation **654**18.2G Ketone Bodies **655****18.3 Fatty Acid Biosynthesis 657**18.3A Mitochondrial Acetyl-SCoA Must Be Transported into the Cytosol **658**18.3B Acetyl-CoA Carboxylase Produces Malonyl-SCoA **659**18.3C Fatty Acid Synthase Catalyzes Seven Reactions **659**18.3D Fatty Acids May Be Elongated and Desaturated **664**18.3E Fatty Acids Are Esterified to Form Triacylglycerols **665**18.3F Regulation of Fatty Acid Metabolism **667****18.4 Synthesis of Other Lipids 669**18.4A Glycerophospholipids Are Built from Intermediates of Triacylglycerol Synthesis **670**18.4B Sphingolipids Are Built from Palmitoyl-SCoA and Serine **673**Box 18.2 Biochemistry in Health and Disease **674**18.4C C₂₀ Fatty Acids Are the Precursors of Prostaglandins **675****18.5 Cholesterol Metabolism 677**18.5A Cholesterol Is Synthesized from Acetyl-SCoA **677**18.5B HMG-CoA Reductase Controls the Rate of Cholesterol Synthesis **681**18.5C Abnormal Cholesterol Transport Leads to Atherosclerosis **683**

Summary / Key Terms / Answers to Check Your Understanding / Problems

19 Amino Acid Metabolism 690**19.1 Protein Degradation 691**19.1A Lysosomes Degrade Many Proteins **692**19.1B Ubiquitin Marks Proteins for Degradation **692**19.1C The Proteasome Unfolds and Hydrolyzes Ubiquitinated Polypeptides **694****19.2 Amino Acid Deamination and the Urea Cycle 697**19.2A Transaminases Use PLP to Transfer Amino Groups **698**19.2B Glutamate Can Be Oxidatively Deaminated **700**19.2C The Urea Cycle Packages Nitrogen for Excretion **701**19.2D The Urea Cycle Is Regulated by Substrate Availability **705****19.3 Breakdown of Amino Acids 706**19.3A Alanine, Cysteine, Glycine, Serine, and Threonine Are Degraded to Pyruvate **706**

- 19.3B Asparagine and Aspartate Are Degraded to Oxaloacetate **709**
- 19.3C Arginine, Glutamate, Glutamine, Histidine, and Proline Are Degraded to α -Ketoglutarate **709**
- 19.3D Methionine, Threonine, Isoleucine, and Valine Are Degraded to Succinyl-S-CoA **710**
- Box 19.1 Biochemistry in Health and Disease **714**
- 19.3E Leucine and Lysine Are Degraded Only to Acetyl-S-CoA and/or Acetoacetate **715**
- 19.3F Tryptophan Is Degraded to Alanine and Acetoacetate **717**
- 19.3G Phenylalanine and Tyrosine Are Degraded to Fumarate and Acetoacetate **718**
- Box 19.2 Biochemistry in Health and Disease **719**
- 19.4 Amino Acid Biosynthesis 720**
- 19.4A Nonessential Amino Acids Are Synthesized from Common Metabolites **721**
- 19.4B Plants and Microorganisms Synthesize the Essential Amino Acids **725**
- 19.5 Other Products of Amino Acid Metabolism 731**
- 19.5A Heme Is Synthesized from Glycine and Succinyl-S-CoA **731**
- Box 19.3 Biochemistry in Health and Disease **733**
- 19.5B Amino Acids Are Precursors of Physiologically Active Amines **735**
- 19.5C Nitric Oxide Is Derived from Arginine **736**
- Biochemistry in Focus: Nitrogen Fixation 738**
- Nitrogenase Reduces N_2 to NH_3 **739**
- Fixed Nitrogen Is Assimilated into Biological Molecules **741**

Summary / Key Terms / Answers to Check Your Understanding / Problems

20 Mammalian Fuel Metabolism: Integration and Regulation **747**

- 20.1 Organ Specialization 748**
- Box 20.1 Biochemistry in Health and Disease **751**
- 20.1A The Brain Requires a Steady Supply of Glucose **751**
- 20.1B Muscle Utilizes Glucose, Fatty Acids, and Ketone Bodies **751**
- 20.1C Adipose Tissue Stores and Releases Fatty Acids and Hormones **753**
- 20.1D Liver Is the Body's Central Metabolic Clearinghouse **753**
- 20.1E Kidney Filters Wastes and Maintains Blood pH **755**
- 20.1F Blood Transports Metabolites in Interorgan Metabolic Pathways **755**
- 20.2 Hormonal Control of Fuel Metabolism 757**
- 20.2A Insulin Release Is Triggered by Glucose **757**

- 20.2B Glucagon and Catecholamines Counter the Effects of Insulin **759**

20.3 Metabolic Homeostasis: The Regulation of Energy Metabolism, Appetite, and Body Weight **762**

- 20.3A AMP-Dependent Protein Kinase Is the Cell's Fuel Gauge **762**
- 20.3B Adipocytes and Other Tissues Help Regulate Fuel Metabolism and Appetite **763**
- 20.3C Energy Expenditure Can Be Controlled by Adaptive Thermogenesis **765**
- 20.4 Disturbances in Fuel Metabolism 766**
- 20.4A Starvation Leads to Metabolic Adjustments **766**
- 20.4B Diabetes Mellitus Is Characterized by High Blood Glucose Levels **768**
- Box 20.2 Pathways of Discovery **769**
- 20.4C Obesity Is Usually Caused by Excessive Food Intake **771**
- 20.4D Cancer Metabolism **772**

Summary / Key Terms / Answers to Check Your Understanding / Problems

21 Nucleotide Metabolism **778**

- 21.1 Synthesis of Purine Ribonucleotides 779**
- 21.1A Purine Synthesis Yields Inosine Monophosphate **780**
- 21.1B IMP Is Converted to Adenine and Guanine Ribonucleotides **783**
- 21.1C Purine Nucleotide Biosynthesis Is Regulated at Several Steps **784**
- 21.1D Purines Can Be Salvaged **785**
- 21.2 Synthesis of Pyrimidine Ribonucleotides 786**
- 21.2A UMP Is Synthesized in Six Steps **786**
- 21.2B UMP Is Converted to UTP and CTP **788**
- 21.2C Pyrimidine Nucleotide Biosynthesis Is Regulated at ATCase or Carbamoyl Phosphate Synthetase II **788**
- 21.3 Formation of Deoxyribonucleotides 790**
- 21.3A Ribonucleotide Reductase Converts Ribonucleotides to Deoxyribonucleotides **790**
- 21.3B dUMP Is Methylated to Form Thymine **794**
- Box 21.1 Biochemistry in Health and Disease **798**
- 21.4 Nucleotide Degradation 799**
- 21.4A Purine Catabolism Yields Uric Acid **800**
- 21.4B Some Animals Degrade Uric Acid **803**
- Box 21.2 Pathways of Discovery **805**
- 21.4C Pyrimidines Are Broken Down to Malonyl-S-CoA and Methylmalonyl-S-CoA **806**

Summary / Key Terms / Answers to Check Your Understanding / Problems

22 DNA Replication 810

- 22.1 Overview of DNA Replication 811**
 - 22.1A DNA Is Synthesized in the 5'→3' Direction 812
 - 22.1B DNA Synthesis Extends RNA Primers 814
- 22.2 Prokaryotic DNA Replication 815**
 - 22.2A DNA Polymerases Add Correctly Paired Nucleotides 815
 - Box 22.1 Pathways of Discovery 816
 - 22.2B Replication Initiation and Elongation Require Helicase and Primase 820
 - 22.2C The Leading and Lagging Strands Are Synthesized Simultaneously 823
 - 22.2D Replication Terminates at Specific Sites 827
 - 22.2E DNA Is Replicated with High Fidelity 829
- 22.3 Eukaryotic DNA Replication 829**
 - 22.3A Eukaryotes Use Several DNA Polymerases 830
 - Box 22.2 Perspectives in Biochemistry 831
 - 22.3B Eukaryotic DNA Is Replicated from Multiple Origins 832
 - 22.3C Telomerase Extends Chromosome Ends 833
 - Box 22.3 Biochemistry in Health and Disease 835

Summary / Key Terms / Answers to Check Your Understanding / Problems

23 DNA Repair and Recombination 839

- 23.1 DNA Damage 840**
 - 23.1A Environmental and Chemical Agents Generate Mutations 841
 - Box 23.1 Perspectives in Biochemistry 843
 - 23.1B Many Mutagens Are Carcinogens 844
- 23.2 DNA Repair 845**
 - 23.2A Some Damage Can Be Directly Reversed 846
 - 23.2B Base Excision Repair Requires a Glycosylase 846
 - Box 23.2 Perspectives in Biochemistry 847
 - 23.2C Nucleotide Excision Repair Removes a Segment of a DNA Strand 848
 - 23.2D Mismatch Repair Corrects Replication Errors 850
 - 23.2E Some DNA Repair Mechanisms Introduce Errors 852
- 23.3 Recombination and Transposons 854**
 - 23.3A Homologous Recombination Involves Several Protein Complexes 854
 - 23.3B DNA Can Be Repaired by Recombination 860
 - 23.3C Transposition Rearranges Segments of DNA 862

Biochemistry in Focus: Antibodies 866

- Antibodies Have Constant and Variable Regions 866
- Classes of Human Immunoglobulins 866
- Antibodies Recognize a Huge Variety of Antigens 867
- Some Antibody-Mediated Autoimmune Diseases 871

Summary / Key Terms / Answers to Check Your Understanding / Problems

24 Transcription and RNA Processing 875

- 24.1 Prokaryotic RNA Transcription 876**
 - 24.1A RNA Polymerase Resembles Other Polymerases 877
 - 24.1B Transcription Is Initiated at a Promoter 879
 - 24.1C The RNA Chain Elongates from the 5' to 3' End 881
 - Box 24.1 Perspectives in Biochemistry 882
 - 24.1D Transcription Terminates at Specific Sites 883
- 24.2 Transcription in Eukaryotes 886**
 - 24.2A Eukaryotes Have Several RNA Polymerases 886
 - Box 24.2 Biochemistry in Health and Disease 887
 - 24.2B Each Polymerase Recognizes a Different Type of Promoter 891
 - 24.2C Transcription Factors Are Required to Initiate Transcription 893
- 24.3 Posttranscriptional Processing 898**
 - 24.3A Messenger RNAs Undergo 5' Capping and Addition of a 3' Tail 898
 - 24.3B Splicing Removes Introns from Eukaryotic Genes 901
 - Box 24.3 Pathways of Discovery 902
 - 24.3C Ribosomal RNA Precursors May Be Cleaved, Modified, and Spliced 910
 - 24.3D Transfer RNAs Are Processed by Nucleotide Removal, Addition, and Modification 913

Summary / Key Terms / Answers to Check Your Understanding / Problems

25 Protein Synthesis 919

- 25.1 The Genetic Code 920**
 - 25.1A Codons Are Triplets That Are Read Sequentially 921
 - 25.1B The Genetic Code Was Systematically Deciphered 922
 - 25.1C The Genetic Code Is Degenerate and Nonrandom 923
 - Box 25.1 Perspectives in Biochemistry 925

- 25.2 Transfer RNA and Its Aminoacylation 926**
 25.2A All tRNAs Have Similar Structures 926
 25.2B Aminoacyl-tRNA Synthetases Attach Amino Acids to tRNAs 928
 25.2C Most tRNAs Recognize More than One Codon 933
 Box 25.2 Perspectives in Biochemistry 934
- 25.3 Ribosomes 935**
 25.3A The Prokaryotic Ribosome Consists of Two Subunits 935
 25.3B The Eukaryotic Ribosome Contains a Buried Prokaryotic Ribosome 941
- 25.4 Translation 943**
 25.4A Chain Initiation Requires an Initiator tRNA and Initiation Factors 944
 25.4B The Ribosome Decodes the mRNA, Catalyzes Peptide Bond Formation, Then Moves to the Next Codon 950
 Box 25.3 Biochemistry in Health and Disease 960
 25.4C Release Factors Terminate Translation 961
- 25.5 Posttranslational Processing 964**
 25.5A Ribosome-Associated Chaperones Help Proteins Fold 965
 25.5B Newly Synthesized Proteins May Be Covalently Modified 966
- Summary / Key Terms / Answers to Check Your Understanding / Problems

26 Regulation of Gene Expression 973

- 26.1 Genome Organization 974**
 26.1A Gene Number Varies among Organisms 975
 26.1B Some Genes Occur in Clusters 978
 26.1C Eukaryotic Genomes Contain Repetitive DNA Sequences 979
 Box 26.1 Biochemistry in Health and Disease 980
- 26.2 Regulation of Prokaryotic Gene Expression 984**
 26.2A The *lac* Operon Is Controlled by a Repressor 984
 26.2B Catabolite-Repressed Operons Can Be Activated 989
 26.2C Attenuation Regulates Transcription Termination 990
 Box 26.2 Perspectives in Biochemistry 993
 26.2D Riboswitches Are Metabolite-Sensing RNAs 994
- 26.3 Eukaryotic Chromosome Structure 996**
 26.3A DNA Coils around Histones to Form Nucleosomes 996
 26.3B Chromatin Forms Higher-Order Structures 999
- 26.4 Regulation of Eukaryotic Gene Expression 1003**

- 26.4A Chromatin Structure Influences Gene Expression 1003
 Box 26.3 Perspectives in Biochemistry 1005
 26.4B Eukaryotic Transcription Factors May Include Zinc Fingers or Leucine Zippers 1015
 26.4C Eukaryotes Contain Multiple Transcriptional Activators 1019
 26.4D Posttranscriptional Control Mechanisms 1025
 Box 26.4 Perspectives in Biochemistry 1026
- 26.5 The Cell Cycle, Cancer, and Development 1032**
 26.5A Progress through the Cell Cycle Is Tightly Regulated 1033
 26.5B Tumor Suppressors Prevent Cancer 1035
 26.5C Development Has a Molecular Basis 1038

Biochemistry in Focus: CRISPR-Cas9, a System for Editing and Regulating Genomes 1044

Summary / Key Terms / Answers to Check Your Understanding / Problems

Appendix A Methods 1051

- A.1 Biomolecule Purification and Analysis 1052**
 A.1A Purifying a Biomolecule Requires a Strategy 1052
 A.1B Salting Out Separates Proteins by Their Solubility 1055
 A.1C Chromatography Involves Interaction with Mobile and Stationary Phases 1055
 A.1D Electrophoresis Separates Molecules According to Charge and Size 1059
 A.1E Ultracentrifugation Separates Macromolecules by Mass 1063
- A.2 Protein Sequencing 1064**
 A.2A Disruption of Quaternary Structure 1064
 A.2B The Polypeptide Chains Are Cleaved 1067
 A.2C Edman Degradation Removes a Peptide's N-Terminal Amino Acid Residue 1069
 A.2D Peptides Can Be Sequenced by Mass Spectrometry 1070
 A.2E Reconstructed Protein Sequences Are Stored in Databases 1071
 A.2F Protein Sequences Reveal Evolutionary Relationships 1073
- A.3 Nucleic Acid Sequencing 1076**
 A.3A Restriction Endonucleases Cleave DNA at Specific Sequences 1077
 A.3B Traditional DNA Sequencing Uses the Chain-Terminator Method 1078
 A.3C Next-Generation Sequencing Technologies Are Massively Parallel 1080
 A.3D Entire Genomes Have Been Sequenced 1081

A.3E Evolution Results from Sequence Mutations	1083
A.4 Manipulating DNA	1085
A.4A Cloned DNA Is an Amplified Copy	1085
A.4B DNA Libraries Are Collections of Cloned DNA	1088
A.4C DNA Is Amplified by the Polymerase Chain Reaction	1090
A.4D Recombinant DNA Technology Has Numerous Practical Applications	1091
A.5 Structural Methods	1094
A.5A Circular Dichroism Spectroscopy Provides Low-Resolution Determination of Secondary Structure	1094
A.5B X-Ray Crystallography Directly Images Molecules in Crystals	1095
A.5C Structures Can Be Determined in Solution by NMR Spectroscopy	1096
A.5D Cryo-Electron Microscopy Directly Images Large Macromolecular Structures	1098
Appendix B Element Color Key	1100
<hr/>	
Solutions to Odd Problems	SP-1
<hr/>	
Glossary	G-1
<hr/>	
Index	I-1
<hr/>	



A variety of complex organic molecules can be found in interstellar gas and dust. The large molecular clouds that give rise to stellar nurseries like those found in this image of the Cederblad 214 nebula (found in the direction of the constellation Cepheus) have been found to contain complex hydrocarbons. These include polycyclic aromatics and many smaller precursor molecules containing carbon, nitrogen, and oxygen that are important constituents of life on Earth. [Photograph by D. Heilman.]

Introduction to the Chemistry of Life

CHAPTER CONTENTS

1.1. The Origin of Life

- A.** Biological Molecules Arose from Inanimate Substances
- B.** Complex Self-Replicating Systems Evolved from Simple Molecules

1.2. Cellular Architecture

- A.** Cells Carry Out Metabolic Reactions
- B.** There Are Two Types of Cells: Prokaryotes and Eukaryotes
- C.** Molecular Data Reveal Three Evolutionary Domains of Organisms
- D.** Organisms Continue to Evolve

1.3. Thermodynamics

- A.** The First Law of Thermodynamics States That Energy Is Conserved
- B.** The Second Law of Thermodynamics States That Entropy Tends to Increase
- C.** The Free Energy Change Determines the Spontaneity of a Process
- D.** Free Energy Changes Can Be Calculated from Reactant and Product Concentrations
- E.** Life Achieves Homeostasis While Obeying the Laws of Thermodynamics

Life on Earth arose from rather curious beginnings. Approximately 4.5 billion years ago our planet formed from a complex soup of interstellar material orbiting a relatively average, newborn dwarf star. Within that soup were precursors—complex, carbon-rich molecules with a penchant for self-assembly—which would combine and grow in complexity and versatility. This would lead to complex molecular systems that could self-replicate and in the process, iterate: a recipe for evolution. Eventually organisms would emerge capable of highly complex interactions with the environment. Extracting energy from chemical compounds or the sun, they converted this into a bewildering array of complex biomolecules from which life would continue to evolve. The Earth underwent a dramatic transition from a desolate and barren place, to a world utterly teeming with life. Through these origins, organisms on Earth have a common ancestry and therefore share the same chemical makeup; there is a single chemical theme that connects all life on this planet. We have a staggeringly diverse and wonderfully complex array of organisms to inform our understanding of life, but we are also profoundly limited in having only one version of life from which to learn. However, the Earth is not the only place where such biological precursor molecules are found. Curiously, the molecules of life are everywhere. The great cosmic spaces between the stars contain clouds of gas and dust that harbor a myriad of complex organic molecules. Ancient asteroids flung from far away worlds and comets from the outer reaches of the solar system do as well. These may have seeded life on other worlds, including our own. The Earth is but one planet among many worlds in a single solar system; it resides in a galaxy with hundreds of billions of solar systems, in a universe with hundreds of billions of galaxies. The molecules of life are everywhere. Is life then unique to Earth, or a common occurrence throughout the universe? We, who evolved from humble and curious beginnings, stand able to explore these mysteries as well as that of our own origins.

Biochemistry is the study of the chemistry of life, which describes how the properties and interactions of the vast array of biological molecules results in the amazing and diverse living systems on Earth. This chapter will discuss the potential origins of life, and the common biological forms and natural trends that are observed, all of which adhere to the same fundamental principles of chemistry and physics to which you have already been introduced. The precise point at which these systems are considered life is a subject of continuing debate, and care is taken not to apply generalizations or unduly restrict our definitions, as science continues to challenge and expand our understanding. The Earth contains a vast and diverse range of organisms that thrive in the most lush and accommodating of habitats on land and sea, but also in utterly dark, scorching, and forbidding environments where we would least expect to find life. We are continually surprised and delighted by the exotic and profound ways in which life can exist. There is much yet to be discovered both on Earth, and perhaps, on other worlds.

1.1 The Origin of Life

LEARNING OUTCOMES

After reading this section, you will be able to:

Discuss the origins and evolution of biological molecules.

- Describe the general composition of biological molecules.
- Identify the common functional groups found in biochemistry.
- Explain the chemical evolution of complex molecules from simple precursors.
- Discuss the concept of chemical complementarity and its importance in self-replication of biological polymers.


1.1A Biological Molecules Arose from Inanimate Substances

Living matter consists of a relatively small number of elements (Table 1.1). For example, C, H, O, N, P, Ca, and S account for ~97% of the dry weight of the human body (humans and most other organisms are ~70% water). Living organisms may also contain trace amounts of many other elements, including B, F, Al, Si, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, As, Se, Br, Mo, Cd, I, and W, although not every organism makes use of each of these substances.

The earliest known fossil evidence of life is ~3.5 billion years old (Fig. 1.1). The preceding **prebiotic era**, which began with the formation of the earth ~4.6 billion years ago, left no direct record, but scientists can experimentally duplicate the sorts of chemical reactions that might have given rise to living organisms during that billion-year period.

The atmosphere of the early earth probably consisted of small, simple compounds such as H₂O, N₂, CO₂, and smaller amounts of CH₄ and NH₃. In the 1920s, Alexander Oparin and J. B. S. Haldane independently suggested that ultraviolet radiation from the sun or lightning discharges caused the molecules of the primordial atmosphere to react to form simple **organic** (carbon-containing) **compounds**. This process was replicated in 1953 by Stanley Miller and Harold Urey, who subjected a mixture of H₂O, CH₄, NH₃, and H₂ to an electric discharge for about a week. Miller's analysis showed that the solution contained several amino acids (which are components of proteins) and other biochemically significant compounds. Following Miller's death in 2007, several sealed vials from the original experiment were analyzed using modern techniques, resulting in detection of over 40 different amino acids and amines. Many research groups have performed similar experiments with the benefit of modern technology and have found a multitude of complex molecules including many more amino acids, dipeptides (simple protein chains), complex cyclic hydrocarbons, and the complete palette of nucleotide bases (building blocks of DNA and RNA). Clearly, these precursors to complex biomolecules were more readily available during the formation of the Earth than previously understood.

Scientists have also suggested that early biological molecules were generated in quite a different way: in the dark and under water. Hydrothermal vents in the ocean floor, which emit solutions of metal sulfides at temperatures as high as 400 °C (Fig. 1.2), may have provided conditions




Courtesy of J. William Schopf, UCLA

FIGURE 1.1 Microfossil of filamentous bacterial cells. This fossil (shown with an interpretive drawing) is from ~3.4-billion-year-old rock from Western Australia.

Element	Dry Weight (%)
C	61.7
N	11.0
O	9.3
H	5.7
Ca	5.0
P	3.3
K	1.3
S	1.0
Cl	0.7
Na	0.7
Mg	0.3

^a Calculated from Frieden, E., *Sci. Am.* 227(1), 54–55 (1972).



OAR / National Undersea Research Program (NURP) / NOAA / Public Domain


FIGURE 1.2 A hydrothermal vent. Such ocean-floor formations are known as “black smokers” because the metal sulfides dissolved in the superheated water they emit precipitate on encountering the much cooler ocean water.

suitable for the formation of amino acids and other small organic molecules from simple compounds present in seawater.

Both of these theories assume a terrestrial origin for early biological molecules, however research indicates that complex biological precursors can also form in the most distant and surprising of places. Nebulae, rich in gas and dust, are ripe with a diverse array of complex carbon compounds. Laboratory experiments conducted by NASA have produced biological precursors under conditions found only in space. Missions that have remotely sampled and analyzed the chemistry of other planets, comets, and asteroids have discovered a wealth of biological precursor molecules. Notably, researchers have found the building blocks of protein and DNA in meteor fragments that are older than the age of the solar system (**Box 1.1**). It's possible that the precursor to life on Earth was seeded from space.

Whatever their actual origin, the early organic molecules became the precursors of an enormous variety of biological molecules. These can be classified in various ways, depending on their composition and chemical reactivity. A familiarity with organic chemistry is useful for recognizing the **functional groups** (reactive portions) of molecules as well as the linkages (bonding arrangements) among them, since these features ultimately determine the biological activity of the molecules. Some of the common functional groups and linkages in biological molecules are shown in **Table 1.2**.

Box 1.1 The Search for Life on Other Worlds



NASA/JPL-Caltech / MSSS / Public Domain

We on Earth are fortunate to have a wealth of organisms to study and understand life. However, all evidence indicates that life on Earth evolved from a common ancestor and as such, all organisms share the same origin, chemical makeup, and strict dependence on liquid water. Are these the only conditions under which life can form? Is life on Earth unique and are we the sole example in the universe? Many biochemists are preoccupied with such questions and with exploring other possible ways that life may form. The discovery of organisms on Earth that thrive in extreme conditions of temperature, pH, and salinity has changed our understanding of where life might flourish. Organisms such as extreme thermophiles survive in utter darkness where temperatures can exceed 100 °C and with pH values as low as 1.5. Many of these organisms use sulfur instead of oxygen in their metabolism and extract energy from chemical compounds instead of using photosynthesis. From the scorching interiors of volcanic fumaroles to the frozen, arid arctic tundra, organisms have adapted to these hostile environments, serving as a strong indication that we may find life existing under similar conditions on other worlds. Jupiter's moon Io is a world of volcanism, stretched and squeezed by the planet's gravity. Europa, another of Jupiter's moons, is an icy world that is likely to have a subsurface ocean warmed by geothermal energy. It is possible that

life could exist on these worlds in our relative backyard where we have, and will continue to, send probes. It is also possible that life may be able to form in solvents other than water, perhaps on the liquid oceans of ethane that exist on Saturn's moon, Titan. Biochemists are studying the types of molecules and chemical strategies for life that might be possible in such a hydrophobic environment.

Exploration of our solar system is now ripe with robotic missions, many of which have the capability to identify complex molecular precursors or conditions under which life could thrive. The NASA Curiosity rover determined that liquid water as well as the chemical building blocks and nutrients needed for supporting life had been present for at least tens of millions of years on Mars. Curiosity's twin, Perseverance followed a number of years later with an enhanced mission to search for signs of ancient life. Deeper into the solar system, probes have been sent to comets and asteroids, representing early steps in studying these distant and ancient bodies. The European Space Agency (ESA) Rosetta mission was the first to orbit a comet nucleus and to land a probe (Philae) on its surface. The Japan Aerospace Exploration Agency (JAXA) successfully sampled the asteroid Ryugu and returned a capsule with material to Earth. Analysis of the material revealed precursor amino acids, complex cyclic aromatic hydrocarbons, and other carbon and nitrogen-containing compounds.

The detection of life on worlds beyond our solar system requires the use of powerful telescopes capable of detecting potentially habitable planets, and the molecular signatures of life, from great distances. NASA's Kepler mission, which surveyed over 500,000 stars in one region of our galaxy, concluded that, on average, nearly every star has at least one planet. Kepler discovered thousands of exoplanets, some of which are rocky planets in habitable zones where liquid water might exist. Missions including the James Webb Space Telescope will assist with follow-up analysis of candidate exoplanet atmospheres with spectroscopic detection of molecules from afar. Evidence gathered so far indicates that the possibility of finding life elsewhere may be much greater than we might have imagined.

TABLE 1.2 Common Functional Groups and Linkages in Biochemistry

Compound Name	Structure ^a	Functional Group or Linkage
Amine ^b	RNH ₂ or R ⁺ NH ₃ R ₂ NH or R ₂ ⁺ NH ₂ R ₃ N or R ₃ ⁺ NH	$\text{—N} \begin{array}{l} \diagup \\ \diagdown \end{array}$ or $\text{—N}^+ \begin{array}{l} \\ \\ \end{array}$ (amino group)
Alcohol	ROH	—OH (hydroxyl group)
Thiol	RSH	—SH (sulfhydryl group)
Ether	ROR	—O— (ether linkage)
Aldehyde	$\begin{array}{c} \text{O} \\ \\ \text{R—C—H} \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{—C—} \end{array}$ (carbonyl group)
Ketone	$\begin{array}{c} \text{O} \\ \\ \text{R—C—R} \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{—C—} \end{array}$ (carbonyl group)
Carboxylic acid ^b	$\begin{array}{c} \text{O} \\ \\ \text{R—C—OH} \end{array}$ or $\begin{array}{c} \text{O} \\ \\ \text{R—C—O}^- \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{—C—OH} \end{array}$ (carboxyl group) or $\begin{array}{c} \text{O} \\ \\ \text{—C—O}^- \end{array}$ (carboxylate group)
Ester	$\begin{array}{c} \text{O} \\ \\ \text{R—C—OR} \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{—C—O—} \end{array}$ (ester linkage) $\begin{array}{c} \text{O} \\ \\ \text{R—C—} \end{array}$ (acyl group) ^c
Thioester	$\begin{array}{c} \text{O} \\ \\ \text{R—C—SR} \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{—C—S—} \end{array}$ (thioester linkage) $\begin{array}{c} \text{O} \\ \\ \text{R—C—} \end{array}$ (acyl group) ^c
Amide	$\begin{array}{c} \text{O} \\ \\ \text{R—C—NH}_2 \\ \text{O} \\ \\ \text{R—C—NHR} \\ \text{O} \\ \\ \text{R—C—NR}_2 \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{—C—N} \begin{array}{l} \diagup \\ \diagdown \end{array} \end{array}$ (amido group) $\begin{array}{c} \text{O} \\ \\ \text{R—C—} \end{array}$ (acyl group) ^c
Imine (Schiff base) ^b	R=NH or R= ⁺ NH ₂ R=NR or R= ⁺ NHR	>C=N— or $\text{>C=N}^+ \begin{array}{l} \diagup \\ \diagdown \end{array}$ (imino group)
Disulfide	R—S—S—R	—S—S— (disulfide linkage)
Phosphate ester ^b	$\begin{array}{c} \text{O} \\ \\ \text{R—O—P—O}^- \\ \\ \text{OH} \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{—P—O}^- \\ \\ \text{OH} \end{array}$ (phosphoryl group)
Diphosphate ester ^b	$\begin{array}{c} \text{O} \quad \text{O} \\ \quad \\ \text{R—O—P—O—P—O}^- \\ \quad \\ \text{O}^- \quad \text{OH} \end{array}$	$\begin{array}{c} \text{O} \quad \text{O} \\ \quad \\ \text{—P—O—P—O}^- \\ \quad \\ \text{O}^- \quad \text{OH} \end{array}$ (phosphoanhydride group)
Phosphate diester ^b	$\begin{array}{c} \text{O} \\ \\ \text{R—O—P—O—R} \\ \\ \text{O}^- \end{array}$	$\begin{array}{c} \text{O} \\ \\ \text{—O—P—O—} \\ \\ \text{O}^- \end{array}$ (phosphodiester linkage)

^a R represents any carbon-containing group. In a molecule with more than one R group, the groups may be the same or different.

^b Under physiological conditions, these groups are ionized and hence bear a positive or negative charge.

^c If attached to an atom other than carbon.

Question Cover the Structure column and draw the structure for each compound listed on the left. Do the same for each functional group or linkage.




FIGURE 1.3 Reaction of a carboxylic acid with an amine. The elements of water are released during condensation. In the reverse process—hydrolysis—water is added to cleave the amide bond. In living systems, condensation reactions are not freely reversible.

Polymer	Monomer
Protein (polypeptide)	Amino acid
Nucleic acid (polynucleotide)	Nucleotide
Polysaccharide (complex carbohydrate)	Monosaccharide (simple carbohydrate)

1.1B Complex Self-Replicating Systems Evolved from Simple Molecules

Evolution During a period of chemical evolution, the prebiotic era, simple organic molecules condensed to form more complex molecules or combined end-to-end as **polymers** of repeating units. In a **condensation reaction**, the elements of water are lost. The rate of condensation of simple compounds to form a stable polymer must therefore be greater than the rate of **hydrolysis** (splitting by adding the elements of water; Fig. 1.3). In this prebiotic environment, minerals such as clays may have catalyzed polymerization reactions and sequestered the reaction products from water. The size and composition of prebiotic macromolecules would have been limited by the availability of small molecular starting materials, the efficiency with which they could be joined, and their resistance to degradation. The major biological polymers and their individual units (**monomers**) are given in Table 1.3.

Obviously, *combining different monomers and their various functional groups into a single large molecule increases the chemical versatility of that molecule*, allowing it to perform chemical feats beyond the reach of simpler molecules. (This principle of emergent properties can be expressed as “the whole is greater than the sum of its parts.”) Separate macromolecules with **complementary arrangements** (reciprocal pairing) of functional groups can associate with one another (Fig. 1.4), giving rise to more complex molecular assemblies with an even greater range of functional possibilities.

Specific pairing between complementary functional groups permits one member of a pair to determine the identity and orientation of the other member. *Such complementarity makes it possible for a macromolecule to replicate, or copy itself, by directing the assembly of a new molecule from smaller complementary units.* Replication of a simple polymer with intramolecular complementarity is illustrated in Fig. 1.5. A similar phenomenon is central to the function of DNA, where the sequence of bases on one strand (e.g., A-C-G-T)




FIGURE 1.4 Association of complementary molecules. The positively-charged amino group interacts electrostatically with the negatively-charged carboxylate group.




FIGURE 1.5 Replication through complementarity. In this simple case, a polymer serves as a template for the assembly of a complementary molecule, which, because of intramolecular complementarity, is an exact copy of the original.

Question Distinguish the covalent bonds from the noncovalent interactions in this polymer.

absolutely specifies the sequence of bases on the strand to which it is paired (T-G-C-A). When DNA replicates, the two strands separate and direct the synthesis of complementary daughter strands. Complementarity is also the basis for transcribing DNA into RNA and for translating RNA into protein.

A critical moment in chemical evolution was the transition from systems of randomly generated molecules to systems in which molecules were organized and specifically replicated. Once macromolecules gained the ability to self-perpetuate, the primordial environment would have become enriched in molecules that were best able to survive and multiply. The first replicating systems were no doubt somewhat sloppy, with progeny molecules imperfectly complementary to their parent molecules. Over time, **natural selection**, the competitive evolutionary process by which reproductive preference is given to the better adapted, would have favored molecules that made more accurate copies of themselves.

The “**RNA world**” hypothesis, proposed in 1962 by Alexander Rich, suggests that RNA may have served as the first self-replicating polymer. Like DNA, RNA can also store, transmit, and duplicate genetic information. However, the single-stranded nature of RNA means that this molecule can use complementarity to fold on itself into a great many structures, many having catalytic activity. The ribosome is an excellent example of an ancient catalytic RNA. According to some evolutionary sequence analyses, the ribosome may predate the evolution of the cell itself. Not unlike some modern viruses, early forms of life may have used RNA as their genome. Whether this hypothetical origin for life existed will remain unknown. Regardless, RNA serves as an excellent model system for the study of potential self-replicating systems.

GATEWAY CONCEPT **Functional Groups**

Different classes of biological molecules are characterized by different types of functional groups and linkages. A biological molecule may contain multiple functional groups that facilitate interactions within and between molecules.

Checkpoint

- Which four elements occur in virtually all biological molecules?
- Summarize the major stages of chemical evolution.
- Practice drawing a simple condensation and hydrolysis reaction.
- Explain why complementarity would have been necessary for the development of self-replicating molecules.

1.2 Cellular Architecture

LEARNING OUTCOMES

After reading this section, you will be able to:

Explain how important features of cellular architecture relate to the structure and function of cells.

- Describe the advantages of compartmentation for self-replicating systems.
- Define metabolic pathways and explain the reasoning for their development in organisms.
- Compare the general features of the two major types of cells.
- Describe features of each of the three evolutionary domains of organisms.
- Explain the theory of endosymbiosis and the origin of eukaryotes.
- Outline the four principles of evolution and provide examples of each using modern organisms.

The types of systems described so far would have had to compete for available resources with all of the other components of the primordial Earth. A system that was sequestered and protected by boundaries of some sort would have a selective advantage. How these boundaries first arose, or even what they were made from, is obscure. One theory is that membranous **vesicles** (fluid-filled sacs) first attached to and then enclosed self-replicating systems. These vesicles would have become the first cells.

1.2A Cells Carry Out Metabolic Reactions

There are several advantages to **compartmentation**. In addition to receiving some protection from adverse environmental forces, an enclosed system can maintain high local concentrations of components that would otherwise diffuse away. More concentrated substances can react more readily, leading to increased efficiency in polymerization and other types of chemical reactions.


A membrane-bound compartment that protected its contents would gradually become quite different in composition from its surroundings. Modern cells contain high concentrations of ions, small molecules, and large molecular aggregates that are found only in traces—if at all—outside the cell. For example, a cell of the bacterium *Escherichia coli* (*E. coli*) contains millions of molecules, representing some 3000 to 6000 different compounds (Fig. 1.6). A typical animal cell may contain 100,000 different types of molecules.

Early cells depended on the environment to supply building materials. As some of the essential components in the prebiotic soup became scarce, natural selection favored organisms that developed **metabolic pathways**, mechanisms for synthesizing the required compounds from simpler but more abundant **precursors**. The first metabolic reactions may have used metal or clay **catalysts** (substances that promote chemical reactions without undergoing a net change). In fact, metal ions are still at the heart of many chemical reactions in modern cells. Some catalysts may also have arisen from polymeric molecules with the appropriate functional groups.

In general, biosynthetic reactions require energy; hence the first cellular reactions also would have needed an energy source. The eventual depletion of preexisting energy-rich substances in the prebiotic environment would have favored the development of energy-producing metabolic pathways. For example, photosynthesis evolved relatively early to take advantage of a practically inexhaustible energy supply, the sun. However, the accumulation of O₂ generated from H₂O by photosynthesis (the modern atmosphere is 21% O₂) presented an additional challenge to organisms adapted to life in an oxygen-poor atmosphere. Metabolic refinements eventually permitted organisms not only to avoid oxidative damage but also to use O₂ for oxidative metabolism, a much more efficient form of energy metabolism than anaerobic metabolism. Vestiges of ancient life can be seen in the anaerobic metabolism of certain modern organisms.



FIGURE 1.6 Cross-section through an *E. coli* cell. The cytoplasm is packed with macromolecules. At this magnification (~1,000,000 \times), individual atoms are too small to resolve. The green structures on the right include the inner and outer membrane components along with a portion of a flagellum. Inside the cell, various proteins are shown in blue, and ribosomes are purple. The gold and orange structures represent DNA and DNA-binding proteins, respectively. In a living cell, the remaining spaces would be crowded with water and small molecules.



From Goodsell, D.S., *The Machinery of Life* (2nd ed.), Springer (2009).
Reproduced with permission.

Early organisms that developed metabolic strategies to synthesize biological molecules, conserve and utilize energy in a controlled fashion, and replicate within a protective compartment were able to propagate in an ever-widening range of habitats. Adaptation of cells to different external conditions ultimately led to the present diversity of species. Specialization of individual cells also made it possible for groups of differentiated cells to work together in multicellular organisms.

1.2B There Are Two Types of Cells: Prokaryotes and Eukaryotes

There are two major classifications of cells: the **eukaryotes** (Greek: *eu*, good or true + *karyon*, kernel or nut), which have a membrane-enclosed **nucleus** encapsulating their DNA; and the **prokaryotes** (Greek: *pro*, before), which lack a nucleus. *Prokaryotes, comprising the various types of bacteria, have relatively simple structures and are almost all unicellular* (although they may form filaments or colonies of independent cells). *Eukaryotes, which can be multicellular or unicellular, are vastly more complex than prokaryotes.*

Prokaryotes are the most numerous and widespread organisms on the earth. This is because their varied and often highly adaptable metabolisms are well-suited to an enormous variety of habitats. Prokaryotes range in size from 1 to 10 μm and have one of three basic shapes (Fig. 1.7): spheroidal (cocci), rodlike (bacilli), and helically coiled (spirilla). Except for an outer cell membrane, which in most cases is surrounded by a protective cell wall, nearly all prokaryotes lack cellular membranes. However, the prokaryotic **cytoplasm** (cell contents) is by no means a homogeneous soup. Different metabolic functions are carried out in different regions of the cytoplasm (Fig. 1.6). The best characterized prokaryote is *Escherichia coli*, a 2 μm by 1 μm rodlike bacterium that inhabits the mammalian colon.

Eukaryotic cells are generally 10 to 100 μm in diameter and thus have a thousand to a million times the volume of typical prokaryotes. However, it is not size, but a profusion of membrane-enclosed **organelles** that best characterizes eukaryotic cells (Fig. 1.8). In addition to a nucleus, eukaryotes have an **endoplasmic reticulum**, the site of synthesis of many cellular components, some of which are subsequently modified in the **Golgi apparatus**. The bulk of aerobic metabolism takes place in **mitochondria** in almost all eukaryotes, and photosynthetic cells contain **chloroplasts**, which convert the energy of the sun's rays to chemical energy. Other organelles, such as **lysosomes** and **peroxisomes**, perform specialized functions. **Vacuoles**, which are more prominent in plant than in animal cells, usually function as storage depots. The **cytosol** (the cytoplasm minus its membrane-bound organelles) is organized by the **cytoskeleton**, an extensive array of filaments that also gives the cell its shape and the ability to move.

The various organelles that compartmentalize eukaryotic cells represent a level of complexity that is largely lacking in prokaryotic cells. Nevertheless, prokaryotes are more efficient than eukaryotes in many respects. Prokaryotes have exploited the advantages of simplicity and miniaturization. Their rapid growth rates permit them to occupy ecological niches in which there may be drastic fluctuations of the available nutrients. In contrast, the complexity of eukaryotes renders them larger and more slowly growing than prokaryotes, giving them the competitive advantage in stable environments with limited resources. It is therefore erroneous to consider prokaryotes as evolutionarily primitive compared to eukaryotes. Both types of organisms are well adapted to their respective lifestyles.

1.2C Molecular Data Reveal Three Evolutionary Domains of Organisms

Evolution The practice of lumping all prokaryotes in a single category based on what they lack—a nucleus—obscures their metabolic diversity and evolutionary history. Conversely, the remarkable morphological diversity of eukaryotic organisms (consider the anatomical differences




FIGURE 1.7 Scale drawings of some prokaryotic cells.




FIGURE 1.8 Diagram of a typical animal cell with electron micrographs of its organelles. Membrane-bound organelles include the nucleus, endoplasmic reticulum, lysosome, peroxisome (not pictured), mitochondrion, vacuole, and Golgi apparatus. The nucleus contains chromatin (a complex of DNA and protein) and the nucleolus (the site of ribosome synthesis). The rough endoplasmic reticulum is studded with ribosomes; the smooth endoplasmic reticulum is not. A pair of centrioles help organize cytoskeletal elements. A typical plant cell differs mainly by the presence of an outer cell wall and chloroplasts in the cytosol.

[Nucleus and Smooth endoplasmic reticulum JOSE LUIS CALVO MARTIN & JOSE ENRIQUE GARCIA-MAURIÑO MUZQUIZ / Getty Images; rough endoplasmic reticulum Professors Pietro M. Motta & Tomonori Naguro / Science Source; mitochondrion CNRI/Science Source; Golgi apparatus and Lysosome Science Source.]

Question With the labels covered, name the parts of this eukaryotic cell.

among, say, an amoeba, an oak tree, and a human being) masks their fundamental similarity at the cellular level. Traditional taxonomic schemes (**taxonomy** is the science of biological classification), which are based on gross morphology, have proved inadequate to describe the actual relationships between organisms as revealed by their evolutionary history (**phylogeny**).

Biological classification schemes based on reproductive or developmental strategies more accurately reflect evolutionary history than those based solely on adult morphology. However, *phylogenetic relationships are best deduced by comparing polymeric molecules—RNA, DNA, or protein—from different organisms*. For example, analysis of RNA led Carl Woese to group all organisms into three domains (**Fig. 1.9**). The **archaea** (also known as **archaebacteria**) are a group of prokaryotes that are as distantly related to other prokaryotes (the **bacteria**, sometimes called **eubacteria**) as both groups are to eukaryotes (**eukarya**). The archaea include some unusual organisms: the **methanogens** (which produce CH_4), the **halobacteria** (which thrive in concentrated brine solutions), and certain **thermophiles** (which inhabit hot springs). The pattern of branches in Woese's diagram indicates the divergence of different types of organisms (each branch point represents a common ancestor). The three-domain scheme also shows that animals, plants, and fungi constitute only a small portion of all life forms. Such phylogenetic trees supplement the fossil record, which provides a patchy record of life prior to about 600 million years before the present (multicellular organisms arose about 700–900 million years ago).

It is unlikely that eukaryotes are descended from a single prokaryote, because the differences among eubacteria, archaea, and eukaryotes are so profound. Instead, eukaryotes probably




FIGURE 1.9 Phylogenetic tree showing the three domains of organisms. The branches indicate the pattern of divergence from a common ancestor. The archaea are prokaryotes, like eubacteria, but share many features with eukaryotes.

Source: Adapted from Wheelis, M.L., Kandler, O., and Woese, C.R. *Proc. Natl. Acad. Sci.* 89, 2931 (1992).

evolved from the association of archaeobacterial and eubacterial cells. The eukaryotic genetic material includes features that suggest an archaeobacterial origin. In addition, the mitochondria and chloroplasts of modern eukaryotic cells resemble eubacteria in size and shape, and both types of organelles contain their own genetic material and protein synthetic machinery, with some unique differences in the genetic code from that of the nucleus. Evidently, as Lynn Margulis proposed, mitochondria and chloroplasts evolved from free-living eubacteria that formed **symbiotic** (mutually beneficial) relationships with a primordial eukaryotic cell (**Box 1.2**). In fact, certain eukaryotes that lack mitochondria or chloroplasts permanently harbor symbiotic bacteria.

1.2D Organisms Continue to Evolve

Evolution The natural selection that guided prebiotic evolution continues to direct the evolution of organisms. Richard Dawkins has likened evolution to a blind watchmaker capable of producing intricacy by accident, although such an image fails to convey the vast expanse of time and the incremental, trial-and-error manner in which complex organisms emerge. Small **mutations** (changes in an individual's genetic material) arise at random as the result of chemical damage or inherent errors in the DNA replication process. *A mutation that increases the chances of survival of the individual increases the likelihood that the mutation will be passed on to the next generation.* Beneficial mutations tend to spread rapidly through a population; deleterious changes tend to die along with the organisms that harbor them.

The theory of evolution by natural selection, which was first articulated by Charles Darwin in the 1860s, has been confirmed through observation and experimentation. It is therefore useful to highlight several important—and often misunderstood—principles of evolution:

1. *Evolution is not directed toward a particular goal.* It proceeds by random changes that may affect the ability of an organism to reproduce under the prevailing conditions. An organism that is well adapted to its environment may fare better or worse when conditions change.
2. *Variation among individuals* allows organisms to adapt to unexpected changes. This is one reason that genetically homogeneous populations (e.g., a corn crop) are so susceptible to a single challenge (e.g., a fungal blight). A more heterogeneous population is more likely to include individuals that can resist the adverse.
3. *The past determines the future.* New structures and metabolic functions emerge from pre-existing elements. For example, insect wings did not erupt spontaneously but appear to have developed gradually from small heat-exchange structures.
4. *Evolution is ongoing,* although it does not proceed exclusively toward complexity. An anthropocentric view places human beings at the pinnacle of an evolutionary scheme, but a quick survey of life's diversity reveals that simpler species have not died out or stopped evolving.

Box 1.2 Pathways of Discovery

Lynn Margulis and the Theory of Endosymbiosis



Cavan Images/Alamy Stock Photo

Lynn Margulis (1938–2011) After growing up in Chicago and enrolling in the University of Chicago at age 16, Lynn Margulis intended to be a writer. Her interest in biology was sparked by a required science course for which she read Gregor Mendel's accounts of his experiments with the genetics of pea plants. Margulis continued her studies at the University of Wisconsin–Madison and at the University of California, Berkeley, earning a doctorate in 1963. Her careful consideration of cellular structures led her to hypothesize that eukaryotic cells originated from a series of endosymbiotic events involving multiple prokaryotes. The term *endo* (Greek: within) refers to an arrangement in which one cell comes to reside inside another. This idea was considered outrageous at the time (in 1967), but many of Margulis's ideas have since become widely accepted.

Endosymbiosis as an explanation for the origin of mitochondria had been proposed by Ivan Wallin in 1927, who noted the similarity between mitochondria and bacteria in size, shape, and cytological staining. Wallin's hypothesis was rejected as being too fantastic and was ignored until it was taken up again by Margulis. By the 1960s, much more was known about mitochondria (and chloroplasts), including the facts that they contained DNA and reproduced by division. Margulis did not focus all her attention on the origin of individual organelles; instead, she sought to explain the origin of the entire eukaryotic cell, which also includes centrioles, another possible bacterial relic. Her paper, "On the origin of mitosing cells," was initially rejected by several journals before

being accepted by the *Journal of Theoretical Biology*. The notion that a complex eukaryotic cell could arise from a consortium of mutually dependent prokaryotic cells was incompatible with the prevailing view that evolution occurred as a series of small steps. Evolutionary theory of the time had no room for the dramatic amalgamation of cells—and their genetic material—that Margulis had proposed. Nevertheless, the outspoken Margulis persisted, and by the time she published *Symbiosis in Cell Evolution* in 1981, much of the biological community had come on board to agree with her.

Two main tenets of Margulis's theory are now almost universally accepted: (1) mitochondria are the descendants of oxygen-respiring bacteria, and (2) chloroplasts were originally photosynthetic bacteria. The third, the idea that the eukaryotic cytoplasm is the remnant of an archaeobacterial cell, is still questioned by some biologists. Margulis was in the process of collecting evidence to support a fourth idea, that cilia and flagella and some sensory structures such as the light-sensing cells of the eye are descendants of free-living spirochete bacteria. Margulis's original prediction that organelles such as mitochondria could be isolated and cultured has not been fulfilled. However, there is ample evidence for the transfer of genetic material between organelles and the nucleus, consistent with Margulis's theory of endosymbiosis. In fact, current theories of evolution include the movement of genetic material among organisms, as predicted by Margulis, in addition to small random mutations as agents of change.

Perhaps as an extension of her work on bacterial endosymbiosis, Margulis came to recognize that the interactions among many different types of organisms as well as their interactions with their physical environment constitute a single self-regulating system. This notion is part of the Gaia hypothesis proposed by James Lovelock, which views the entire earth as one living entity (Gaia was a Greek earth goddess). However, Margulis had no patience with those who sought to build a modern mythology based on Gaia. She was adamant about the importance of using scientific tools and reasoning to discover the truth and was irritated by the popular belief that humans are the center of life on earth. Margulis understood that human survival depends on our relationships with waste-recycling, water-purifying, and oxygen-producing bacteria, with whom we have been evolving, sometimes endosymbiotically, for billions of years.

Sagan, L., On the origin of mitosing cells, *J. Theor. Biol.* 14, 255–274 (1967).

Checkpoint

- Explain the selective advantages of compartmentation and metabolic pathways.
- Discuss the differences between prokaryotes and eukaryotes.
- List the major eukaryotic organelles and their functions.
- Explain why a taxonomy based on molecular sequences is more accurate than one based on morphology.
- Which of the three domains are prokaryotic? Which domain is most similar to eukaryotes?
- Explain how individual variations allow evolution to occur.
- Why is evolutionary change constrained by its past but impossible to predict?

1.3 Thermodynamics

LEARNING OUTCOMES

After reading this section, you will be able to:

Distinguish the first and second laws of thermodynamics.

- Relate the concept of enthalpy to the first law of thermodynamics.
- Relate the concept of entropy to the second law of thermodynamics.
- Define free energy and spontaneity and relate the two for any process.
- Explain how the sign of enthalpy or entropy will affect the spontaneity of a process.
- Define state functions and biochemical standard state.
- Calculate the free energy of a chemical reaction under standard and non-standard conditions.
- Explain the non-equilibrium steady state and its relationship to living systems.

The normal activities of living organisms demand an almost constant input of energy. Even at rest, organisms devote a considerable portion of their biochemical apparatus to the acquisition and utilization of energy. The study of energy and its effects on matter falls under the purview of thermodynamics (Greek: *therme*, heat + *dynamis*, power). Although living systems present some practical challenges to thermodynamic analysis, *life obeys the laws of thermodynamics*. Understanding thermodynamics is important not only for describing a particular process—such as a biochemical reaction—in terms that can be quantified, but also for predicting whether that process *can* actually occur. To begin, this section will review the fundamental laws of thermodynamics. It will then turn your attention to free energy and how it relates to chemical reactions. Finally, we will look at how biological systems deal with the laws of thermodynamics.

1.3A The First Law of Thermodynamics States That Energy Is Conserved

In thermodynamics, a **system** is defined as the part of the universe that is of interest, such as a chemical reaction or an organism; the rest of the universe is known as the surroundings. The system has a certain amount of **energy, E** . *The first law of thermodynamics states that total energy of the universe is constant and that energy can be neither created nor destroyed during any physical or chemical process.* This means that when the system undergoes a change, some of its energy can be transferred or change form, but it cannot be consumed. For example, the energy stored in chemical bonds can be converted to kinetic energy to perform work. Energy can be used to perform different kinds of work and it is useful to speak of energy in specific forms, such as mechanical energy, electrical energy, or chemical energy—all of which are relevant to living systems.

The change that occurs in the internal energy of a system (ΔE) corresponds to the sum of the heat transferred (q) and work done (w):

$$\Delta E = q + w \quad (1.1)$$

where the upper case Greek letter Δ (delta) indicates change. For many chemical systems, w is defined by pressure-volume work ($w = -P\Delta V$), especially where large amounts of gas are produced, increasing the volume. However, for most biological processes we are not concerned with pressure-volume work as volume changes are typically insignificant.

$$\Delta E = q - P\Delta V = q_v \quad (1.2)$$

In open systems, these processes are typically at constant pressure. Under such conditions q is equivalent to a thermodynamic quantity called **enthalpy** (Greek: *enthalpein*, to warm in), symbolized H , with the following relationship:

$$\Delta E = \Delta H - P\Delta V \quad (1.3)$$

Enthalpy refers to the heat *content* of a system. Since you already know that volume changes in most biological processes are insignificant, you can see that under conditions of constant pressure, the energy change for the reacting system is equivalent to its enthalpy change and thus, q :

$$\begin{aligned} \Delta E &= \Delta H - P\Delta V = q_p + w \\ \Delta E &= \Delta H - 0 = q_p + 0 \\ \Delta E &= \Delta H = q_p \end{aligned} \quad (1.4)$$

Enthalpy, like energy, heat, and work, is given units of joules. Some commonly used units, biochemical constants, and other conventions are given in **Box 1.3**.

Thermodynamics is useful for indicating the **spontaneity** of a process; a determination of whether the process *can* occur (regardless of whether a process *will* occur). A spontaneous process occurs without the input of additional energy from outside the system (although keep in mind that thermodynamic spontaneity has nothing to do with how quickly a process occurs). However, the first law of thermodynamics cannot by itself determine whether a process is spontaneous. Consider two objects of different temperatures that are brought together. Heat flows spontaneously from the warmer object to the cooler one, never vice versa, yet heat flow in either direction would be consistent with the first law of thermodynamics since the aggregate energy of the two objects would not change. Therefore, heat alone (enthalpy in this case) is not enough to determine spontaneity; an additional thermodynamic parameter is needed.

Box 1.3 Perspectives in Biochemistry

Biochemical Conventions

Modern biochemistry generally uses Système International (SI) units, including meters (m), kilograms (kg), and seconds (s) and their derived units, for various thermodynamic and other measurements. The following lists the commonly used biochemical units, some useful biochemical constants, and a few conversion factors.

Units

Energy, heat, work	joule (J)	$\text{kg}\cdot\text{m}^2\cdot\text{s}^{-2}$ or $\text{C}\cdot\text{V}$
Electric potential	volt (V)	$\text{J}\cdot\text{C}^{-1}$

Prefixes for units

mega (M)	10^6	nano (n)	10^{-9}
kilo (k)	10^3	pico (p)	10^{-12}
milli (m)	10^{-3}	femto (f)	10^{-15}
micro (μ)	10^{-6}	atto (a)	10^{-18}

Conversions

angstrom (\AA)	10^{-10} m
calorie (cal)	4.184 J
kelvin (K)	degrees Celsius ($^{\circ}\text{C}$) + 273.15

Constants

Avogadro's number (N)	6.0221×10^{23} molecules $\cdot\text{mol}^{-1}$
Coulomb (C)	6.241×10^{18} electron charges
Faraday (F)	96,485 C $\cdot\text{mol}^{-1}$ or 96,485 J $\cdot\text{V}^{-1}\cdot\text{mol}^{-1}$
Gas constant (R)	8.3145 J $\cdot\text{K}^{-1}\cdot\text{mol}^{-1}$
Boltzmann constant (k_B)	1.3807×10^{-23} J $\cdot\text{K}^{-1}(R/N)$
Planck's constant (h)	6.6261×10^{-34} J $\cdot\text{s}$

Throughout this text, molecular masses of particles are expressed in units of **daltons (Da)**, which are defined as 1/12th the mass of a ^{12}C atom (1000 Da = 1 **kDa**). Biochemists also use molecular weight, a dimensionless quantity defined as the ratio of the particle mass to 1/12th the mass of a ^{12}C atom, which is symbolized M_r (for relative molecular mass).

I-2 SUBJECT INDEX

- Antioxidants, 585–86
 Antiparallel strands, DNA, 159
 Antiparallel β sheet, 77
 Antiport, 250
 Antisense, 877
 Antisense RNA, 1027
 AP endonuclease, 847
 Apaf-1, 589
 Apical domain, 217
 Apoenzyme, 272
 Apolipoproteins, 638
 Apoptosis, 586–90
 Apoptosome, 589
 Apoptotic bodies, 587
 APP. *See* A β precursor protein
 Appetite, regulation of, 762–66
 APRT. *See* Adenine phosphoribosyltransferase
 Aquaporins, 245–46
 Archaea, 10
 Archaeobacteria, 10
 Architectural proteins, 1006
 AREs. *See* AU-rich elements
 Arginase, 704
 Arginine
 breakdown of, 709–10
 nitric oxide from, 736–38
 precursor to, 723
 production of, 704
 Argininosuccinase, 704
 Argininosuccinate synthetase, 704
 Argonaute, 1028
 ARS. *See* Autonomously replicating sequences
 Artificial sweeteners, 133–34
 Artificial uncoupling agents, 583
 Ascorbic acid (vitamin C), 80
 Asparagine
 breakdown of, 709
 N-linked oligosaccharides, 144–46
 synthesis of, 721–22
 Aspartate, 725
 breakdown of, 709
 synthesis of, 721–22
 Aspartate aminotransferase, 465
 Aspartate transcarbamoylase (ATCase), 327, 788–89
 feedback inhibition, 327
 structural changes in, 330
 substrate-binding sites of, 327–30
 Assimilation, 739
 Asymmetric centers, 57
 ATCase. *See* Aspartate transcarbamoylase
 Atherosclerosis, 683–85
 ATP synthase, 568
 F₀ component, 573–74
 F₁ component, 573
 F₁F₀-ATPase, 576–78
 flow of protons, 574–79
 P/O ratios, 579
 structure of, 572–74
 synthesis of, 575–76
 ATP synthesis, 568–71
 driving, 616–17
 ATP-citrate lyase, 536
 ATP-dependent amidation, 721
 ATP. *See* Adenosine triphosphate
 ATR, 1037
 Attenuation, 990–93
 AU-rich elements (AREs), 1026
 Autocatalytic, 297
 Autoimmune diseases, 870–71
 Autonomously replicating sequences (ARS), 832
 Autophagy, 692
 Autophosphorylation, 353
 Autoradiography, 1059, 1089
 Autotrophs, 393
 Axial positions, 128
- B**
 B antigens, 148
 B-DNA
 definition, 164
 majority of DNA as, 168
 stacking energies for, 162
 structural features of, 166
Bacillus stearothermophilus, 821
Bacillus subtilis, 881
Bacillus thuringiensis, 1093
 Bacitracin, 509
 Backbone, 72
 Backtrack, 890
 BACs. *See* Bacterial artificial chromosomes
 Bacterial artificial chromosomes (BACs), 1086
 Bacterial biofilms, 139–40
 Bacterial cell walls, 141–43
 Bacteriochlorophyll *a* (Bchl *a*), 598
 Bacteriochlorophyll *b* (Bchl *b*), 598
 Bacteriophage λ , 1086
 Bacteriophages, 1077
 Bacteriorhodopsin, 557–58
 Banting, Frederick, 769
 Base deamination, 42
 Base excision repair (BER), 846–48
 Bases
 conjugate, 38
 defined, 38
 flipping, 846
 pairs, 159, 166
 Basic helix–loop–helix (bHLH), 1018
 Basic solutions, 36
 Basolateral domain, 217
 Bcl-2, 589
 Beadle, George, 182
 Beer–Lambert law, 1054
 BER. *See* Base excision repair
 Beriberi, 458–59
 Best, Charles, 769
 Beta propeller motif, 590
 bHLH. *See* basic helix–loop–helix
 Bilayers, 32–33
 Bile acids, 635–37
 Bimolecular reaction, 305
 Binding
 GH receptors, 349–50
 IP₃ and Ca²⁺ release, 376–77
 Binding change mechanism, 575–76
 Binding energy, 269
 Bioavailability, 336
 Biochemical conventions, 14
 Biochemical signaling, 343–82,
 760–61
 heterotrimeric G proteins, 366–75
 hormones, 344–50
 phosphoinositide pathway, 375–82
 receptor tyrosine kinases, 351–65
 Biochemical standard state, 18
 Biofilm, 139–40
 Biomolecule purification
 chromatography, 1055–59
 electrophoresis, 1059–63
 salting out separate proteins, 1055
 strategy for, 1052–55
 ultracentrifugation, 1063–64
 Biomolecules
 crystal structures, 1095–96
 from inanimate substances, 3–5
 interaction energies in, 29
 self-replicating systems from, 6–7
 Bioppterin, 718
- Biotin, 462–63, 649
 Bisphosphoglycerate, 117
 Bisphosphoglycerate mutase, 446
 Bisubstrate mechanisms,
 315–16
 Bisubstrate reactions, 314–16
 Bitopic proteins, 205
 Blastoderm, 1038
 Blood buffering system, 43
 Blood coagulation cascade, 298
 Blood glucose, 767
 Blood–brain barrier, 336
 Blunt ends, 1078
 Body weight, regulation of, 762–66
 Bohr effect, 116–17
 Boltzmann constant, 15
 Botulinum, 226
 Bovine pancreatic trypsin inhibitor (BPTI), 295–96
 Bovine spongiform encephalopathy (BSE), 108
 Boyer, Herbert, 1086
 BPG. *See* d-2,3-bisphosphoglycerate
 BPTI. *See* bovine pancreatic trypsin inhibitor
 Brain, glucose in, 751
 Branch migration, 854
 Branching enzyme, 498
 Briggs, Geroge E., 308
 Bromodomains, 1009–11
 Brownian ratchet, 890
 Bubonic plague, 364
 Buffering capacity, 42
 Buffers, 40–43
- C**
 C value, 975
 C-terminal domain (CTD), 889
 C-terminal sequence KDEL, 225
 C-terminus., 63
 C-value paradox, 975
 C2'-endo, 163
 C₂₀ fatty acids, 675–76
 C3'-endo, 163
 C₄ cycle 627–28
 Ca²⁺-ATPases Pump, 254
 Cahn–Ingold–Prelog system (*RS* system), 58
 Cahn, Robert, 58
 Cairns, John, 843
 Calmodulin (CaM), 377–78
 Calvin cycle, 618–23
 controlled indirectly by light,
 624–26
 conversions in, 623–24
 free energy changes for reactions
 of, 625
 RuBP carboxylase, 621–23
 stages of, 619–21
 Calvin, Melvin, 618
 CaM. *See* Calmodulin
 cAMP, 500–501
 cAMP receptor protein (CRP), 989–90
 cAMP-dependent protein kinase (cAPK), 371
 cAMP-PDEs. *See*
 cAMP-phosphodiesterases
 cAMP-phosphodiesterases (cAMP-PDEs), 374
 cAMP. *See* Adenosine-3',5'-cyclic monophosphate
 Cancer, 835
 metabolism, 772–74
 therapy, 798
 and tumor suppressor, 1035–38
 Cap-binding complex (CBC), 898
 Cap-binding protein, 949
 CAP. *See* Catabolite gene activator protein
 Capillary electrophoresis (CE), 1063
 cAPK. *See* cAMP-dependent protein kinase
 CapZ, 386
 Carbamates, 117
 Carbamoyl phosphate, 703, 786
 Carbamoyl phosphate synthetase (CPS), 703
 Carbamoyl phosphate synthetase II, 788–89
 Carbohydrate synthesis, other pathways of, 506–9
 Carbohydrates, 123–51
 defined, 124
 glycoproteins, 140–49
 monosaccharides, 124–31
 polysaccharides, 131–40
 Carbon-carbon bond cleavage, 477–78
 Carbon, oxidation states of, 397
 Carbonic anhydrase, 117
 Carboxyatractyloside (CATR), 548–49
 Carboxyl terminus, 63
 Carboxylic acid side chains, 52–53
 Carboxymethyl (CM), 1056
 Carcinogens, 844–45
 Cardiac glycosides, 253
 Cardiovascular disease, 191
 Carnitine, 643
 Carotenoids, 600
 Carrier ionophores, 237
 Caspase-7, 587
 Caspase-8, 587
 Caspase-10, 587
 Caspase-activated DNase, 590
 Caspases, 587
 Catabolism, 393
 Catabolite gene activator protein (CAP), 989–90
 Catabolite repression, 989–90
 Catalysts, 8
 Catalytic constant, 311–12
 Catalytic mechanisms
 acid–base catalysis, 273–75
 association with cofactors, 271–73
 covalent catalysis, 276–77
 lysozymes, 280–87
 metal ion catalysis, 277–78
 orientation effects, 278–80
 proximity effects in, 278–80
 serine proteases, 292–97
 Catalytic perfection, 440
 Catalytic triad, 290
 Cataplerotic reactions, 535
 Catecholamines, 347, 759–61
 Catenate, 170
 Cation exchangers, 1056
 Cations, 162
 CATR. *See* Carboxyatractyloside
 CBC. *See* Cap-binding complex
 CCA-adding polymerase, 915
 CCAAT box, 892
 Cdks. *See* Cyclin-dependent protein kinases
 cDNA. *See* Complementary DNA
 cDNA library, 1089
 Celebrex, 337
 Celecoxib (Celebrex), 200
 Cell cycle, 996, 1033–34
 Cell membrane, transmitting signals across, 351–55
 Cells
 antioxidant mechanisms, 585–86
 death of, 586–90
 defining shape of, 213–15

- Cellular architecture, 7–12
 continuous evolution, 11–12
 metabolic reactions, 8–9
 molecular data, 9–11
 types of cells, 9
- Cellular immunity, 866
- Cellulose, 136–37, 623–24
- Central dogma of molecular biology, 182–83
- Central pore, 244
- Centromeres, 979
- Ceramides, 193
- Cerebrosides, 194
- CF₁CF₀ complex, 617
- CFTR. *See* cystic fibrosis transmembrane conductance regulator
- Chain-terminator method, 1078–79
- Channel-forming ionophores, 237
- Channeling, 703
- Chaotropic agents, 100
- Chaperones, protein folding by, 105–10
- Chargaff's Rules, 158
- Checkpoints, 1033
- Chemical agents, 841–44
- Chemical energy, 601–2
- Chemical mutagens, 841
- Chemical potential, 235
- Chemiosmotic theory, 568–71
- Chemolithotrophs, 394
- Chi sequence, 858
- Chiral centers, 57–59
- Chiral molecules, 58–59
- Chirality, 57
- Chitin, 136–37
- Chloramphenicol, 960
- Chlorophyll, 598–99
- Chlorophyll *a* (Chl *a*), 598
- Chlorophyll *b* (Chl *b*), 598
- Chloroplasts, 9, 597–600
- Cholesterol
 exit of, 684–85
 precursor to, 677–78
 uses of, 680–81
 yielding, 680
- Cholesterol metabolism, 677–85
 atherosclerosis, 683–85
 precursors, 677–78
 rate of synthesis, 681–83
 squalene cyclization, 680
 squalene formation, 678–80
- Chou, Peter, 81
- Chromatin, 996
- Chromatin structure, 996–1003
 forming higher-order structures, 999–1002
 histones, 996–99
 influencing gene expression, 1003–15
- Chromatin-remodeling complexes, 1004
- Chromatography, 1055–59
- Chromodomain, 1012
- Chromophore, 1054
- Chromosome inactivation, 1005
- Chromosomes, 168, 996
- Chronic myelogenous leukemia (CML), 362–63
- Chylomicrons, 637, 638–39
- Circular dichroism spectroscopy, 1094
- cis* cisternae, 222
- cis* conformation, 72
- cis* Golgi network, 221
- Cis-acting regulatory elements, 1019
- Cisternae, 221
- Citrate, 514
- Citrate synthase, 523–25
- Citric acid cycle, 512–43
 acetyl-S-CoA synthesis, 517–23
 changes of reactions of, 533
 discovery of, 516
 enzyme organization, 534
 enzymes of, 523–30
 evolution of, 538–39
 and fuel metabolism, 748
 general features, 514
 glyoxylate cycle similarities, 539–41
 overview of, 514–16
 products of, 531
 rate of, 533–34
 reactions of, 315
 reactions related to, 535–41
 regulation of, 531–34
 succinyl-S-CoA and, 654
- Citrulline, 704
- CKIs. *See* Cyclin-dependent kinase inhibitors
- Cl–channels, 244–45
- Claisen condensation, 660
- Clamp loader, 825
- Clathrin, 222–24
- Cleavage and polyadenylation specificity factor (CPSF), 899
- Cleavage factors I/II, 899
- Cleavage, polypeptides, 1066–68
- Cleland notation, 315
- Clinical trials, 336
- Cloned DNA, 1085–88
- Cloning vector, 1085–86
- Cloning, DNA, 1085–88
- Closed complex, 877
- Closed systems, 20
- CML. *See* Chronic myelogenous leukemia
- CO₂ (carbon dioxide), 526
 Calvin cycle fixing, 618–23
 concentrating, 627–28
 storing, 628
- Coactivators, 1010
- Coated vesicles, 222
- Coatomer, 222
- Cockayne syndrome, 850
- Coding strand, 877
- Codons, 183, 920–22, 933–35
- Coenzyme A, 396, 519
- Coenzyme B₁₂, 649
- Coenzyme Q (CoQ), 198, 551
- Coenzymes
 and cofactors, 271
 in Complex I, 554–56
 and vitamins, 395
- Cofactors, 271–73
- Cohen, Stanley, 1086
- Coil of coils, 95
- Collagen, 79
- Colligative properties, 34
- Colony, 1089
- Combinatorial chemistry, 335
- Compartmentation, 8
- Competitive inhibitors
 definition, 316–19
 degree variance, 320–21
 human immunodeficiency virus (HIV), 318–19
 measurement, 321–22
- Complementary arrangements, 6
- Complementary DNA (cDNA), 1089
- Complex I, 551, 554–55
- Complex II, 551, 559–61
- Complex III, 551
- Complex IV, 551, 565–67
- Complex systems, 380–82
- Composite transposons, 863
- Concentration, free energy, 18–19
- Condensation reaction, 6, 63
- Configuration, monosaccharides, 126–28
- Conjugate acids, 38
- Conjugate bases, 38
- Conjugate redox pair, 414
- Conservation of sequence vs. structure, 91–92
- Conservatively substituted, 1073
- Constant region, 867
- Constitutive enzymes, 883
- Continuous evolution, 11–12
- Contour length, 996
- Contraction, muscles, 752
- Convergent evolution, 292
- Cooling, renaturation by, 163
- Cooperative binding, 113
- Cooperative denaturation, 99
- Cooperativity, 106
- COPI protein, 222
- COPII protein, 222
- Core enzyme, 877
- Core promoter element, 891
- Core proteins, 140–41
- Corepressor, 991
- Corey, Robert, 75–76
- Cori cycle, 755–56
- Cori, Gerty, 488
- Cori's disease, 493
- Cortex, 347
- Cortisol, 348
- Cotranslational glycosylation, 145
- Coupled reactions, 405
- Coupled enzymatic reaction, 1053
- Covalent catalysis, 276–77
- Covalent modification, 326, 331–34, 401
- Covalent modification control, 500–504
- COX, 675–76
- COX-1, 676
- COX-2, 676
- Cox, Michael, 860
- CpG island, 976
- CPS I, 703
- CPS II, 703
- CPS. *See* Carbamoyl phosphate synthetase
- CREB. *See* Cyclic AMP response element-binding protein
- Creutzfeldt–Jakob disease (CJD), 108
- CRISPR–Cas system, 1044–47
- Cristae, 546
- Crosslinking, 90–91
- CRP. *See* cAMP receptor protein
- Cryo-electron microscopy (cryoEM), 82, 84, 1098–99
- CryoEM. *See* Cryo-electron microscopy
- CTD kinases, 889
- CTD phosphatases, 889
- CTD. *See* C-terminal domain
- CTP synthetase, 788
- Cu_A center, 566
- Cyanobacteria, 596
- Cyanogen bromide (CNBr), 1068
- Cyclic AMP response element-binding protein (CREB), 98
- Cyclic sugars, 127–28
- Cyclic symmetry, 94
- Cyclin-dependent kinase inhibitors (CKIs), 1034
- Cyclin-dependent protein kinases (Cdks), 1033–34
- Cyclins, 1033
- Cyclooxygenases (COX-1), 200
- CYP2E1, 337
- Cysteine
 breakdown of, 706–8
 deriving from 3-phosphoglycerate, 724–25
- Cysteine protease, 587
- Cystic fibrosis transmembrane conductance regulator (CFTR), 256–57
- Cytochrome *a*, 566
- Cytochrome *a*₃, 566
- Cytochrome *b*, 561
- Cytochrome *bc*₁ complex, 605
- Cytochrome *b*₅₅₉, 608
- Cytochrome *b*_{6f} complex, 606
- Cytochrome *b*₆, 611–13
- Cytochrome *c*, 210, 551, 566–67, 1073
- Cytochrome *c*₂, 605
- Cytochrome *c*₁, 561, 564–65
- Cytochrome *f*, 611
- Cytochromes, 560
- Cytochromes P450, 337
- Cytoglobin, 112
- Cytokine receptors, 1022
- Cytokines, 360, 1022
- Cytoplasm, 9
- Cytoskeleton, 9
- Cytosol, 9
- D**
- D* (dielectric constant), 29
- D arm, 926
- D-2,3-bisphosphoglycerate (BPG), 117
- D-glucose, 125
- D-β-hydroxybutyrate, 655
- Da. *See* daltons
- DAG. *See* 1,2-diaclyglycerol daltons (Da), 14
- Dam methyltransferase, 851
- Damage, reversal of, 846
- Dark reactions, 618–28
 Calvin cycle, 618–23
 conversions, 623–24
 definition, 596
 indirect control by light, 624–26
 photorespiration, 626–28
- Database storage of sequences, 1071–73
- ddNTP. *See* 2',3'-dideoxynucleoside triphosphate
- Deadenylases, 1025
- Deamination, 691, 697–705
 glutamate dehydrogenase, 700–701
 transamination, 690–700
- Death ligand, 587
- Death receptor, 587
- Debranching enzyme, 135
- Decapping enzyme, 1025
- Decarboxylation, 660
- Decoding, 950–52
- Degenerate, 921
- Demethylases, 1013
- Denaturation
 DNA (deoxyribonucleic acid), 162–63
 and pH, 1053
 proteins, 99–101
- Denatured proteins, 81, 99–101
- Density gradients, 1064
- Deoxy sugars, 129
- Deoxyhemoglobin, 113, 117
- Deoxynucleoside triphosphates (dNTPs), 1078
 production of, 794

I-4 SUBJECT INDEX

- Deoxyribonucleotides
(deoxynucleotides), 790–98
ribonucleotide conversion to,
790–94
thymine formation, 794–97
- Dephosphorylation, 334–35
- Depolarization, 242
- Derivatives, amino acids, 60–3
- Desaturases, 664–65
- Desensitization, 372–74
- Developmental patterns, 1039–41
- Dextrorotatory, 57
- DHAP. *See* Dihydroxyacetone
phosphate
- DHFR. *See* Dihydrofolate reductase
- Diabetes mellitus, 768–71
- Diacylglycerol (DAG), 379–80
- Diacylglycerophospholipids, 670–72
- Dialysis, 34
- Diazotrophs, 738
- Dicer, 1027
- Dideoxy method, 1078
- Dielectric constant (*D*), 29
- Diet-induced thermogenesis, 765–66
- Diethylaminoethyl (DEAE), 1056
- Diffraction pattern, 83
- Diffusion, 34
- Diffusion-controlled limit, 311
- Digitalis, 335
- Dihedral symmetry, 94
- Dihydrofolate reductase (DHFR),
712, 797
- Dihydrolipoamide, 520
- Dihydrolipoyl dehydrogenase
(E3), 517
- Dihydrolipoyl transacetylase
(E2), 517
- Dihydrolipoyl transsuccinylase, 527
- Dihydropteridine reductase, 719
- Dihydroxyacetone phosphate
(DHAP), 436–37
- Diisopropylphosphofluoridate
(DIPF), 287–88
- Dinucleotide-binding, 86
- Dipeptides, 63
- DIPF. *See*
Diisopropylphosphofluoridate
- Diploid, 168
- Disaccharides, 132–34
- Disease genes, 977–78
- Dissociation constant, 36
- Dissociation constants, 38–39
- Disturbances, fuel metabolism,
766–74
cancer metabolism, 772–74
diabetes mellitus, 768–71
obesity, 771–72
starvation, 766–68
- Disulfide bond, 53
- Divergent evolution, 292
- DNA (deoxyribonucleic acid)
carrying genetic information,
181–82
copying one strand of, 877–79
denaturation, 162–63
double helix, 158–61
double-helical model, 159–61
helical structure of, 158–59
hydrogen bonding in, 161–62
and *lac* repressor, 987–89
methylation of, 843
polymorphisms, 982–83
recombination, 854–65
renaturation, 162–63
repetitive sequences, 979–83
secondary structures of, 163–68
supercoiling of, 168–75
tertiary structures, 168–75
uracil lack, 847
Watson-Crick structure of, 157,
159–61
- DNA chip. *See* DNA microarray
- DNA damage, 840–45
carcinogens, 844–45
mutations, 841–44
reversal of, 846
- DNA fingerprinting, 1090–91
- DNA glycosylases, 847
- DNA ligase, 813, 827
- DNA manipulation, 1085–94
cloned DNA as amplified copy,
1085–88
- DNA methylation, 1013–15
- DNA methyltransferases (DNA
MTases), 1012–13
- DNA microarray (DNA chip), 1089
- DNA MTases. *See* DNA
methyltransferases
- DNA photolyases, 846
- DNA polymerase I (Klentaq1),
816–18, 1078
- DNA polymerase III (Pol III), 818–19
- DNA polymerase γ (Pol γ), 830
- DNA polymerase η (Pol η), 852
- DNA polymerases (Pol)
collisions, 882
eukaryotic, 830–32
prokaryotic, 815–20
synthesizing DNA, 812–13
- DNA repair, 845–54
base excision repair, 846–48
direct damage reversal, 846
introduction of errors, 852–54
mismatch repair, 850–52
nucleotide excision repair, 848–50
- DNA replication, 810–38
central dogma, 812
eukaryotic, 829–35
overview, 811–15
prokaryotic, 815–29
semiconservative, 811
semicontinuous, 813
- DNA-binding domain, 1020
- DnaB, 821
- DnaC, 822
- DnaG, 814–15
- dNDPs, phosphorylation of, 794
- dNTPs. *See* Deoxynucleoside
triphosphates
- Dolichol pyrophosphate, 508
- Domains
organisms, 9–11
proteins, 85–87
- Dopamine, 735–36
- Double helix
DNA, 158–61
RNA, 176
- Double-blind tests, 336
- Double-displacement reactions, 315
- Double-helical model, DNA, 159–61
- Double-reciprocal plot, 312
- Double-strand breaks (DSBs),
852–53, 860–62
- Downstream promoter element
(DPE), 891
- Drosophila*, 1038–39, 1042
- Drug design, 335–38
adverse drug reactions, 337–38
bioavailability and toxicity, 336
clinical trials, 336–37
discovery techniques, 335–36
- Drug–drug interactions, 337
- Drugs, affecting cell signaling, 374
- DSBs. *See* Double-strand breaks
- Dual-specificity tyrosine
phosphatases, 364
- dUTP diphosphatase (dUTPase), 794
- E**
- E. coli* (*Escherichia coli*)
aspartate transcarbamoylase from,
327–31
cryoEM structure of, 858
helicases in, 821
operon, 878
recombination in, 856–57
ribosomes, 936
soluble protein factors, 948
SOS response, 853–54
stop codons in, 961
Ter sites in, 833
translation initiation pathway
in, 947F
transposition in, 862
tryptophan biosynthesis in, 991
X-ray structure of ATCase
from, 328F
X-ray structure of lactose permease
from, 258F
- E. See* energy
- E3 binding protein, 518
- E4P. *See* Erythrose-4-phosphate
- EC classification, 265
- Ectodomain, 353
- Edman degradation, 1069–70
- Effector (executioner) caspase, 587
- Eicosanoids, 199–200
- EJC. *See* Exon-junction protein
complex
- Electroblotting, 1062
- Electrochemical cell, 414
- Electrochemical potential, 236
- Electromotive force (emf), 415
- Electron acceptor, 414
- Electron carriers, 412–14
- Electron density, 83
- Electron donor, 414
- Electron sink, 700
- Electron transport, 550–67
ATP synthesis and, 568–71
bacterial, 571
Complex I, 554–59
Complex II, 559–61
Complex III, 561–65
Complex IV, 565–67
complexes, 551
as exergonic process, 550–51
generating proton gradient, 611
inhibitors reveal workings of chain,
552–54
noncyclic, 617
in photosynthetic bacteria, 603–5
plastocyanin, 611–13
proton gradient, 569–71
reduction potentials, 553
sequence of events, 551–54
uncoupling proteins and, 582–83
- Electron-transport chain, 545
linking acyl-CoA dehydrogenase,
644–46
protoxidized special pair, 605
- Electronic complementarity, 265
- Electrons
from coenzyme Q, 562–64
motivating proton gradient
formation, 615–16
multistep path of, 556–57
returning to special pair, 605
transporting to PSI, 611–13
- Electrophoresis, 1059–63
blotting experiments, 1062
- capillary electrophoresis, 1063
gel, 1059
nucleic acids, 1061–62
polyacrylamide gel, 1059
SDS-PAGE, 1059–60
two-dimensional, 1060–61
- Electrospray ionization (ESI), 1070
- Electrostatic catalysis, 279
- Electrostatic interactions, protein, 90
- Elementary reactions, 304–5
- Elion, Gertrude, 805
- ELISA. *See* Enzyme-linked
immunosorbent assay
- Elongases, 664–65
- Elongation, 896–97
cycle, 961
factors, 950
prokaryotic DNA replication,
820–23
RNA chain, 881–83
- Elongator, 897
- Eluant, 1056
- Emergent properties, 380–82
- emf. *See* electromotive force
- Endergonic, 16
- Endocrine glands, 344
- Endocrine hormones, 344
- Endoglycosidases, 132
- Endonuclease, 169, 1077
- Endopeptidases, 1067
- Endoplasmic reticulum (ER), 9,
215, 966
- Endosomes, 228, 640
- Endosymbiosis, 12
- Energy (*E*), 13
- Energy expenditure, 765–66
- Energy reserves, triacylglycerols as,
190–91
- Energy transformation, 403
in nitrogen fixation, 738–42
- Energy, nitrogen fixation, 738–42
- Enhanceosome, 1020
- Enhancers, 1019
- Enolase, 446
- Enolpyruvate, 447
- Enthalpy, 14
- Entropy, 15
- Environmental agents, 841–44
- Enzyme activity, 326–34
allosteric control, 327–31
control, 326
covalent modification, 331–34
- Enzyme catalysis, 262–302
- Enzyme inhibition, 316–26
competitive inhibitors, 316–22
mixed inhibition, 324–26
uncompetitive inhibition, 322–24
- Enzyme kinetics, 303–16
bisubstrate reactions, 314–16
data analysis, 312–14
Michaelis–Menten equation,
307–12
rate equations, 304–7
- Enzyme-linked immunosorbent
assay (ELISA), 1053
- Enzyme–substrate complex (ES),
307–10
- Enzymes
activation energy and, 267–70
activity, 326–34
catalytic mechanisms, 271–80
of citric acid cycle, 523–30
classification, 264–65
differing from ordinary chemical
catalysts, 264
in eukaryotic DNA replication, 832
in fatty acid oxidation, 647–48

- general properties, 263–66
 geometric specificity, 266
 inactive precursors of, 297–99
 inhibition, 316–26
 kinetics, 303–16
 metabolic pathways, 395–98
 pH effect on activity of, 274
 preferential binding, 269–70
 rat liver enzymes, 692
 stereospecificity of, 265–66
 substrate specificity of, 265–66
Enzymes, citric acid cycle, 523–30
 α -ketoglutarate dehydrogenase, 527
 aconitase, 525–26
 citrate synthase, 523–25
 fumarase, 530
 isocitrate dehydrogenase, 526
 malate dehydrogenase, 530
 succinate dehydrogenase, 529
 succinyl-CoA synthetase, 527–29
Enzymology, 264
Epidermal growth factor receptor (EGFR), 206
Epigenetic, 1013
Epimers, 126
Epinephrine, 347, 504
 as antagonist, 505–6
 as precursor to physiologically active amines, 735–36
 preparing body for action, 347–48
Equatorial position, 128
Equilibrium, 17
Equilibrium constant (K_{eq}), 19
Equilibrium, temperature, 19
ER-resident proteins, 225
ER. See Endoplasmic reticulum
eRF1, 961
ERKs. See Extracellular-signal-regulated kinases (ERKs)
Errors (DNA repair), 852–54
Erythrocytes, 112, 117
Erythroid cells, 733
Erythrose-4-phosphate (E4P), 477
ES. See Enzyme-substrate complex
***Escherichia coli* (*E. coli*), 8**
ESEs. See Exonic splicing enhancers
ESI. See Electrospray ionization
Essential amino acids, 721
Essential fatty acid, 665
Essential light chains, 384
ESSs. See Exonic splicing silencers
Estrogens, 196, 348
ESTs. See Expressed sequence tags
Ethidium ion, 1961
Eubacteria, 10, 696
Euchromatin, 1003
Eukarya, 10
Eukaryotes, 9
Eukaryotic DNA replication, 829–35
 DNA polymerases, 830–32
 origins of, 832–33
 telomerase, 833–35
Eukaryotic gene expression, 996–1032
 chromatin structure, 996–15
 posttranscriptional control mechanisms, 1025–32
 transcription factors, 1015–19
 transcriptional activators, 1019–25
Eukaryotic transcription, 886–97
 promoter recognitions, 891–92
 RNA polymerases, 886–91
 termination sites, 897
 transcription factors, 893–97
European Space Agency (ESA), 4
Evans, Philip, 650
Evolution
 coenzymes, 395
 continuation of, 11–12
 domains of organisms, 9–11
 protein structure, 91–92
 self-replicating systems, 6–7
 serine proteases, 289–92
 α/β barrel enzymes, 439–40
 Evolutionary relationships, revealing, 1073–76
Exciton transfer, 602
Exergonic, 16
Exergonic process, electron transport, 550–51
Exit site, 940
Exocrine gland, 345
Exocytosis, 225
Exoglycosidases, 132
Exome, 1089
Exon junction complex (EJC), 909
Exon-junction protein complex (EJC), 1026
Exonic splicing enhancers (ESEs), 908
Exonic splicing silencers (ESSs), 908
Exons, 901–10
 spliced in two-stage reaction, 902–4
Exonuclease, 1077
Exopeptidases, 1067
Expansion segments, 941
Expressed sequence tags (ESTs), 976
Expressed sequences. See Exons
Expression vector, 1091
Extinction coefficient, 1054
Extracellular-signal-regulated kinases (ERKs), 358
Extrinsic pathway, 587
F
F-actin, 385
F-type ATPases, 251
 F_1F_0 -ATPase, 568, 576–78
F2,6P. See Fructose-2,6-bisphosphate
F6P. See Fructose-6-phosphate
Fab fragments, 866
Facilitated diffusion, 217
FAD. See Flavin adenine dinucleotide
FADD, 587
FADH₂, 396, 529
Fas ligand, 587
Fasman, Gerald, 81
Fats, 190
Fatty acid biosynthesis, 657–69
 acetyl-CoA carboxylase, 659
 acetyl-CoA transport, 658–59
 elongases and desaturases, 664–65
 fatty acid synthase, 659–64
 mammalian metabolism, 659
 regulation, 667–69
 triacylglycerols, 665–66
Fatty acid oxidation, 641–56
 activation, 642–43
 additional enzymes in, 647–48
 carnitine, 643
 as highly exergonic, 647
 ketone bodies, 655–56
 oxidation variations, 654–55
 yielding propionyl-CoA, 649–54
 β oxidation, 642, 644–47
Fatty acid synthase, 659–64
Fatty acid-binding protein, 636–37
Fatty acids, 188–90
 and adipose tissue, 753
 AMPK promotion, 763
 degradation of, 644–47
 fuel metabolism and, 748
 in muscles, 751–53
 polyunsaturated, 664–65
Fatty acyl-CoA, 642–43
Favorable, 17
FBP. See Fructose-1,6-bisphosphate
FBPase. See Fructose-1,6-bisphosphatase
FBPase-2. See Fructose bisphosphatase-2
Fc fragment, 866
Fd. See Ferredoxin
Fe-protein, 739
Feedback inhibitor, 327
Feedforward activation, 785
Female sex hormones, 348
FeMo-cofactor, 739
Fen. See Fenfluramine
Fen-phen, 336
FEN1. See Flap endonuclease-1
Fenfluramine (fen), 336
Fermentation, 454–60
 alcoholic fermentation, 456–59
 energetics of, 459–60
 homolactic fermentation, 455–56
 pyruvate, 455
Ferredoxin (Fd), 615
Ferredoxin-NADP⁺ reductase (FNR), 606
Ferredoxin-thioredoxin reductase, 626
Ferritin, 1093
Fibrous protein, 81
Fidelity, prokaryotic DNA replication, 829
First law of thermodynamics, 13–14
First-order reaction, 305
Fischer convention, 57
Fischer projections, 57
FISH. See Fluorescence in situ hybridization
Flap endonuclease-1 (FEN1), 832
Flavin adenine dinucleotide (FAD), 412–14
Flavin mononucleotide (FMN), 554
Flexibility, proteins, 97–98
Flip-flop, 202
Flippases, 217
Fluid mosaic model, 211–13
Fluorescence, 602
Fluorescence in situ hybridization (FISH), 1002
Fluorescence recovery after photobleaching (FRAP), 211
Flux, 400
FMN. See Flavin mononucleotide
FNR. See Ferredoxin-NADP⁺ reductase
Folding funnel, 102
Folding pathways, 101–4
Folding, proteins, 99–110
Footprinting, 880
Fos, 358
Fractional saturation, 112
Fractionation procedures, 1054
Frameshift mutations, 921
Franklin, Rosalind, 165
FRAP. See Fluorescence recovery after photobleaching
Free energy, 16
 calculations, 18–19
 spontaneous process, 16–18
Free energy of activation (ΔG^\ddagger), 267, 268–69
Fructokinase, 450
Fructose bisphosphatase-2 (FBPase-2), 472
Fructose-1-phosphate, 450–52
Fructose-1-phosphate aldolase, 450
Fructose-1,6-bisphosphatase (FBPase), 466, 470–71
Fructose-1,6-bisphosphate (FBP), 435–36
Fructose-2,6-bisphosphate (F2,6P), 468
Fructose-6-phosphate (F6P), 434–35, 477
Fructose, conversion of, 450–52
Fuel metabolism
 disturbances in, 766–74
 hormonal control of, 757–61
 metabolic homeostasis, 762–66
 and organ specialization, 748–56
 regulation of, 763–65
Fumarase, 274, 530
Fumarate, 514, 704
Functional groups, 4, 5
 molecular behavior and, 52
Furanoses, 126
Fusion peptide, 228
Fusion protein, 227
Futile cycle, 471
G
G proteins, 355–58
G-actin, 385
G-protein-coupled receptors (GPCRs), 366–68
G-quartets, 834–35
G₀ phase, 1033
G₁ phase, 1033
G1P. See Glucose-1-phosphate
G₂ phase, 1033
G6P. See Glucose-6-phosphate
G6PD. See Glucose-6-phosphate dehydrogenase
GABA. See γ -Aminobutyric acid
Galactokinase, 452
Galactose-1-phosphate, 452
Galactose-1-phosphate uridylyltransferase, 452
Galactose, conversion of, 452–53
Galactosemia, 452–53
GalNAc transferase, 507
Gangliosides, 194
Gap junctions, 246–47
GAP. See Glycerinaldehyde-3-phosphate; GTPase-activating protein
GAPDH. See Glycerinaldehyde-3-phosphate dehydrogenase
Gating, 241–42
GDH. See Glutamate dehydrogenase
GEF. See Guanine nucleotide exchange factor
Gel electrophoresis, 1059
Gel filtration chromatography, 1057
Gene clusters, 978–79
Gene expression, 973–1050
 and cancer, 1035–38
 and cell cycle, 1033–34
 definition, 974
 eukaryotic, 996–1032
 genome organization, 974–83
 molecular basis of development, 1038–43
 regulation of prokaryotic, 984–995
Gene knockout, 1093
Gene number, 975–78
Gene therapy, 093
General acid catalysis, 273
General base catalysis, 273
General transcription factors (GTFs), 893

I-6 SUBJECT INDEX

- Genes
 disease genes, 977–78
 exons and introns, 901–10
 expressing cloned genes, 1091–92
 homeotic genes, 1041–42
 splicing, 905–6
 yielding proteins from, 906–9
- Genetic anticipation, 980
- Genetic code, 920–25
 deciphering, 922–23
 evolution of, 925
 expansion of, 934
 features of, 923–25
 standard, 924–25
- Genetic control, 402
- Genetic information, carrying, 181–82
- Genetic manipulation, 421–22
- Genome organization, 974–83
 gene clusters, 978–79
 gene number, 975–78
 repetitive DNA sequences, 979–83
- Genomes, 168
- Genomes, system for editing/
 regulating, 1444–47
- Genomic library, 1088
- Genomics, 974
- Geometric complementarity, 265
- Geometric specificity, 266
- GFP (green fluorescent protein), 61
- GH. *See* Growth hormone
- GH receptor dimer, 349–50
- Ghrelin, 765
- Gibbs free energy, 16
- GlcNAc. *See* *N*-acetyl-d-glucosamine
- Globin, 111
- Globular protein, 81
- Glucagon, 345, 504
 countering insulin, 759–61
- Glucocorticoids, 196, 348
- Glucocortic amino acids, 706
- Glucokinase, 753–54
- Glucokinase regulatory protein, 754
- Gluconeogenesis, 346, 432, 461–66
 and AMP-dependent protein
 kinase, 762
 fuel metabolism and, 748
 insulin in, 758–59
 phosphoenolpyruvate, 461–65
 regulations, 466–73
 requiring metabolite transport, 465
 and starvation, 767–68
- Glucose
 aerobic conditions, 773–74
 and AMPK, 763
 in blood, 755–56
 in brain, 751
 in muscles, 751–53
- Glucose biosynthesis, 535
- Glucose metabolism, 427–84
 fermentation, 454–60
 gluconeogenesis, 461–66
 glycolysis, 430–31
 other hexoses, 450–54
 overview, 428–29
 pentose phosphate pathway, 474–81
 regulations, 466–73
- Glucose-1-phosphate (G1P), 452–53,
 488, 492–94
- Glucose-6-phosphatase, 466
- Glucose-6-phosphatase
 deficiency, 493
- Glucose-6-phosphate (G6P), 432–33,
 480–81, 492–94, 754
- Glucose-6-phosphate dehydrogenase
 (G6PD), 476
- Glucose–alanine cycle, 756
- GLUT1, 246–50
- GLUT4, 505
- GLUT4 storage vesicles, 758
- Glutamate, 700–701
 breakdown of, 709–10
 metabolism, 774
 as precursor, 723
 synthase, 741
 synthesis of, 721–22
- Glutamate dehydrogenase (GDH),
 536, 700–701
- Glutaminase, 703
- Glutamine
 and anabolic processes, 774
 breakdown of, 709–10
 synthetase, 722–23
 synthesis of, 721–22
- Glutathione disulfide (GSSG), 2
- Glycans, 131
- Glyceraldehyde, 450
- Glyceraldehyde kinase, 450
- Glyceraldehyde-3-phosphate (GAP),
 436–47, 477
- Glyceraldehyde-3-phosphate
 dehydrogenase, 441–42
- Glycerol, 190
- Glycerol kinase, 450
- Glycerol phosphate
 dehydrogenase, 451
- Glycerol-3-phosphate, 450–52
- Glyceroneogenesis, triacylglycerol
 biosynthesis and, 666
- Glycerophosphate shuttle, 547
- Glycerophospholipids, 191–92,
 670–73
- Glycine
 breakdown of, 706–8
 deriving from 3-phosphoglycerate,
 724–25
 heme biosynthesis, 731–35
- Glycine cleavage system, 707
- Glycoconjugates, 147
- Glycogen, 134–36
 breakdown of, 487–94
 debranching enzyme, 491–92
 fuel metabolism and, 748
 synthesis of, 494–99
- Glycogen branching enzyme,
 495, 498
- Glycogen debranching enzyme,
 136, 488
- Glycogen metabolism, 485–511
 allosteric control, 499
 breakdown, 487–94
 carbohydrate synthesis pathways,
 506–9
 control of, 499
 covalent modification control,
 500–504
 hormonal control, 504–6, 757–61
 overview, 486
 studies of, 488
 and synthesis, 494–99
- Glycogen phosphorylase, 136, 488
 conformational changes, 490–91
 degrading glycogen, 489–90
 reaction mechanism of, 490
- Glycogen storage diseases, 493–94
- Glycogen synthase, 495–98
- Glycogen synthase kinase β
 (GSK3 β), 503–4
- Glycogen synthesis, 494–99
 glycogen branching enzyme, 498
 glycogen synthase, 496–98
 UDP–glucose pyrophosphorylase,
 495–96
- Glycogenin, 498
- Glycogenolysis, 346, 488
 insulin in, 758–59
- Glycolipids, 129
- Glycolysis, 428, 430–31, 762
 assessing stage II of, 448–49
 flux-controlling enzyme of, 467–70
 fuel metabolism and, 748
 reactions of, 432–49
 regulations, 466–73
- Glycolytic ATP, 460
- Glycomics, 140
- Glycoproteins, 129, 140–49
 bacterial cell walls, 141–43
 determining structure, function,
 and recognition, 146–48
 glycosylated proteins, 143–46
 proteoglycans, 140–41
- Glycosaminoglycans, 137–41
- Glycosidic bond, 130–31
- Glycosylated proteins, 143–46
- Glycosylation, 143
 blocking, 509
 as quality control mechanism,
 968–69
- Glycosylphosphatidylinositol (GPI)-
 linked proteins, 209–10
- Glycosyltransferases, 146
- Glyoxylate, 539
- Glyoxylate cycle, 535
- Glyoxysome, 539
- Golgi apparatus, 9
- Gonads, 348
- Gout, 803–5
- GPCR kinase 2 (GRK2), 372
- GPCRs. *See* G-protein-coupled
 receptors
- Gram-negative bacteria, 143
- Gram-positive bacteria, 143
- Grana, 598
- Grb2, 357
- GreA (protein), 890
- GreB (protein), 890
- Greek key motif, 85
- Green fluorescent protein (GFP), 61
- Green sulfur bacteria, 613
- gRNAs. *See* Guide RNAs
- GroEL, 105–10
- GroEL/ES chaperonin, 105–10
- GroES, 105–10
- Group I introns, 912
- Group II introns, 912
- Growth factors, 139
- Growth hormone (GH), 349–50
- GSSG (glutathione disulfide), 62
- GTFs. *See* General transcription
 factors
- GTP hydrolysis, 954–55
- GTP, producing, 527–29
- GTPase, 357
- GTPase-activating protein (GAP),
 357–58
- Guanine nucleotide exchange factor
 (GEF), 357
- Guanine, IMP conversion, 783–84
- Guanylate cyclase, 375
- Guide RNAs (gRNAs), 909, 1028
- H**
- H antigens, 148
- Haber-Bosch process, 738
- Haldane, John B. S., 308–9
- Half-life, 306
- Half-reactions, 414, 416–18
- Halobacteria, 10
- Halobacterium salinarum*, 206
- Haploid, 168
- HATs. *See* Histone acetyltransferases
- Haworth projections, 128
- HDACs. *See* Histone deacetylases
- HDL. *See* High density lipoproteins
- HDR. *See* Homology-directed repair
- Heart attacks, 584
- Heart, muscles of, 752–53
- Heat shock proteins (Hsp), 105
- Heavy chains (H), 384, 866
- Helical structure, DNA, 158–59
- Helicase, 821–23
- Helicase II, 850
- Helix–turn–helix (HTH), 987
- Heme b_H , 561
- Heme biosynthesis, 731–35
- Heme b_L , 561
- Heme c_1 , 561, 611
- Heme f , 611
- Heme groups
 biosynthesis, 731–35
 and cytochromes, 560
 degradation products, 733–35
 in oxygen transport, 111
- Heme proteins, 560
- Heme x , 611
- Hemifusion, 226
- Hemimethylation, 851
- Hemoglobin
 bisphosphoglycerate binding to
 deoxyhemoglobin, 117
 Bohr effect and, 116–17
 different affinities for oxygen,
 114–19
 Hill equation and, 113–14
 malaria protection, 119
 oxygen binding cooperatively to,
 113–14
 sickle-cell anemia, 118–19
 as tetramer with two
 conformations, 112–13
 triggering conformational change,
 114–16
- Hen egg white (HEW), 291
- Henderson–Hasselbalch equation, 389
- Henri, Victor, 308
- Heparan sulfate, 139
- Heparin, 139
- Heptad repeats, 1017
- Heptoses, 124
- Hers' disease, 493
- Heterochromatin, 1003
- Heterologous DNA, 854
- Heteropolysaccharides, 131
- Heterotrimeric G proteins, 366–75
 adenylate cyclase synthesizes,
 370–4
 dissociating on activation, 368–70
 phosphodiesterases, 374–75
 transmembrane helices, 367–68
- Heterotrophs, 394
- Heterozygotes, 118
- HEW. *See* hen egg white
- Hexokinase, 432–33
- Hexokinase IV, 753–54
- Hexose monophosphate shunt, 474
- Hexoses, 124
- High density lipoproteins (HDL),
 637, 640
- High mobility group (HMG), 1006
- High phosphoryl group-transfer
 potentials, 407–10
- High-energy compounds, 402–12
 adenosine triphosphate (ATP),
 403–5
 definition, 402–3
 high phosphoryl group-transfer
 potentials, 407–10

- nature of, 404–5
 phosphoryl group transfers, 406
 thioesters, 410–11
- High-performance liquid chromatography (HPLC), 1056
- High-throughput screening, 335
- Highly repetitive DNA, 980
- Hill constant, 114
- Hill equation, 114
- Hill, Archibald, 113
- Histamine, 735–36
- Histidine
 biosynthesis, 729–30
 breakdown of, 709–10
- Histone acetyltransferases (HATs), 1008
- Histone code, 1008
- Histone deacetylases (HDACs), 1011
- Histone H4, 1075
- Histone methyltransferases (HMTs), 1011–12
- Histones, 996–99, 1006–8
- HIV. *See* human immunodeficiency virus
- HMG box, 1006
- HMG-CoA reductase, 681–83
- HMG-SCoA, 677–78
- HMG. *See* High mobility group
- Hodgkin, Dorothy Crowfoot, 651
- Holliday junction, 854
- Holoenzyme, 272, 364, 877
- Homeodomain, 1042
- Homeostasis, 344
 thermodynamics and, 20–21
- Homeotic genes, 1041–42
- Homocitrate, 739
- Homocysteine, 711, 714
- Homolactic fermentation, 455–56
- Homologous end-joining, 861
- Homologous recombination, 854–60
- Homology-directed repair (HDR), 861
- Homolytic cleavage, 653
- Homopolysaccharides, 131
- Homozygotes, 118
- Hormonal control, 757–61
 glucagon and catecholamines, 759–61
 glycogen metabolism and, 504–6
 insulin, 757–59
- Hormone response elements (HREs), 1024
- Hormones
 and adipose tissue, 753
 definition, 344
 endocrine, 344
 epinephrine, 347–48
 growth hormones, 349–50
 norepinephrine, 347–48
 pancreatic islet hormones, 345–47
 steroid hormones, 348–49
- Hox genes, 1042–43
- HPLC. *See* High-performance liquid chromatography
- HREs. *See* Hormone response elements
- Hsp. *See* heat shock proteins
- HTH. *See* Helix-turn-helix
- Human body, most abundant elements in, 3
- human immunodeficiency virus (HIV), 318–19
- Humoral immunity, 866
- Hyaluronate. *See* hyaluronic acid
- Hyaluronic acid (hyaluronate), 138–39
- Hydrophobic lipids, interactions with, 205–8
- Hydration, 28
- Hydrogen bonding, 26–30
 in DNA, 161–62
- Hydrolysis, 6
- Hydrolytic reactions, 466
- Hydronium ion, 36
- Hydrophobicity, 89
- Hydrophobicity scale, 89
- Hydrophilic substances, 27–30
- Hydrophobic collapse, 101
- Hydrophobic effect, 30–33, 201–2
- Hydrophobic interaction chromatography, 1056
- Hydrophobic substances, 28
- Hydroxide ion, 36
- Hydroxy groups, 52
- Hydroxyacyl-CoA dehydrogenases (HADs), 646
- Hydroxyl radical, 585, 737
- Hydroxyurea, 119
- Hyperbola, 112
- Hypercholesterolemia, 684
- Hyperchromic effect, 162
- Hyperglycemia, 770
- Hypervariable, 1073
- Hypervariable residues, 867
- Hypotonic environments, 141–42
- I**
- I bands, 382
- I-cell disease, 224
- Ibuprofen (Advil), 200
- Ice, 27
- Identity elements, 930
- IDL. *See* Intermediate density lipoproteins
- Igs. *See* Immunoglobulins
- Illumina sequencing, 1080
- Imidazole side chains, 53–54
- Immune system, 866
- Immunoaffinity chromatography, 1058
- Immunoassays, 1053
- Immunoblot, 1062
- Immunoblotting, 1059
- Immunoglobulin chain genes, 868–69
- Immunoglobulin fold, 867
- Immunoglobulins (Igs), 866
- IMP. *See* Inosine monophosphate
- Imprinting, genomic, 1015
- In situ hybridization, 1089
- In vivo* assessment, 17
- Inactivators, 316
- Independent regulation, 471–73
- Indirect readout, 992–93
- Individual body parts, development of, 1041–42
- Indole, 728–29
- Inducer, 985
- Ingold, Christopher, 58
- Inhibition
 competitive inhibition, 316–22
 feedback inhibition, 327
 mixed inhibition, 324–26
 noncompetitive inhibition, 324
 product inhibition, 317
 uncompetitive inhibition, 322–24
- Inhibition constant, 318
- Inhibitors, 316
 competitive inhibitors, 316–22
 electron-transport chain, 552–54
 feedback inhibitor, 327
- Initial velocity (v_0), 310
- Initiation factors, 948
- Initiation, prokaryotic DNA replication, 820–23
- Initiation, translation, 944–50
 base pairing, 945–46
 eukaryotes, 949–50
 prokaryotes, 949–50
 soluble protein factors, 946–49
- Initiator caspases, 587
- Inner membrane, 546–47
- Inorganic pyrophosphatase, 407
- Inosine monophosphate (IMP), 780–82
- Inositol polyphosphate 5-phosphatase, 380
- Inositol-1,4,5-trisphosphate (IP₃), 376–77
- Inr (initiator) element, 891
- Insertion sequences, 863
- Insertion/deletion mutations, 841–43
- Insulators, 1022
- Insulin, 345, 757–59
 as antagonist, 505–6
 countering effects of, 759–61
 discovery of, 769
- Insulin receptor, 351
- Insulin receptor substrate (IRS), 380
- Insulin resistant, 770–71
- Insulin-dependent diabetes, 769–70
- Insulin-stimulated protein kinase, 375, 502
- Integral membrane proteins
 asymmetry of, 205
 definition, 204
- Integrases, 865
- Interaction energies, 29
- Intercalation, 1061
- Intermediate density lipoproteins (IDL), 637
- Intermediates, 305
 citric acid cycle, 535–41
 methylmalonyl-CoA mutase and, 652–53
 transferring, 522–23
- Intermembrane space, 547
- Internal conversion, 602
- Interphase, 1002–3
- Intervening sequences. *See* Introns
- Intracellular vesicles, 221–25
- Intrasteric mechanism, 378
- Intrinsic pathway, 587
- Intrinsic terminator, 883
- Intrinsically disordered proteins, 97
- Intronic splicing silencers (ISSs), 908
- Introns
 cloned genes, 1091
 discovery of, 902
 splicing exons and, 901–10
- Invariant residue, 1073
- Ion channels, 240–45
 central pore, 244
 Cl⁻ channels, 244–45
 gating, 241–42
 nerve impulses, 242
 second gate of, 243–44
 selectivity and speed of, 240–41
 voltage gating, 242–43
- Ion exchange chromatography, 1056
- Ion gradients, active transport driven by, 257–59
- Ion-dipole interactions, 29
- Ionic interactions, 28
- Ionizable groups, pK_a values of, 54
- Ionization
 polar side chains, 52–53
 water, 36
- Ionophores, 237–38
- Ions
 mitochondria and, 547–49
 solvation of, 28
- IP₃. *See* inositol-1,4,5-trisphosphate
- iPTG. *See* Isopropylthiogalactoside
- Iron sensor, 525–26
- Iron-sulfur cluster, 525, 555
- Irreversible, 17
- Ischemia, 112
- Ischemic cardiac muscle, 762
- Islets of Langerhans, 345
- Isoaccepting tRNAs, 93
- Isocitrate, 525
- Isocitrate dehydrogenase, 526
- Isocitrate lyase, 539
- Isoelectric focusing (IEF), 1060
- Isoforms, 332
- Isolated systems, 20
- Isoleucine
 breakdown of, 710–15
 extracting from pyruvate, 725–26
- Isomerase, 647
- Isopentenyl pyrophosphate, 677–78
- Isopeptide bond, 62, 693
- Isoprenoids, 198–99
- Isopropylthiogalactoside (IPTG), 985
- Isozymes, 332
- ISSs. *See* Intronic splicing silencers
- J**
- JAK-STAT pathway, 1022–24
- Japan Aerospace Exploration Agency (JAXA), 4
- Jun, 358
- Junk DNA, 906, 982
- K**
- K_{eq} (equilibrium constant), 19
- K⁺ channels, 240–41
- Kaback, Ronald, 257
- kbp. *See* Kilobase pair
- Keratin, 95
- Ketoacidosis, 768
- Ketogenesis, 655
- Ketogenic amino acids, 706
- Ketone bodies, 655–56
 in muscles, 751–53
 and starvation, 768
- Ketoses, 124–26
- Ketosis, 768
- Kidneys, 755
- Kilobase pair (kbp), 168
- Kinase cascade, 355, 358–60
- Kinases, 315
 high phosphoryl group-transfer potentials, 408
 nucleoside triphosphates and, 409–10
- Klenow fragment, 816–17
- Klentaq1. *See* DNA polymerase I
- K_M (Michaelis constant), 309
- K_M value of, 312–14
- Kornberg, Arthur, 816
- Kornfeld, Stuart, 145
- Koshland, Daniel, 330
- Kozak sequence, 949
- Krebs, Hans, 516
- Ku (protein), 851
- Kv channels, 242–43
- Kynureninase, 717–18
- L**
- lac repressor, 984–89
- Lactate, 455
 in blood, 755–56
- Lactate dehydrogenase (LDH), 455
- Lactose, 132–34

I-8 SUBJECT INDEX

- Lactose Intolerance, 132
 Lactose permease, 257–59
 Lactose synthesis, 507
 Lagging strand DNA, 813, 823–27
 Lanosterol, 680
 Lariat structure, 903
 Lateral diffusion, 202
 fluid mosaic model and, 211–13
 LBHBs. *See* low-barrier hydrogen bonds
 LDH. *See* Lactate dehydrogenase
 LDL. *See* Low density lipoproteins
 Le Chatelier's principle, 18
 Lead compound, 335
 Leader sequence, 991
 Leading strand DNA, 813, 823–27
 Lectins, 147
 Leghemoglobin, 741
 Leptin, 764
 Lesch–Nyhan syndrome, 785
 Leucine
 breakdown of, 715–17
 extracting from pyruvate, 725–26
 Leucine zippers, 1016–19
 Leukocytes, 147
 Levorotatory, 57
 LHC. *See* Light-harvesting complex
 Lienhard, Gustav, 269
 Life, 1–21
 cellular architecture, 7–12
 origin, 2–7
 thermodynamics, 13–21
 Ligand, 1058
 Ligand binding, 349
 Ligand-gated channels, 242
 Ligands, 90
 Ligation, 1086
 Light chains (L), 384, 866
 Light energy, chemical energy from, 601–2
 Light reactions, 601–18
 in Calvin cycle, 624–25
 chemical energy from light energy, 601–2
 electron transport in
 photosynthetic bacteria, 603–5
 photophosphorylation, 616–17
 two-reaction-center electron transport, 605–16
 Light reactions, 596
 Light-harvesting complex (LHC), 599–600
 Light, absorbing, 598–900
 Lignin, 136
 Limited proteolysis, 1067
 LINES. *See* Long interspersed nuclear elements
 Lineweaver–Burk plot, 12
 Link proteins, 141
 Linkages, 5
 Linker DNA, 997
 Lipase, 635
 Lipid bilayers
 fluidlike properties, 202–3
 formation of, 201–2
 Lipid classification
 fatty acids, 188–90
 glycerophospholipids, 191–92
 metabolic roles, 197–200
 sphingolipids, 192–94
 steroids, 194–97
 triacylglycerols, 190–91
 Lipid metabolism, 633–89
 cholesterol metabolism, 677–85
 digestion, absorption, and transport, 634–41
 fatty acid biosynthesis, 657–69
 fatty acid oxidation, 641–56
 prostaglandins, 675–76
 sphingolipids, 673–75
 synthesis of other lipids, 669–76
 Lipid raft, 217–18
 Lipid-linked proteins, 208–10
 Lipid–water interface, 635–36
 Lipids, 188
 absorption of, 634–41
 add membrane proteins, 204–10
 atherosclerosis and, 683–84
 bilayers, 201–3
 classification of, 188–200
 diacylglycerophospholipids and, 670–72
 digestion of, 634–41
 intestinal absorption of, 636–37
 as lipoproteins, 637–41
 membrane structure and assembly, 210–29
 membrane subdomains, 217–18
 storage diseases, 674–75
 synthesis of other lipids, 669–76
 transport of, 634–41
 Lipmann, Fritz, 403
 Lipoamide, 519
 Lipogenesis, 762
 Lipolysis, 763
 Lipoproteins, 637–41
 as complexes, 637–38
 major classes of, 637
 surface coating, 638
 Liposomes, 202
 Lipoyllysyl arm, 522–23
 Liquid water, structure of, 27
 Liver
 heme biosynthesis and, 733
 as metabolic clearinghouse, 753–55
 Liver glycogen synthase deficiency, 494
 Liver phosphorylase deficiency, 493
 Liver, transporting cholesterol to, 641
 lncRNAs. *See* Long noncoding RNAs, 1031
 London dispersion forces, 30
 Long interspersed nuclear elements (LINEs), 981
 Long noncoding RNAs (lncRNAs), 1031
 Long terminal repeats (LTRs), 981
 Long-chain enoyl-SCoA, 646
 Longevity, increasing, 768
 Low density lipoproteins (LDL), 637, 639–40
 Low-barrier hydrogen bonds (LBHBs), 295
 LTRs. *See* Long terminal repeats
 Luciferase, 1080
 Lysine
 breakdown of, 715–17
 synthesis of, 725
 Lysophospholipid, 193
 Lysosomal proteins
 coated vesicles transporting, 222
 Lysosomes, protein degradation, 9, 692
 Lysozymes, 142, 280–87
 catalysis strategies, 281
 catalytic site of, 281–83
 reaction of, 283–87
 residues of, 283–84
 role of strain in, 284–86
 support, 286–87
- M**
 M disk, 382
 M phase, 1033
 M-protein, 386
 MacKinnon, Roderick, 240
 Maintenance methylation, 1013
 Major grooves, 159
 Malaria, 119
 Malate, 465, 514
 Malate–aspartate shuttle, 547
 Malate dehydrogenase, 465, 530
 Malate, producing, 530
 Malate synthase, 539
 Male sex hormones, 348
 Malonyl-SCoA, 657, 806
 Maltose, 133
 Mammalian cells, oxidation in, 654–55
 Mammalian metabolism, acetyl-CoA Carboxylase, 659. *See also* Fuel metabolism
 Mammals, fuel metabolism in, 747–77
 Mannose-6-phosphate, 454
 Mannose, conversion of, 454
 MAP kinase kinase (MEK), 358, 359
 MAP kinase kinase kinases (MKKKs), 359
 MAPKs. *See* Mitogen-activated protein kinases
 Margulis, Lynn, 12
 Marmur, Julius, 163
 Mass spectrometry, 286–87, 1070–71
 Matrix, 547
 Maximal velocity (V_{max}), 310
 Mb. *See* myoglobin
 McArdle's disease, 493
 McClintock, Barbara, 862
 MCM, 832
 Mechanosensitive channels, 242
 Medial cisternae, 222
 Mediated transport, 236, 249
 Mediator, 1021
 Medulla, 347
 MEK. *See* MAP kinase kinase
 Melting temperature (T_m), 163, 203
 Membrane anchor, 19
 Membrane potential, 236
 Membrane proteins
 coated vesicles transporting, 222
 integral, 204
 interactions with hydrophobic lipids, 205–8
 lipid-linked proteins, 208–10
 loose associations, 210
 peripheral, 204
 secretory pathway, 218–21
 transmembrane, 205
 types, 204–5
 Membrane structure/assembly, lipids, 210–29
 asymmetrical distribution, 215–18
 cell shape definition, 213–15
 fluid mosaic model, 211–13
 intracellular vesicles, 221–25
 secretory pathway, 218–21
 skeleton, 213–15
 vesicle fusion, 225–29
 Membrane transport, 234–61
 active transport, 250–59
 passive-mediated transport, 237–50
 thermodynamics, 235–37
 Membrane-enveloped virus, 227
 Memory B cells, 866
 Menquinone, 603
 Menten, Maud, 308
 Messenger RNA (mRNA), 178, 876
 base pairing, 945–46
 controlling, 1031–32
 and cytoplasm, 909–10
 degradation of, 1025–26
 editing, 909
 5' caps, 898–99
 intron splicing, 901–10
 poly(A) tails, 899–901
 yielding multiple proteins, 906–9
 Metabolic flux, 400–402, 467
 Metabolic homeostasis, 757, 762–66
 Metabolic pathways, 8
 enzymatic reactions, 395–98
 and fuel metabolism, 748
 Metabolic reactions, 8–9
 Metabolic syndrome, 772
 Metabolism, 392–426
 aerobic metabolism, 584–86
 amino acid metabolism, 690–746
 definition, 393
 flux control, 400–402
 glucose metabolism, 427–84
 glycogen metabolism, 485–511
 high-energy compounds, 402–12
 hormonal control, 757–61
 lipid metabolism, 633–89
 metabolic pathways, 395–98
 nutrition and, 393–94
 overview of, 393–402
 oxidation–reduction reactions, 412–18
 steroid hormones, 348–49
 study of, 419–23
 thermodynamics, 399–400
 Metabolites, 395
 blood transporting, 755–56
 mitochondria and, 547–49
 tracing, 419–21
 Metabolix flux, 531
 Metabolomics, 423
 Metabolon, 534
 Metagenomic sequencing, 1082
 Metal chelate affinity chromatography, 1058
 Metal ion, 90
 catalysis, 277–78
 DNA polymerase catalytic mechanism, 813
 Metalloenzymes, 277
Methanococcus jannaschii, 220
 Methanogens, 10
 Methionine
 breakdown of, 710–15
 synthesis of, 725
 Methylation, 843
 Methylcobalamin, 725
 Methylmalonyl-CoA mutase, 650–53
 Micelles, 32–33
 Michaelis constant (K_M), 309
 Michaelis–Menten equation, 307–12
 catalytic constant, 311–12
 operational definition of constant, 310
 origins of, 307–8
 steady state, 308–10
 Michaelis, Leonor, 308
 Micro RNAs (miRNAs), 1027, 1029–30
 Microbiome, 751, 1082
 Microdomains, 217
 Microheterogeneity, 140
 Mineralocorticoids, 196, 348
 Minerals, metabolic reactions, 394–95
 Minor grooves, 159
 miRNAs. *See* Micro RNAs
 Misfolding, proteins, 108–10
 Mismatch repair (MMR), 850–52
 Mitchell, Peter, 570
 Mitochondria, 9
 cell death and, 586–90

- inner membrane of, 546–47
ions and metabolites, 547–49
phosphate carrier in, 549
reduction potentials in, 553
Mitochondrial β oxidation, 654–55
Mitogen-activated protein kinases (MAPKs), 358
Mixed inhibition, 324–26
MKKKs. *See* MAP kinase kinase kinases
MLCK. *See* myosin light chain kinase
Motor protein, 386
MMR. *See* mismatch repair
Moderately repetitive DNA, 982
Modification methylase, 1077
MoFe-protein, 739
Molecular basis of development, 1038–43
Molecular chaperones, 105–10
Molecular cloning, 1085
Molecular crowding, 91
Molecular sieve
 chromatography, 1057
Molecularity, 305
Molten globule, 101
Monoclonal antibodies, 867
Monomers, 6
Monosaccharides, 124–31
 aldoses and ketoses, 124–26
 configuration and conformation, 126–28
Monotopic proteins, 205
Moonlighting, 525–26
Motif ten element (MTE), 891
Motifs, secondary structures, 85
Mouse cells, fusing with humans, 212
mRNA. *See* Messenger RNA
Multienzyme complexes, 517
Multiple myeloma, 867
Multiprotein complexes, 93, 97
Muscle
 fuels of, 751–53
 glycolysis in, 467–70
 insulin in, 758
Muscle phosphofructokinase deficiency, 493
Muscle phosphorylase deficiency, 493
Mutarotation, 128
Mutase, 444
Mutations, 11, 183, 840, 841–44
MutH, 851
MutL, 850
MutS, 850
Myc, 358, 1037
Mycobacterium leprae, 859
Myo-1,6-glucosidase, 493
Myofibrils, 382
Myoglobin (Mb), 111–12
 heme prosthetic group, 111
 oxygen binding by, 111–12
Myomensin, 386
Myosin, 384
Myosin-binding protein, 386
Myosin head, 384
Myosin light chain kinase (MLCK), 378
Myristoylation, 209
- N**
N⁵-methyl-THF, 712
N⁵-formimino-THF, 713
N⁵,N¹⁰-methylene-THF, 707
N-acetyl-D-glucosamine (GlcNAc), 138
N-acetylglucosamine (NAG), 281
N-acetylglutamate (NAG), 705
N-acetylmuramic acid (NAM), 142, 281
N-end rule, 693
N-formimino-glutamate, 709
N-formylmethionine, 945
N-linked oligosaccharides, 141, 144–46, 508–9
N-terminus, 63
NAD⁺ (nicotinamide adeninedinucleotide), 86, 271, 412, 413, 519, 827
NADH (nicotinamide adenine dinucleotide hydrogen), 396
 accepting electrons from, 554–59
 pentose phosphate pathway, 474–75
NADP, in oxidative metabolism, 580–82
NADP⁺, proton gradient formation, 615–16
NADPH (nicotinamide adenine dinucleotide phosphate)
 dissipation of, 626–27
 two-reaction-center electron transport and, 605–16
NADPH-P450 reductase, 337
NAG. *See* N-acetylglucosamine; N-acetylglutamate
NAM. *See* N-acetylmuramic acid
Naproxen (Aleve), 200
NASA, 4
Native proteins, 81
Natural selection, 7
ncRNAs. *See* Noncoding RNAs
Near-equilibrium reactions, 399
Nebulin, 386
Necrosis, 587
Negative regulator, 989
Negatively cooperative binding, 114
NER. *See* Nucleotide excision repair
Nernst equation, 414–15
Nerve impulses, 242
Nerve poisons, 288
Neuroglobin, 112
Neurospora crassa, 182
Neurotransmitters, 225
Neutral solutions, 36
Next generation sequencing, 976
NHEJ. *See* Nonhomologous end-joining
Nick translation, 820
Nicotinamide adenine dinucleotide (NAD⁺), 271, 412–14, 436
Nicotinamide adenine dinucleotide phosphate (NADP⁺), 271
Nitric oxide, 736–38
Nitrogen fixation, 738–42
Nitrogen metabolism, 722–23
Nitrogen, packaging, 701–4
NMD. *See* Nonsense-mediated decay
NMR. *See* Nuclear magnetic resonance
No-go decay, 1026
Non-equilibrium steady state, 20
Non-insulin-dependent diabetes, 770–71
Non-standard state, 18
Non-steroidal anti-inflammatory drugs (NSAIDs), 200
Noncoding RNAs (ncRNAs), 876, 976
Noncoding strand, 877
Noncompetitive inhibition, 324
Noncooperative binding, 114
Nonessential amino acids, 721–25
Nonhomologous end-joining (NHEJ), 852
Nonmediated transport, 236, 250
Nonpolar side chains, 49–52
Nonreceptor tyrosine kinases (NRTKs), 360–63
Nonreducing sugars, 131
Nonsense codons, 923
Nonsense mutation, 963
Nonsense suppressor, 964
Nonsense-mediated decay (NMD), 1026
Nonsteroidal anti-inflammatory drugs (NSAIDs), 675–76
Nonstop decay, 1026
Norepinephrine, 347–48, 504, 735–36
Northern blot, 1062
NPCs. *See* Nuclear pore complexes
NRTKs. *See* Nonreceptor tyrosine kinases
NADP, in oxidative metabolism, 580–82
NTPs. *See* Nucleoside triphosphates (NTPs)
Nuclear blebbing, 590
Nuclear magnetic resonance (NMR), 82–84, 158, 1096–97
Nuclear pore complexes (NPCs), 910
Nuclear receptor superfamily, 1024
Nucleases, 1053
Nucleic acid function, 180–83
Nucleic acid sequencing, 1076–85
 chain-terminator method, 1078–79
 of genomes, 1081–82
 mutations and evolution, 1083–85
 restriction endonucleases, 1077–78
 sequencing-by-synthesis methods, 1080–81
Nucleic acid structure
 DNA, 157–75
 RNA, 175–80
Nucleic acids
 definition, 152
 negative charges of, 162
 structure, 157–80
Nucleobase, 153–57
Nucleoporins, 910
Nucleosidases, 799
Nucleoside diphosphate kinase, 784
Nucleoside diphosphates, 783–84
Nucleoside monophosphate kinases, 784
Nucleoside monophosphates, 783–84
Nucleoside phosphorylases, 799
Nucleoside triphosphates (NTPs), 409–10, 783–84
Nucleosides, 153–57
Nucleosome core particle, 997
Nucleosomes, forming, 996–99
Nucleotide biosynthesis, 729–30
Nucleotide degradation, 799–806
 purine catabolism, 800–801
 pyrimidine breakdown, 806
 uric acid degradation, 803–5
Nucleotide excision repair (NER), 848–50
Nucleotide metabolism, 778–809
 deoxyribonucleotide formation, 790–98
 nucleotide degradation, 799–806
 purine ribonucleotide synthesis, 779–85
 pyrimidine ribonucleotide synthesis, 786–89
Nucleotide sugars, 506–7
Nucleotides, 153–57
 definition, 152
 DNA polymerase and correctly paired, 815–20
 metabolic reaction participation, 155–56
 polynucleotides and, 153–57
Nucleus, 9
Nutrition, 393–94
- O**
O-linked oligosaccharides, 141, 146, 508
O⁶-methylguanine, 842
Obesity, 771–72
Ocean acidification, 37
ODCase. *See* OMP decarboxylase
OEC. *See* Oxygen-evolving center
Oils, 190
Okazaki fragments, 813
Oligomers, 93
Oligopeptides, 63
Oligosaccharide, 132
 as antigenic determinants, 148
 defining protein structure, 146–47
 mediating recognition events, 147–48
 N-linked, 141
 O-linked, 141, 146
Oligosaccharide processing, 145
OMP decarboxylase (ODCase), 787
OMP. *See* Orotidine-5'-monophosphate
Oncogenes, 358
Open reading frames (ORFs), 976, 1082
Open systems, 20
Operator, 986
Operons, 878
Optical activity, 56
Optical density, 1054
ORC. *See* Origin recognition complex
Ordered mechanism, 314
ORFs. *See* Open reading frames
Organ specialization, 748–56
 adipose tissue, 753
 blood, 755–56
 brain, 751
 intestinal microbiome, 751
 kidneys, 755
 liver, 753–55
 muscle, 751–53
Organelles, 9
Organic compounds, 3
Organism, evolutionary domains of, 9–11
oriC, 820
Orientation effects, catalytic mechanisms, 278–80
Origin recognition complex (ORC), 832
Origin-independent replication restart, 860
Origins of life
 inanimate substances, 3–5
Ornithine, 704
 precursor to, 723
Ornithine transcarbamoylase, 704
Orotidine-5'-monophosphate (OMP), 787
Orthophosphate cleavage, 407
Osmosis, 34–35
Osmotic pressure, 34
Overproducer, 1091
Overwinding, DNA, 169
Oxaloacetate, 514, 530, 709, 721–22
Oxalosuccinate, 526
Oxidation, 397
Oxidation-reduction reactions
 electron carriers, 412–14
 Nernst equation, 414–15
 spontaneity, 416–18

I-10 SUBJECT INDEX

- Oxidative metabolism, 580–86
 aerobic metabolism, 584–86
 ATP/NADH concentrations, 580–82
 pathways of, 58–182
 reactive oxygen species (ROS), 585
 uncoupling of, 582–83
 Oxidative phosphorylation, 408, 545, 568–79
 ATP synthase and, 568
 bacterial electron transport, 571
 chemiosmotic theory, 568–71
 fuel metabolism and, 749
 Oxidative reactions, 476
 Oxidation, ribonucleotide reductase, 793
 Oxidizing agent, 414
 OxoG. *See* 8-Oxoguanine
 Oxonium ion, 283
 Oxyanion hole, 294
 Oxygen
 binding, heme prosthetic group, 111
 debt, 756
 deprivation, 584
 two-reaction-center electron transport, 605–16
 Oxygen transport, 110–19
 hemoglobin, 112–19
 myoglobin, 111–12
 Oxygen-evolving center (OEC), 608
 Oxygen, generation of, 610–11
 Oxygen, reducing to water, 565–67
 Oxygenation, 111
 Oxyhemoglobin, 113
- P**
 P-cluster, 739
 P-type ATPases, 251–54
 P/O ratios, 579
 p53, 1035–38
 P680, 608
 Palmitoyl-SCoA, 673–75
 Palmitoylation, 209
 Pancreatic islet hormones, 345–47
 Parallel β sheet, 77
 Partial pressure (pO_2), 112
 Passenger RNA, 1028
 Passive-mediated transport
 aquaporins, 245–46
 conformation alternation, 246–50
 definition, 237
 ion channels, 240–45
 ionophores and, 237–38
 porins and, 239
 Pasteur effect, 460
 Pathogens, 866
 Pauling, Linus, 75–76, 269
 PBG. *See* Porphobilinogen
 PbRC. *See* Photosynthetic bacteria
 PCR. *See* Polymerase chain reaction
 PDC. *See* Pyruvate decarboxylase complex
 PDI. *See* Protein disulfide isomerase
 Pectins, 139
 Penicillin, 143
 Penicillinase, 143
Penicillium notatum, 143
 Pentose phosphate pathway, 429, 474–81
 carbon-carbon bond cleavage/formation, 477–78
 NADPH and NADH, 474–75
 oxidative reactions, 476
 regulation of, 478–81
 Ru5P-R5P conversion, 477
 Pentoses, 124
 PEP. *See* Phosphoenolpyruvate
 PEP carboxykinase (PEPCK), 462, 464
 PEPCK. *See* PEP carboxykinase
 Peptide bonds, 63–64
 Peptides, defined, 63
 Peptidoglycan, 141–43
 Peptidyl site, 940
 Peptidyl transferase, 940
 Peptidyl-tRNA, 940
 Peripheral membrane proteins, 204
 Peroxisomal β oxidation, 654–55
 Peroxisome proliferator-activated receptor- γ (PPAR- γ), 771
 Peroxisomes, 9, 654–55
 Perturbation, system, 421–22
 PFK-2. *See* Phosphofructokinase-2
 PFK. *See* Phosphofructokinase
 PGI. *See* Phosphoglucose isomerase
 PGK. *See* Phosphoglycerate kinase (PGK)
 pH
 acid and base impact on, 37–39
 buffers and, 40–43
 common substances, 36
 effects on enzyme activity, 274
 and kidneys, 755
 weak acids and bases, 38–39
 zwitterons, 49
 Pharmacogenomics, 338
 Pharmacokinetics, 336
 PHD finger, 1012
 phen. *See* Phentermine
 Phenolic side chains, 53–54
 Phenotype, 1083
 Phentermine (phen), 336
 Phenylalanine
 breakdown of, 718–20
 synthesis of, 727
 Phenylisothiocyanate (PITC), 1069
 Phenylketonuria, 134, 719
 Phenylthiocarbonyl (PTC), 1069
 Phenylthiohydantoin (PTH), 1069
 Philadelphia chromosome, 362
 Phillips, David, 281
 Phosphagens, 409
 Phosphate carrier, 549
 Phosphatidic acids, 192
 Phosphatidylinositol, 199
 Phosphatidylinositol-4,5-bisphosphate (PIP 2), 377
 Phospho-Tyr residues, binding, 355
 Phosphoanhydride, 404
 Phosphocreatine, 408, 409
 Phosphodiester bond, 157
 Phosphodiesterases, 374–75
 Phosphoenolpyruvate (PEP), 446–47, 461–65, 727
 Phosphofructokinase, 467–70
 Phosphofructokinase (PFK), 467–70, 435–36
 Phosphofructokinase-2 (PFK-2), 472
 Phosphoglucomutase, 488, 492–94
 Phosphoglucose isomerase (PGI), 434–35
 Phosphoglycerate kinase (PGK), 443–44
 Phosphoinositide 3-kinases (PI3Ks), 380
 Phosphoinositide pathway
 calmodulin, 377–79
 complex systems, 380–82
 definition, 375
 diacylglycerol, 379–80
 ligand binding, 376–77
 Phospholipase C (PLC), 376–77
 Phosphomannose isomerase, 454
 Phosphoprotein phosphatase inhibitor 1, 502
 Phosphoprotein phosphatase-1 (PP1), 364, 500–503
 Phosphorolysis, 332, 488
 Phosphoryl group transfers, 406
 Phosphoryl group-transfer potentials, 404
 Phosphorylase kinase, 500
 Phosphorylase kinase deficiency, 493
 Phosphorylation, 334–35
 Photoautotrophs, 394
 Photons, 599
 absorption of, 604
 Photooxidation, 602
 Photophosphorylation, 616–17
 Photoreactivation, 846
 Photorespiration, 626–28
 Photosynthesis, 595–632
 chloroplasts, 597–600
 dark reactions, 618–28
 definition, 595
 light absorption, 598–900
 light reactions, 601–18
 with noncyclic electron transport, 617
 photorespiration competing with, 626–28
 Photosynthetic bacteria (PbRC), 603–5
 PSI RC resembling, 613–15
 PSII resembling, 607–9
 Photosynthetic reaction centers, 599
 Photosystem I (PSI), 605
 resemblances, 613–15
 segregation of, 611
 transporting electrons to, 611–13
 Photosystem II (PSII), 605
 resemblances, 613–15
 resembling PbRC, 607–9
 segregation of, 611
 Photooxidation, 604–5
 Phylloquinone, 613
 Phylogenetic tree, 1073–75
 phylogeny, 10
 Physiologically active amines, 735–36
 π -cation interaction, 29
 PIC. *See* Preinitiation complex
 Pigment molecules, 598–600
 Pigments, complexes containing, 599–600
 P_{II} helix, 79–81
 P_{II} strand, 79
 Ping Pong reactions, 315
 PIP 2. *See* phosphatidylinositol-4,5-bisphosphate, 377
 PITC. *See* Phenylisothiocyanate
 Pitch, 75
 PK. *See* Pyruvate kinase
 PKA. *See* Protein kinase A
 PKC. *See* Protein kinase C
 Placebo, 336
 Planar peptide group, 72–74
 Plaque, 1088
 Plasmalogen, 192, 672–73
 Plasmids, 1085
Plasmodium, 335
 Plastocyanin, 611–13
 Plastoquinol (QH₂), 606
 Plastoquinone (Q), 606
 PLC. *See* phospholipase C
 PLP. *See* Pyridoxal-5'-phosphate
 PMP. *See* Pyridoxamine-5'-phosphate
 Point mutations, 841–42, 1083
 Pol III holoenzyme, 823–27
 Pol III. *See* DNA polymerase III
 Pol γ . *See* DNA polymerase γ , 831
 Pol ϵ , 830
 Pol η . *See* DNA polymerase η
 Pol. *See* DNA polymerases
 Polar molecule, water as, 25–26
 Polar side chain, 52–54
 Polarimeter, 56
 Polarity
 of side chains, 87–89
 of water, 25–27
 Poly(A) binding protein II (PAB II), 900
 Poly(A) polymerase (PAP), 899
 Poly(A) tail, 899–901
 Poly(A)-binding protein (PABP), 900
 Polyacrylamide, 1059
 Polyacrylamide gel electrophoresis (PAGE), 1059
 Polyclonal, 867
 Polymerase chain reaction (PCR), 1090
 Polymers, 6
 Polymorphic, 337
 Polymorphisms, 982–83, 1090
 Polynucleotides
 chemical structure of, 156
 definition, 156
 primary structure of, 156–57
 Polypeptide chain confirmations, 72–74
 Polypeptides
 defined, 63
 domains formed by, 85–87
 limitations of, 64
 proteins and, 63–65
 theoretical possibilities of, 64
 Polyproteins, 318
 Polyprotic acids, 41
 Polyribosomes, 944
 Polysaccharides, 124, 131–40
 disaccharides, 132–34
 glycosaminoglycans, 137–40
 storage, 134–36
 structural, 136–37
 Polytopic proteins, 205
 Polyubiquitin, 693
 Polyunsaturated fatty acids, 664–65
 Pompe's disease, 493
 Porins, 207, 239
 Porphobilinogen (PBG), 731
 Porphyrins, 733
 Positive regulator, 989
 Positively cooperative binding, 114
 Posttranscriptional control
 mechanisms, eukaryotic gene expression, 1025–32
 Posttranscriptional modification, 898
 Posttranscriptional processing, 898–916
 5' capping, 898–901
 intron splicing, 901–10
 rRNA, 910–13
 3' tail for, 898–901
 tRNA, 913–15
 Posttranslational modification, 219
 Posttranslational processing, 964–69
 PP1. *See* Phosphoprotein phosphatase-1
 PP2A, 364
 PPAR- γ . *See* peroxisome proliferator-activated receptor- γ
 pRb, 1037–38
 pre-miRNAs, 1030
 Pre-RC. *See* Prereplication complex
 Pre-RNAs, 910
 Pre-tRNAs, 915
 Prebiotic era, 3
 Precursors, 8

- Preinitiation complex (PIC), 893
 Prelog, Vladimir, 58
 Prenylated proteins, 208
 Preproteins, 219
 Prereplication complex (pre-RC), 832
 Presequences, 219
 pri-miRNAs, 1030
 Pribnow box, 879
 Primary active transport, 251
 Primary structure, 64, 70
 Primary transcripts, 989
 Primer, 1078
 Primosome, 823
 Prion, 108
 Probe, 1089
 Procaspases, 587
 Procaspase-7, 587
 Procaspase-10, 587
 Processive enzyme, 815
 Prochiral molecule, 266
 Product inhibition, 317
 Proenzymes, 297
 Progestins, 349
 Programmed cell death, 586
 Prokaryotes, 9
 Prokaryotic DNA replication, 815–29
 DNA polymerases, 815–20
 fidelity, 829
 initiation and elongation, 820–23
 leading and lagging strand synthesis, 823–27
 termination, 827–28
 Prokaryotic gene expression, 984–95
 attenuation, 990–93
 catabolite repression, 989–90
lac repressor, 984–89
 riboswitches, 994–95
 Prokaryotic transcription, 876–86
 5' to 3' chain growth, 881–83
 initiation of, 879–81
 RNA polymerase and other polymerases, 877–79
 termination of, 883–86
 Proline
 breakdown of, 709–10
 precursor to, 723
 Promoters, 879–81, 891–92, 896
 Proofreading, 819, 931–32, 954–55
 Proporphyrin, 111
Propionibacterium shermanii, 650
 Propionyl-SCoA, 649–54, 712
 Prostaglandin synthase enzymes (PTGS), 200
 Prostaglandins, 199
 Prosthetic groups, 272
 Proteases, 1053, 1067
 Protein degradation
 lysosomes, 692
 proteasome, 694–96
 ubiquitin, 692–94
 ubiquitinated proteins, 694–96
 Protein denaturation, 99–101
 Protein disulfide isomerase (PDI), 104
 Protein folding
 denaturation and renaturation, 99–101
 diseases from misfolding, 108–10
 molecular chaperones in, 105–10
 Protein kinase A (PKA), 371, 500–501
 Protein kinase C (PKC), 379–80
 Protein kinases, 193, 331, 334
 Protein mass fingerprinting, 1071
 Protein misfolding diseases, 108–10
 Protein phosphatases, 194, 331
 Protein renaturation, 99–101
 Protein sequencing, 1064–76
 database storage of sequences, 1071–073
 disruption of quaternary structure, 1064–66
 Edman degradation, 1069–70
 mass spectrometry, 1070–71
 polypeptide cleavage, 1066–68
 revealing evolutionary relationships, 1073–76
 separating subunits, 1064–66
 Protein Ser/Thr phosphatases, 364–65
 Protein structures
 conservation of, 91–92
 determination of, 83–84
 molecular crowding and, 91
 NMR determination, 83–84
 prediction of, 103
 primary structure, 64, 70
 quaternary structure, 93–98
 secondary structure, 70, 71–82
 stability of, 89–91
 tertiary, 82–92
 Protein synthesis, 919–72
 effect of antibiotics on, 960–61
 and genetic code, 920–25
 posttranslational processing, 964–69
 ribosomes, 935–42
 translation, 943–64
 and tRNA, 926–35
 Protein tyrosine kinase (PTK), 353
 as targets of anticancer drugs, 362–63
 Protein tyrosine phosphatases (PTPs), 363–65
 protein-protein interfaces, 97
 Proteins, 69–122
 chaperones facilitating evolution of, 110
 cholesterol exit, 684–85
 compositions of, 65
 core, 140–41
 degradation of, 691–96
 denatured, 81
 depiction of, 78
 design of, 103
 determining concentrations, 1054
 directed to lysosome, 224–25
 ER-resident, 225
 flexibility of, 97–98
 fibrous, 81
 folding pathways of, 101–4
 fusion, 227
 genome encoding, 975–77
 globular, 81
 glycosylated, 143–46
 glycosylphosphatidylinositol-linked, 209–10
 green fluorescent protein (GFP), 61
 heterotrimeric G proteins activating, 379
 intracellular vesicles transporting, 221–25
 intrinsically disordered, 97
 levels of structure, 70–71
 link, 141
 lipid-linked, 208–10
 lipoproteins and, 637–38
 mediating vesicle fusion, 225
 membrane, 204–10
 multiprotein complexes, 93
 native, 81
 newly synthesized, 966–69
 nonrepetitive structure in, 81–82
 polypeptides and, 63–65
 prenylated, 208
 primary structure of, 64–65
 protein-protein interfaces, 97
 quantitation of, 1053
 side chains, 60
 structure determination, 83–84
 structure predictions, 103
 synthesis of, 182–83
 tertiary structures, 82–92
 thermostability, 100
 uncoupling proteins, 582–83
 Proteoglycans, 140–41
 Proteome, 976
 Proteomics, 423, 1060
 Proteosome, 694–96
 Protomer, 94
 Proton gradient, generating, 569–71, 611, 615–16, 616–17
 Proton motive force (pmf), 569
 Proton pump, 557–58
 Protons
 acid as donors, 38
 acid-base catalysis and, 273–75
 translocating, 558–59
 Protoporphyrin IX, 732
 Proximity effects, catalytic mechanisms, 278–80
 PRPP. *See* 5-Phosphoribosyl- α -pyrophosphate
 Pseudo-first-order reaction, 307
 Pseudogenes, 979
 Pseudouridine, 911, 926
 PSI. *See* Photosystem I
 PSII. *See* Photosystem II
 PTC. *See* Phenylthiocarbonyl
 Pterin-4a-carbinolamine, 719
 Pterin-4a-carbinolamine dehydratase, 719
 Pterins, 718–20
 PTH. *See* Phenylthiohydantoin
 PTK. *See* Protein tyrosine kinase
 PTPs. *See* Protein tyrosine phosphatases
 pUC18, 1086
 Pulsed field gel electrophoresis (PFGE), 1061
 Purine, 153
 derivatives of, 805
 Purine catabolism, 800–801
 Purine nucleotide biosynthesis, 784–85
 Purine nucleotide cycle, 801
 Purine ribonucleotide, synthesis of, 779–85
 inosine monophosphate, 780–82
 Purines, salvaging, 785
 Pyranose, 126
 Pyridoxal-5'-phosphate (PLP), 489, 698
 Pyridoxamine-5'-phosphate (PMP), 699
 Pyrimidine, 153
 breakdown of, 806
 Pyrimidine dimers, 841
 Pyrimidine nucleotide, biosynthesis of, 788–89
 Pyrimidine ribonucleotide synthesis, 786–89
 Pyrimidine synthesis, regulating, 327
Pyrobaculum aerophilum, 905
Pyrolobus fumarii, 100
 Pyrophosphate, 404
 Pyrophosphate cleavage, 407
 Pyrosequencing, 1080
 Pyrrole, 111
 Pyrrole-2-carboxylate, 270
 Pyruvate, 721
 amino acid degradation to, 706–8
 converting to
 phosphoenolpyruvate, 461–65
 essential amino acids and, 725–26
 hydrolytic reactions, 466
 nonessential amino acids and, 721–22
 Pyruvate carboxylase, 462–63
 Pyruvate decarboxylase, 456
 Pyruvate decarboxylase complex (PDC), 97
 Pyruvate dehydrogenase, 517
 coenzymes and prosthetic groups of, 519
 complex, 519–23
 as multienzyme complex, 517–18
 regulations, 532–33
 Pyruvate dehydrogenase kinase, 532
 Pyruvate dehydrogenase phosphatase, 532
 Pyruvate, glycolysis producing, 455
 Pyruvate kinase (PK), 447–49
 PYY_{3–36}, 765
- Q**
 Q cycle, 561–65
 Q-SNAREs, 226
 Quantum yield, 604
 Quaternary structure, 70
 proteins, 93–98
 disruption of, 1064–66
 Quinine, 335
- R**
 R groups, 49
 R state, 114
 R-SNAREs, 225
 R5P. *See* Ribose-5-phosphate
 Racemic mixture, 58
 Radioactive isotopes, 420
 Radioimmunoassay (RIA), 346, 1053
 Radionuclides, 420
 Raf, Ser/Thr kinase, 358
 Ramachandran diagram, 73–74
 Random mechanism, 315
 Ras, G protein, 355
 Rat liver enzymes, 692
 Rate constant, 305
 Rate equations, 304–7, 306
 Rate of sequence divergence, 1075–76
 Rate-determining step, 268
 Rational drug design, 335
 RC. *See* Reaction center
 Reaction center (RC), 603
 Reaction coordinate diagram, 267
 Reaction kinetics. *See* Enzyme kinetics
 Reaction mechanism
 drawing, 272
 establishing, 313–14
 Reaction order, 305
 Reaction spontaneity, variation of, 17
 Reactions, citric acid cycle, 535–41
 Reactions, glycolysis, 432–49
 aldolase, 436–37
 fructose-1,6-bisphosphate, 435–36
 G6P conversion, 434–35
 glyceraldehyde-3-phosphate dehydrogenase, 441–42
 hexokinase, 432–33
 phosphoenolpyruvate, 446–47
 2-phosphoglycerate (2PG), 444–46
 3-phosphoglycerate (3PG), 443–44
 phosphoglycerate kinase (PGK), 443–44
 pyruvate kinase, 447–49
 triose phosphate isomerase, 437–40

I-12 SUBJECT INDEX

- Reactive oxygen species (ROS), 561, 585
- Reads, 1079
- RecA (protein), 856–57
- RecBCD (protein), 857–58
- Receptor tyrosine kinases (RTKs), 351–65
- activating, 353–55
 - nonreceptor tyrosine kinases, 360–63
 - protein phosphatases, 363–65
 - relaying signals, 355–60
 - signal transmission, 351–55
- Receptor-mediated endocytosis, 228, 640
- Receptor–ligand binding, 352
- Receptors
- desensitization, 372–74
 - metabolic regulation, 760–61
- Recombinant DNA technology, 1085
- Recombination, 854–65
- homologous, 854–60
 - in nucleic acid sequencing, 1083
 - repair through, 860–62
 - transposition, 862–65
- Recombination repair, 852
- Recombination signal sequences (RSSs), 870
- Redox centers, 545
- Redox cofactors, 718–20
- Redox couple, 414
- Reduced coenzymes, 545
- Reducing agent, 414
- Reducing End, 135
- Reducing sugars, 131
- Reduction, 397
- Reduction potential, 415
- Regulation, citric acid cycle, 531–34
- Regulations, glucose metabolism, 466–73
- independent regulation, 471–73
 - phosphofructokinase, 467–70
 - substrate cycling, 470–71
- Regulatory light chains, 384
- Relative configuration, 57
- Relaxed circles, 169
- Release factors, 961–64
- Renaturation
- DNA (deoxyribonucleic acid), 162–63
 - protein, 99–101
- Repair. *See* DNA repair
- Reperfusion injury, 112
- Repetitive DNA sequences, 979–83
- Replica plating, 1089
- Replication, 6, 181
- Replication factor C (RFC), 830
- Replication forks, 812, 833
- Replication protein A (RPA), 832
- Replicons, 833
- Replisome, 823
- Resequencing, 1084
- Resistin, 771
- Resonance energy transfer, 602
- Restart primosome, 860
- Restriction endonuclease, 1077
- Restriction–modification system, 1077
- Retinal, 198
- Retinol binding protein, 86
- Retro-Claisen condensation, 646
- Retrograde transport, 222
- Retrotransposons, 865
- Reverse transcriptase, 318, 831, 1089
- Reverse turns, 79
- Reversible, 17
- RF-1, 961
- RF-2, 961
- RF-3, 963
- RFC. *See* Replication factor C
- Rhamnose, 139
- Rho factor, 883–86
- RIA. *See* Radioimmunoassay
- Ribonuclease A (RNase A), 100
- Ribonucleoprotein, 834, 966–68
- Ribonucleotide reductase (RNR)
- oxidization of, 790
- Ribonucleotides, 783–84
- conversion of, 790–94
- Ribose, 153
- Ribose-5-phosphate (R5P), 474
- Ribosomal recycling factor (RRF), 963
- Ribosomal RNA (rRNA), 176–78, 876, 910–13
- secondary structures of, 936
- Ribosomes, 183
- buried prokaryotic ribosomes, 941–42
 - as entropy trap, 956
 - helping protein fold, 965–66
 - molecular mimicry, 957
 - monitoring correct codon–anticodon pairing, 952–53
 - prokaryotic, 935–41
 - proofreading, 954–55
 - three-dimensional structure of, 936–41
 - translation activities, 950–61
 - translocation activities, 957
 - transpeptidation activities, 955–56
 - tRNA-binding sites, 940–41
- Riboswitches, 994–95
- Ribothymidine, 926
- Ribozymes, 178–80, 955
- Ribulose bisphosphate carboxylase (RuBP carboxylase), 621–23
- Ribulose-5-phosphate (Ru5P), 474, 618
- Ribulose-5-phosphate epimerase, 477
- Ribulose-5-phosphate isomerase, 477
- Rieske center, 561
- RISC. *See* RNA-induced silencing complex
- RNA interference (RNAi), 1027–31
- RNA ligase, 915
- RNA polymerase I (RNAP I), 887, 891
- RNA polymerase II (RNAP II), 886, 891–92
- RNA polymerase III (RNAP III), 886, 892
- RNA polymerases (RNAPs), 876
- collisions, 882
 - correcting mistakes of, 890–91
 - eukaryotic, 886–91
 - and other polymerases, 877–79
 - as processive, 882
 - promoter recognition, 891–92
 - structure of, 889–90
- RNA primers, 814–15, 823
- RNA template, 833–34
- RNA world, 7, 176, 178–79
- RNA-dependent RNA polymerase, 1028
- RNA-induced silencing complex (RISC), 1027
- RNAi. *See* RNA interference
- RNAPs. *See* RNA polymerases
- RNAs, 175–80
- as catalysts, 178–80
 - double helix of, 176
 - riboswitches, 994–95
 - RNA world, 176, 178
 - rRNA molecules, 176–78
 - structures, 176–78
 - tRNA structures, 176
- RNase A, acid-base catalysis, 274–75
- RNase H1, 832
- RNase P, 914
- RNR. *See* Ribonucleotide reductase
- Roberts, Richard, 902
- ROS. *See* Reactive oxygen species
- Rosetta@home, 103
- Rosiglitazone (Avandia), 337
- Rossmann fold, 86
- Rotational symmetry, 94
- RPA. *See* Replication protein A
- RRF. *See* Ribosomal recycling factor
- rRNA. *See* Ribosomal RNA (rRNA)
- RS system (Cahn-Ingold-Prelog system), 58
- RSSs. *See* Recombination signal sequences
- RTKs. *See* Receptor tyrosine kinases
- Ru5P. *See* Ribulose-5-phosphate
- RuBP carboxylase. *See* Ribulose bisphosphate carboxylase
- RuvABC (protein), 859–60
- S**
- S phase, 1033
- S-adenosylmethionine (SAM), 711
- S7P. *See* Sedoheptulose-7-phosphate
- Saccharides, 124
- Salmonella typhimurium*, 728–29
- Salt, solvation of, 28
- Salting in, 1055
- Salting out, 1055
- Salvage pathways, 785
- Sarcin-ricin loop, 954–55
- Sarcoplasmic reticulum, 388
- Saturated enzyme, 310
- Saturated lipid, 188–90
- Scaffold, 1001–2
- Scaffold proteins, 358–60
- Schiff base (imine), 698–99
- Schulz, Georg, 49
- Scissile, 287
- Screening, 1089
- Scrunching, 882
- SDS-PAGE, 1059–60
- Sec61, 220
- Second gate, ion channels, 243–44
- Second law of thermodynamics, 15–16
- Second-order reaction, 305
- Secondary active transport, 251
- Secondary structures (proteins), 70, 71–82
- combinations in tertiary structures, 82–87
 - motifs in, 85
 - P_{II} helix, 79–81
 - P_{II} strand, 79
 - planar peptide group of, 72–74
 - turns in, 79
 - α helix, 75
 - β sheet, 75–79
 - β strand, 75–79
- Secondary structure (DNA)
- A-DNA base pairs, 166
 - B-DNA, 164–65
 - sugar–phosphate backbone, 163–64
 - Z-DNA, 166–68
- Secretory pathway, 218–21
- Secretory proteins, coated vesicles
- transporting, 222
- SecY, 220
- Sedoheptulose-7-phosphate (S7P), 477
- Segmental duplications, 980
- Selectable markers, 1087
- Selectins, 147
- Self-compartmentalized proteases, 696
- Self-replicating systems, 6–7
- Self-splicing, 911–12
- Semialdehyde (glutamate-5-semialdehyde), 709
- Semiconservative mode, replication, 811
- Semidiscontinuous replication, 813
- Semiquinone state., 414
- Sense strand, 877
- Spectrin, 213
- Sequence of events, electron transport, 551–54
- Sequence recognition, 993
- Sequencing-by-synthesis methods, 1080–81
- Sequential model of allostery, 330
- Sequential reactions, 314
- Serine, 146, 673–75
- breakdown of, 706–8
 - deriving from 3-phosphoglycerate, 724–25
- Serine proteases, 287–99
- active site, 287–89
 - catalytic mechanisms, 292–97
 - convergent evolution, 292
 - divergent evolution, 292
 - low-barrier hydrogen bonds, 294–95
 - preferential transition state binding, 294
 - tetrahedral intermediate, 295–96
 - X-ray structure, 289–92
 - zymogens, 297–99
- Serotonin, 735–36
- SET domain, 1012
- Sexual development
- gonads, 348–49
 - steroid hormones and, 348–49
- SH3 domains, 357
- Sharp, Phillip, 902
- Shine–Dalgarno sequence, 945
- Short interfering RNAs (siRNAs), 1027
- Short interspersed nuclear elements (SINEs), 981
- Short tandem repeats (STRs), 980, 1091
- Shotgun cloning, 1088
- Sialic acids, 129
- Sickle-cell anemia, 118–19
- Sickle-cell hemoglobin, 118
- Side chains, 49–54
- Side chains, amino acids
- allosterism in
 - phosphofructokinase, 469 - hydropathy, 89
 - hydropathy scale, 89
 - polarity and location of, 87–89
- SIGMA σ factors, 881
- Sigmoidal, 113
- Signal peptidase, 219
- Signal peptides, 219
- Signal recognition particle (SRP), 219, 967
- Signal transduction, 350
- Signal-anchor sequences, 220
- SINEs. *See* Short interspersed nuclear elements
- Single nucleotide polymorphisms (SNPs), 977
- Single Particle CryoEM, 84
- Single-blind tests, 336
- Single-displacement reactions, 314

- Single-nucleotide polymorphisms, 1084
- Single-stranded DNA-binding protein (SSB), 823
- siRNAs. *See* Short interfering RNAs
- Site-directed mutagenesis, 1092
- Skeletal muscle, 763
- Sliding clamp, 824
- Sliding filament model, 382
- Sm motif proteins, 905
- Small nuclear ribonucleoproteins (snRNPs), 904
- Small nuclear RNAs (snRNAs), 904–5
- Small nucleolar RNAs (snoRNAs), 911
- Small ubiquitin-related modifier (SUMO), 966
- SNAREs, 225–27
- snoRNAs. *See* Small nucleolar RNAs
- SNPs. *See* Single nucleotide polymorphisms
- snRNAs. *See* Small nuclear RNAs
- snRNPs. *See* Small nuclear ribonucleoproteins
- Solvation, 28
- Somatic hypermutation, 868, 870
- Somatic recombination, 868, 870
- Somatostatin, 345
- Sos protein, 357
- SOS response, 853–54
- Southern blotting, 1062
- Special pair, protoxidizing, 604
- Sphingolipids, 192–9, 673–75
- Sphingomyelins, 194
- Sphingophospholipids, 194
- Spliceosome, 904
- Splicing, 901–10
self-splicing, 911–12
- Splicing endonuclease, 915
- Spontaneity, 14, 416–18
- Spontaneous process, 16–18
- Squalene
cyclization, 680
formation, 678–80
- Squelching, 1020
- Src homology 2 (SH2) domains, 355
- Src, structure, 360–61
- SRP receptor, 219
- SRP. *See* Signal recognition particle
- SSB. *See* Single-stranded DNA-binding protein
- Stability, protein structures, 89–91
- Stabilization, tertiary structures (proteins), 89–91
- Stacking interactions, 161–62
- Standard reduction potential, 415, 416
- Staphylococcus aureus*, 142
- Starch, 134–36, 623–24
- Start codons, 923
- Starvation, 766–68
- State functions, 17
- Statins, 682–83
- Steady state, 20, 400
definition, 308
establishing reaction mechanism, 313–14
fuel metabolism, 750
Michaelis-Menten equation, 308–10
- Steady state assumption, 308
- Stemloop structures, 175
- Stercobilin, 735
- Stereoisomers, 57
- Steroid hormones, 196
- Steroid receptors, 348
- Steroids, 194–97
anabolic steroids, 349
gonadal steroids, 348–49
hormones, 348–49
receptors, 348
- Sterol, 194
- Sticky ends, 1078
- Stop codons, 923
- Storage polysaccharides, 134–36
- Strain, lysozymes, 284–86
- Strand, copying, 877
- Streochemistry, 56–59
- Streptomyces lividans*, 240
- Striated muscle
thick filaments, 382–86
thin filaments, 386–88
- Strokes, 584
- Stroma, 597
- Stromal lamellae, 598
- Strong acids, 38
- STRs. *See* Short tandem repeats
- Structural genes, 878
- Structural methods, 1094–99
- Structural polysaccharides, 136–37
- Structure-based drug design, 335
- Structured turns, 79
- Structural biochemistry, 76
- Substrate cycles, 402, 470–71
- Substrate specificity, 265–66, 289–92
- Substrate-level phosphorylation, 408
- Substrates, 264
- Subunits, 64
proteins, 93–96
separating, 1064–66
- Succinate, 514
- Succinate dehydrogenase, 529
- Succinyl-phosphate, 528
- Succinyl-CoA, 527, 654, 806
heme biosynthesis, 731–35
- Sucrose, 132–34, 623–24
- Sugar-phosphate backbone, 163–64
- Sugars
amino, 129
anomeric forms, 127–28
conformations, 128
covalent linking, 128–31
deoxy, 129
modification of, 128–31
nonreducing, 131
reducing, 131
- Sulfate, 139
- Sulfonamides, 782
- SUMO. *See* Small ubiquitin-related modifier
- Supercoiled DNA, 169
- Supercoiling, 169
- Superhelicity, 169
- Superoxide radical, 585
- Suppressors, 921
- Svedbergs (S), 1063
- SWI/SNF complex, 1004
- Switch regions, 369
- symbiotic, 11
- Symmetry model of allostereism, 330
- Symport, 250
- syn conformations, 164
- Syncytium, 1038
- Synonyms, 923
- Systematic name, 265
- Systems, 13
- Systems biology, 422–23
- T**
- T lymphocytes, 866
- T state, 114
- T. elongatus*, 09, 614
- T. thermophilus*, 573
- Taq polymerase, 1090
- Tarui's disease, 493
- TATA box, 895–97
- TATA-binding protein (TBP), 893–97
- Tatum, Edward, 182
- Tautomerization, 799
- Tautomers, 158
- TBP. *See* TATA-binding protein
- Telomerase, 833–35
- Telomeres, 833
- Temperature, and equilibrium constant, 19
- Termination
eukaryotic transcription, 897
prokaryotic transcription, 883–86
Rho factor and, 883–86
translation, 961–64
- Termination, prokaryotic DNA replication, 827–28
- Termolecular reaction, 305
- Terpenoids, 198
- Tertiary structure (proteins), 70, 82–92
combinations of secondary structures in, 82–87
conservation of, 91–92
polarity and side chain location, 87–89
stabilization of, 89–91
- Tertiary structures (DNA), 168–75
overwinding, 169
relaxed circles, 169
underwinding, 169
- Testosterone, 196, 348
- Tetanus, 226
- Tetracycline, 960
- Tetrahedral intermediate, 292–96
- Tetrahydrofolate (THF), 712, 797
- Tetrahymena* group I, 912–13
- Tetrahymena thermophila*
GCN5, 1009
- Tetroses, 124
- TF. *See* Trigger factor
- Therapeutic index, 337
- Thermodynamics
first law, 13–14
free energy, 16–19
homeostasis and, 20–21
hydrocarbons, 31
metabolism and, 399–40
second law, 15–16
of transport, 235–27
- Thermophiles, 10
- Thermostable proteins, 100
- Thermus aquaticus*, 817
- THETA θ Structures, 812
- Thiamine pyrophosphate (TPP), 457, 519
- Thick filaments, 382–86
- Thin filaments, 382, 386–88
- Thioesters, 410–11
- Thiol side chains, 53–54
- Thiolase reaction, 646
- Thiolysis, 644
- Thioredoxin, 626, 793
reduction of, 793
regulation of, 793–94
- Threonine, 146
breakdown of, 706–8, 710–15
synthesis of, 725
- Thylakoid, light reactions in, 597–600
- Thymidylate synthase, 795–97
- Thymidylate synthesis, 798
- Thymine, formation of, 794–97
- TIM. *See* Triose phosphate isomerase
- Titin, 386
- Titration curves, 40–41
- TMV. *See* Tobacco mosaic virus
- TNBS. *See*
Trinitrobenzenesulfonic acid
- Tobacco mosaic virus (TMV), 95
- Topoisomerases, 169–75
definition, 169
inhibitors of, 174
types, 170–73
- Toroidal pores, 589
- Torpedo model, 901
- Torsion angles, 72–73
- Totipotent, 1038
- Toxoplasma gondii*
- TPP. *See* Thiamine pyrophosphate
- Tranlation, 182
- Trans* cisternae, 222
- Trans* conformation, 72
- Trans* fats, 191
- Trans* Golgi network, 221
- Trans*-acting factors, 1019
- Transaldolase, 477
- Transaminases, 698–700
- Transamination, 473, 698
- Transcortin, 348
- Transcription, 182, 875–918
enhancers in, 892
eukaryotic, 886–97
inhibitors of, 887–88
prokaryotic, 876–86
rapidity, 882–83
- Transcription bubble, 877, 880
- Transcription factors, 358, 893–97
- Transcription factors, eukaryotic
gene expression, 1015–19
- Transcriptional activators, eukaryotic
gene expression, 1019–25
- Transcriptome, 1089
- Transfer RNA (tRNA), 176, 876
attaching to amino acids, 928–32
binding sites, 940–41
in chain initiation, 944–50
codon recognition, 933–35
frequently used codons, 934–35
modified bases of, 927
processing, 913–15
structures of, 926–28
tertiary structure, 927–28
- Transformed substance, 181
- Transgene, 1092
- Transimination, 700
- Transition state, 267
enzyme preferential binding in, 269–70
- Transition state analogs, 270, 318
- Transition state theory, 267–68
- Transition temperature, 203
- Transitions, 841
- Transketolase, 477
- Translation, 943–64
chain initiation, 944–50
polyribosomes and, 944
ribosomal activities, 950–61
termination of, 961–64
- Translesion DNA synthesis, 852
- Translocation, 950, 957–60
- Translocon, 219–21
- Transmembrane helices, 367–68
- Transmembrane proteins
definition, 205
passing through ER membrane, 218–20
PbRC, 603–4
 α helices in, 206–7
 β -barrels in, 207–8
- Transmissible spongiform encephalopathies (TSEs), 108
- Transpeptidation, 950, 955–56
- Transport proteins, 235

I-14 SUBJECT INDEX

- Transporters
 ABC transporters, 255–57
 mitochondria and, 547–49
 Transposable elements, 863
 Transposition, 862–65, 1083
 Transposons, 854
 Transverse diffusion, 202
 Transversions, 841
 Triacylglycerols, 34, 190–91, 665–66
 absorption of, 635–37
 digestion of, 635–37
 intermediates, 670–73
 in liver, 754
 Tricarboxylate transport system, 658
 Trifluoroacetic acid, 1069
 Trigger factor (TF), 105, 965
 Trinitrobenzenesulfonic acid (TNBS), 215
 Trinucleotide repeat diseases, 980–81
 Triose phosphate isomerase (TIM), 437–40
 Tripeptides, 63
 Triskelions, 223–24
 tRNA. *See* Transfer RNA
 Tropomodulin, 386
 Tropomyosin, 385
 Troponin, 386
Trp operon, 990
 Trypsin, 1067
 Tryptophan, 991–93
 breakdown of, 717–18
 synthesis of, 727
 Tryptophan Synthase, 728–29
 Tumor suppressor, 1035–38
 Turnover number, 311
 Two-dimensional (2D) gel electrophoresis, 1060
 Two-dimensional NMR spectroscopy, 1096
 Two-reaction-center electron transport, 605–16
 motivating proton gradient formation, 615–16
 oxygen generation, 610–11
 photosystems in, 605–7
 plastocyanin, 611–13
 proton gradient generation, 611
 PSII resembling PbRC, 607–9
 resemblances in, 613–15
 Type 1 diabetes mellitus, 768
 Type 2 diabetes mellitus, 768
 Type IA Topoisomerases, 170–72
 Type IB Topoisomerases, 172
 Type II Topoisomerases, 173
 Tyrosine
 breakdown of, 718–20
 synthesis of, 727
- U**
 Ubiquinone, 198, 551
 Ubiquitin, 692–94
 Ubiquitin-activating enzyme, 692
 Ubiquitin-conjugating enzymes, 693
 Ubiquitin-protein ligase, 693
 Ubiquitinated proteins, 694–96
 UDP-galactose, 452
 UDP-galactose-4-epimerase, 452
 UDP-glucose pyrophosphorylase, 452
 UDPG. *See* Uridine diphosphate glucose
 Ultracentrifugation, 1063–64
 UMP. *See* Uridine monophosphate
 Uncompetitive inhibition, 322–24
 Uncoupling proteins, 582–83
 Underwinding, DNA, 169
 Unfavorable, 17
 Unfolding, proteins, 99–110
 Unimolecular reaction, 305
 Uniport, 250
 Universal minimum consensus structure, 915
 Unsaturated fatty acid, 188–89
 Upstream promoter element, 891
 Uracil, 847
 Urea, 701
 Urea cycle, 701–5
 enzymes carrying out, 703–4
 packaging nitrogen, 701–4
 regulation of, 705
 Uric acid, 701, 779
 degradation of, 803–5
 purine catabolism and, 800–801
 Uridine diphosphate glucose (UDPG), 495
 Uridine monophosphate (UMP)
 conversion to UTP, 788
 synthesis, 786–88
 Uridine triphosphate (UTP), 788
 Urobilin, 735
 Uronic acids, 129
 Uroporphyrinogen III, 731
 UvrABC endonuclease, 849
- V**
v (velocity), 305
 V-type ATPases, 251
 Vacuoles, 9
 Valine
 breakdown of, 710–15
 synthesis from pyruvate, 725–26
 Valinomycin, 238
 van der Waals distance, 26
 van der Waals forces, 30
 van't Hoff plot, 19
 Variable region, 867
 Vector, 1085
 Velocity (*v*), 305
 Vesicle fusion, 225–29
 Vesicles, 7
 Vioxx, 337
 Virulence, 143
 Viruses, fusion proteins, 227–29
 Vitamin A, 198, 1093
 Vitamin B₁, 457–59
 Vitamin B₁₂, 651
 Vitamin C (ascorbic acid), 80
 Vitamin D, 197
 Vitamin D₂ (ergocalciferol), 197
 Vitamin D₃ (cholecalciferol), 197
 Vitamin E, 198
 Vitamin K, 198
 Vitamins, 198
 assisting metabolic reactions, 394–95
 characteristics of, 394
 converting to coenzymes, 395
 VLDL. *See* Low density lipoproteins
 V_{max} , value of, 312–14
 v_o (initial velocity), 310
 Voltage gating, 242–43
 Voltage-gated channels, 242
 von Gierke's disease, 493
- W**
 Warburg, Otto, 429
 Water, 24–46
 buffers and, 40–43
 chemical properties, 35–43
 hydrogen bonds of, 26–27
 hydrophilic substances and, 27–30
 hydrophobic effect and, 30–33
 ionization, 36
 osmosis, 34–35
 physical properties of, 25–27
 as polar molecule, 25–27
 structure of, 27
 Water-splitting reaction, 610–11
 Water, reducing oxygen to, 565–67
 Waters of hydration, 28
 Watson-Crick structure, 157, 159–61
 Watson-Crick base pairs, 817
 Weak acids, 38
 Wernicke-Korsakoff syndrome, 458–59
 Western blot, 106
 Western blotting, 1059
 Wild-type sequence, 1092
 Wobble hypothesis, 933–34
 Wolfenden, Richard, 269
- X**
 X-gal, 1087
 X-Linked adrenoleukodystrophy (X-ALD), 655
 X-ray crystallography, 83, 286–87, 1095
 Xanthine oxidase, 802
 Xenobiotics, 336
 X-Linked phosphorylase kinase deficiency, 493
 Xu5P. *See* Xylulose-5-phosphate
 Xylulose-5-phosphate (Xu5P), 474
- Y**
 YACs. *See* Yeast artificial chromosomes
 YAFH. *See* Yeast alcohol dehydrogenase
 Yalow, Rosalyn, 346
 Yeast alcohol dehydrogenase (YADH), 459
 Yeast artificial chromosomes (YACs), 1086
- Z**
 Z disks, 382
 Z-DNA
 definition, 166
 forming left-handed helix, 166–68
 structural features of, 166
 Z-scheme, 607
 Zellweger syndrome, 655
 Zeroth order, 307
 Zinc fingers, 90, 1016
 Zwitterions, 49
 Zymogens, 297–99